Download Swog Fall 2012 Group Meeting PDF

SWOG 

FALL 2012 GROUP MEETING 

© C.E. Andersen 

OCTOBER 17-20, 2012 

CHICAGO, ILLINOIS

2 Fall 2012 

Welcome to SWOG’s Fall 2012 Meeting! 

There sure seems to be lots going on – from national political campaigns, to new 

guidelines governing the cooperative groups and forming a new NCI network, to 

the transition of SWOG’s leadership. While all of that’s important, nothing is more 

important than continuing the work of the group, much of which gets accomplished 

at meetings such as this one. 

If you’ve got a smart phone, download our mobile guidebook and use it to schedule 

your time at the meeting. If you’re a regular Twitter user, use our #SWOG2012fa 

hash tag when you tweet from the meeting so your fellow members can stay 

informed. 

Here’s to a productive and educational Chicago meeting! 

Warmly, 

Laurence H. Baker, D.O. 

Group Chairman 

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda 3 

Integrating clinical research with care and medical practice 

Annetine C. Gelijns, Ph.D. 

Chair, 

Department of Health Evidence and Policy, 

Mount Sinai School of Medicine 

Value-based insurance design 

A. Mark Fendrick, M.D. 

Co-Director, 

Center for Value-Based Insurance Design, 

University of Michigan 

Placebos as treatment for metastatic cancer in clinical trials 

Lowell E. Schnipper, M.D. 

Clinical Director and 

Chief of Hematology/Oncology, 

Beth Israel Deaconess Medical Center 

Discussant 

Rick Bangs, M.B.A. 

Chair, 

SWOG Patient Advocate Committee 

Does health care reform open new possibilities for better integrating clinical research 

with patient care and medical practice For a more rational balance of costs and care 

through value-based insurance reimbursement For more ethical approaches to incorporating 

placebos into clinical trials And once the doctors speak to these questions, 

what are patients to make of their answers 

Experts from a variety of disciplines and backgrounds will address these issues at the Fall 

2012 SWOG Group Meeting plenary session, with a patient advocate as rapporteur for 

the event. 

Health Care Reform and Clinical Trials 

A plenary session - SWOG Fall 2012 Group Meeting 

12:15 – 2:45 pm 

Friday, October 19 

Regency B – D 

Hyatt Regency Chicago 



GROUP MEETING INDEX 

.PAGE(S) 

Plenary Session.................................................................................................................................................................... 3 & 15 

Hyatt Regency Chicago Travel and Hotel Information and Hotel Maps.................................................................................. 7-8 

Schedule of Events.................................................................................................................................................................13-16 

Roster of Committee Speakers..............................................................................................................................................17-18 

Administrative Committees......................................................................................................................................................... 19 

The Hope Foundation................................................................................................................................................................... 20 

Accrual Information (Accrual by Institution and Accrual by Institution and Committee)..................................................23-30 

Committee Information 

Barlogie-Salmon Myeloma Committee...................................................................................................................15 & 31-34 

Board of Governors............................................................................................................................................................. 16 

Bone Marrow & Stem Cell Transplantation Committee........................................................................................................ 15 

Breast Committee.................................................................................................................................................15 & 35-42 

Cancer Control and Prevention Committees......................................................................................................14-15 & 43-64 

Cancer Survivorship Committee.................................................................................................................. 15 & 43-46 

Molecular Epidemiology Committee.................................................................................................................. 14 & 47 

Outcomes and Comparative Effectiveness Committee...................................................................................... 14 & 48 

Prevention Committee................................................................................................................................. 14 & 49-50 

Symptom Control and Quality of Life Committee.........................................................................................14 & 51-52 

Clinical Practices Committee............................................................................................................................................... 16 

Early Therapeutics Committee.................................................................................................................................... 14 & 65 

Gastrointestinal Committee...................................................................................................................................15 & 66-70 

Genitourinary Committee......................................................................................................................................16 & 71-74 

Gynecologic Committee....................................................................................................................................................... 75 

Leukemia Committee.............................................................................................................................................15 & 76-80 

Lung Committee....................................................................................................................................................16 & 81-85 

Lymphoma Committee...........................................................................................................................................16 & 86-89 

Melanoma Committee...........................................................................................................................................15 & 90-93 

Pharmaceutical Sciences Committee................................................................................................................................... 16 

Radiation Therapy Committee............................................................................................................................................. 16 

Surgery Committee.................................................................................................................................................... 15 & 22 

Training & Workshops 

CRA Clinical Trials Training Course..................................................................................................................................... 13 

Clinical Research Associates Continuing Education Workshop.................................................................................... 15 & 22 

Clinical Research Associates Open Forum................................................................................................................... 14 & 21 

Jeri and Noboru Oishi Symposium.............................................................................................................................. 13 & 21 

Special Symposia................................................................................................................................................... 5, 21 & 22 

Future Group Meeting Dates....................................................................................................................................................... 94 

Group Meeting Supporters................................................................................................................................................... 9 & 96 



SWOG 

FallÊ2012Ê 

GroupÊMeeting 

Special 

Symposium: 

TheÊUseÊofÊ 

JamesÊHicks,ÊPh.D. 

SWOGÊInvestigator 

ProfessorÊofÊCancerÊGenomics 

ColdÊSpringÊHarborÊLaboratory 

SessionÊchair 

DanielÊF.ÊHayes,ÊM.D. 

StuartÊB.ÊPadnosÊProfessorÊofÊBreastÊCancerÊResarch 

ClinicalÊDirector,ÊBreastÊOncologyÊProgram 

UniversityÊofÊMichigan 

CTCs:ÊCurrentÊtechnologyÊandÊfutureÊapplications 

HowardÊI.ÊScher,ÊM.D. 

ChiefÊofÊGenitourinaryÊOncologyÊand 

D.ÊWayneÊCallowayÊChairÊinÊUrologicÊOncology 

SidneyÊKimmelÊCenterÊforÊUrologicÊandÊProstateÊCancers 

MemorialÊSloan-KetteringÊCancerÊCenter 

CirculatingÊtumorÊcellsÊasÊaÊreflectionÊofÊ 

Ê prostateÊcancerÊdiseaseÊbiology 

StefanieÊS.ÊJeffrey,ÊM.D. 

ChiefÊofÊSurgicalÊOncologyÊand 

ProfessorÊofÊSurgery 

StanfordÊUniversity 

TumorÊheterogeneityÊandÊsingleÊcellÊprofiling 

CirculatingÊTumorÊCellsÊ 

inÊCancerÊResearch 

Thursday, 

OctoberÊ18th 

1:00ÊÐÊ2:45Êpm 

RegencyÊAÊÐÊB 

AllÊSWOGÊmembersÊareÊinvited. 

SupportedÊbyÊTheÊHopeÊFoundation 



Go Mobile at the Meeting! 

To manage your Group Meeting experience from your 

smartphone, download our mobile guidebook. 

You’ll be able to plan your day with a personalized 

schedule and browse exhibitors, maps and general show 

info, all in the palm of your hand. 

The guidebook app is compatible with iPhones, iPads, 

Android, and Blackberry devices. 

To get the app, use your phone’s QR-code reader to scan 

the code at right. Or choose one of these methods: 

1. Download 'Guidebook' from the Apple App Store or the Android Marketplace OR 

2. Go to m.guidebookapp.com from your Blackberry OR 

3. Visit guidebookapp.com/getit from your phone's browser. 

Once you’ve installed the Guidebook app, search for the SWOG Fall 2012 Group Meeting 

Guide in the "download guides" section of the app. 

Tweeting the Meeting 

Tag your Group Meeting tweets 

with 

#SWOG2012fa 

We’ll post the live stream of tagged Group Meeting 

updates to the SWOG website, for ease of following by 

those who couldn’t make it. 

Follow SWOG at twitter.com/SWOG. Our username is @SWOG. 



Hyatt Regency Chicago 

151 East Wacker Drive 

Chicago, Illinois 60601 

Phone: 312-565-1234 

Fax: 312-239-4414 

Chicago Travel & Hotel Information 

Arrival/Departure: 

Check-in time is 3:00 p.m. Check-out time is 12:00 noon. 

Room amenities include a full bath, hair dryer, ironing 

board and iron. The concierge staff serves as a liaison between 

guests and the hotel and outside services. 

Hotel Safety Deposit Boxes: 

For your convenience, safety deposit boxes are available 

at the front desk for your valuables. Please do not leave 

valuables in your room. 

Recreational Facilities: 

The fitness center offers a variety of exercise equipment, 

free weights, treadmills, and more, exclusively for hotel 

guests. It is open 24 hours a day. 

Hotel Restaurants and Lounges: 

• Stetson’s Chop House and Bar provide guests with an 

elegant atmosphere specializing in steaks and seafood. 

• The Bistro at 151 specializes in a variety of American 

and Mediterranean cuisine and offers guests a relaxing 

atmosphere to enjoy breakfast and lunch. 

• DaddyO’s Pub and Piano Bar features snacks and 

cocktails. 

• J’s Express offers breakfast, lunch or dinner for a 

quick meal. 

• The BIG Bar features the longest free-standing bar 

in North America and specializes in a wide variety of 

cocktails, wines, champagnes and cognacs. 

• In-room dining is available from 6:00 a.m. - 12:00 a.m. 

daily. 

Business Center: 

The Business Center is located on the Purple level in the 

East Tower of the hotel. It is open 24 hours a day, 7 days 

a week. The Business Center offers fax machines, computer 

services, color copies, mail drop, Internet access 

and photocopying. 

Ground Transportation: 

• A taxi ride from O’Hare airport to the hotel is approximately 

$35.00 one-way. 

• A taxi ride from Midway airport to the hotel is approximately 

$30.00 one-way. 

• Valet parking at the hotel is $52.00 per day for hotel 

guests. 

Temperature: 

The average high for October is 64 degrees and the average 

low is 46 degrees. 

Area Attractions: 

• Adler Planetarium and Astronomy Museum 

• Architectural Boat Tours 

• Art Institute of Chicago 

• Brookfield Zoo 

• Chicago ArchiCenter 

• Chicago Architecture Foundation 

• Chicago Botanic Garden 

• Chicago Cultural Center 

• Field Museum of National History 

• Frank Lloyd Wright Home and Studio 

• John G. Shedd Aquarium 

• John Hancock Center Observatory 

• Millennium Park 

• Museum of Contemporary Art 

• Museum of Science and Industry 

• Rockefeller Memorial Chapel 

• Sears Tower Skydeck 

Local Restaurants: 

(The hotel concierge can assist with reservations and suggestions) 

• Alinea - Eclectic 

• Atwood Cafe - American 

• Billy Goat Tavern - Burgers 

• Bistro 110 - Continental 

• Cape Cod Room - Seafood 

• Charlie Trotters - Eclectic 

• Heaven on Seven - American Regional 

• Mia Francesca - Italian 

• Mon Ami Gabi - French 

• Shaw’s Crab House and Blue Crab Lounge - Seafood 

• Silver Cloud - American 

• Spiaggia - Italian 



HYATT REGENCY CHICAGO 

Meeting Rooms/Hotel Services 

31 

Acapulco, West Tower, Gold Level 

8 

2 

4 

6 

1 

3 

5 

7 

9 

Business Center 

and Package Pick-Up 

located on the Purple 

Level of the East Tower 

(one level below the 

Gold Level) 

7 Addams, West Tower, Silver Level 

36 Atlanta, West Tower, Gold Level 

20 Buckingham, West Tower, Bronze Level 

2 Burnham, West Tower, Silver Level 

24 Columbian, West Tower, Bronze Level 

37 Columbus A-F, East Tower, Gold Level 

SILVER LEVEL 

38 Columbus G-L, East Tower, Gold Level 

27 

Comiskey, West Tower, Bronze Level 

10 

14 

16 

Concierge, East Tower, Blue Level 

Crystal Ballrooms A-C, West Tower, Green Level 

11 

12 

13 

15 

14 

8 

6 

29 

DuSable, West Tower, Silver Level 

Field, West Tower, Silver Level 

Fitness Center, East Tower, Bronze Level 

13 

Front Desk, East Tower, Blue Level 

BLUE LEVEL 

21 

22 

32 

Gold Coast, West Tower, Bronze Level 

Haymarket, West Tower, Bronze Level 

Hong Kong, West Tower, Gold Level 

16 

1 

Horner, West Tower, Silver Level 

18 

4 

McCormick, West Tower, Silver Level 

17 

19 

39 

35 

3 

23 

New Orleans, West Tower, Gold Level 

Ogden, West Tower, Silver Level 

Picasso, West Tower, Bronze Level 

20 

22 

23 

24 

21 25 

26 

27 

28 

GREEN LEVEL 

* 

29 

SWOG 

Registration 

Desk 

39 Plaza Ballrooms, East Tower, Green Level 

30 Regency Ballrooms A-D, West Tower, Gold Level 

34 San Francisco, West Tower, Gold Level 

9 Sandburg, West Tower, Silver Level 

26 Soldier Field, West Tower, Bronze Level 

33 

Toronto, West Tower, Gold Level 

10 

Truffles, West Tower, Blue Level 

30 

BRONZE LEVEL 

31 

32 

33 

35 

34 36 

38 

37 

25 Water Tower, West Tower, Bronze Level 

5 Wright, West Tower, Silver Level 

28 Wrigley, West Tower, Bronze Level 

Restaurants/Bars 

19 151-Bistro, Bar and Club, East Tower, Green Level 

15 BIG Bar, East Tower, Blue Level 

11 DaddyO’s Pub and Piano Bar, West Tower, Blue Level 

WEST TOWER 

GOLD LEVEL 

EAST TOWER 

18 

12 

17 

J’s Express, East Tower, Green Level 

Pronto Mama’s Italian Kitchen, West Tower, Blue Level 

Stetson’s Chop House & Bar, East Tower, Green Level 



CME Credit Information 

Procedures for CME Credit 

CME credit forms for the Group Meeting are available on pages 

95 and 97 of the Group Meeting agenda booklet. Only one form 

per person is required to list the CME credits for the entire meeting. 

Credits for each committee session are listed on the form. 

Forms should be turned in to the Registration Desk before the 

desk closes at 12:30 p.m. on October 20, 2012. If the forms are not 

turned in to the desk, they can be mailed to the Operations Office the 

week following the Group Meeting. The Operations Office will submit 

all CME forms to the accrediting institution at one time. Forms will be 

submitted 30 days following the meeting. You will then receive 

a certificate of completion in the mail following submission and 

processing of the CME forms by the accrediting institution. 

Group Meeting Target Audience and Educational Objectives 

SWOG meets semi-annually to keep its members abreast of Group science. 

The target audience for these meetings are Physicians, Nurse Oncologists 

and Clinical Research Associates. 

The educational objectives of these meetings are: to educate attendees 

about active and proposed studies so that they may implement the studies 

at their local institutions; to educate attendees about new treatments 

and prevention strategies that are available; to identify areas that can be 

improved in cancer research and study implementation and educate attendees 

on the best ways to implement the solutions at the local level. 

These objectives apply to the following areas: Cancer Control and Prevention, 

including Outcomes and Comparative Effectiveness Committee, 

Symptom Control and Quality of Life Committee, Prevention Committee, 

Molecular Epidemiology Committee, Cancer Survivorship Committee and 

Harry Hynes Symposium; Genitourinary Committee; Early Therapeutics 

Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; 

Radiation Therapy Committee; Plenary Session; Leukemia Committee; 

Breast Committee; Gastrointestinal Committee; Lung Committee 

and Lymphoma Committee. 

SWOG gratefully acknowledges the 

support of our CME Commercial Supporters* 

*Supporters as of September 10, 2012 

Double Platinum Supporters 

Eli Lilly & Co. 

Platinum Supporters 

Amgen 

Novartis 

Silver Supporters 

Genomic Health 

Bronze Supporters 

Bayer Healthcare Pharmaceuticals 

Bristol-Myers Squibb 

Eisai 

Merck 

Sigma-Tau Pharmaceuticals 

Varian 

Speaker and Planner CME Disclosure Information 

Each speaker and planner for The Hope Foundation - CME courses has 

been requested to complete a Faculty Disclosure Form prior to the activity. 

Information regarding affiliations or interests that might be perceived as a 

potential conflict of interest is provided in the agenda book, for everyone 

to review. 

Continuing Medical Education Credit 

The Hope Foundation is accredited by the Accreditation Council for 

Continuing Medical Education to provide continuing medical education 

for physicians. 

The Hope Foundation designates this live activity for a maximum of 

22.00 AMA PRA Category 1 Credits. Physicians should only claim 

credit commensurate with the extent of their participation in the activity. 



Disclosure of Relevant Financial Relationships with Commercial Companies 

The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the 

American Medical Association. 

The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by 

scientific evidence. 

Everyone who is in a position to control the content of a continuing medical education activity is required to disclose relevant 

relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME 

considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. 

Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that 

might be of potential importance to their evaluation of a presentation. 

All potential conflicts of interest have been resolved prior to this program. 

Acknowledging a relevant relationship with the following companies or organizations having a direct interest in the subject of this 

presentation include: 

Planner/Faculty Member Nature of Relationship Company 

Christine Ambrosone, Ph.D. 

Laurence Baker, D.O. 

Rick Bangs 

Charles Blanke, M.D. 

Powell Brown, M.D. 

Harry Erba, M.D. 

Carol Fabian, M.D. 

No Disclosures 





Speaker’s Bureau 

Research Grant 


Celgene, Novartis, Incyte 

Novartis, Sanofi-Aventis, Ambit, Ascenta, Sunesis, Chroma, Eli-Lilly, 

Millennium 

A. Mark Fendrick, M.D. Consultant 


Grant Research 

Abbott, AonHewitt, AstraZeneca, Aventis, Blue Shield of CA, BMS, 

Center for Medicare and Medicaid Services, Genentech, GSK, Health 

Alliance Plan, Highmark BlueCross BlueShield, Merck and Co., 

National Business Coalition on Health, National Pharmaceutical 

Council, Neocure Group LLC, Pennsylvania State Trooper’s 

Association, Pfizer Inc., POZEN Inc., Precision Health Economics 

LLC, Thomson Reuters, TriZetto, zanzors 

Merck and Co., Pfizer Inc. 

Abbott, AstraZeneca, Aventis, Eli Lilly, Genentech, GSK, Merck and 

Co., Novartis, Pfizer Inc. 

Richard Fisher, M.D. Consultant Roche, Millennium and Pfizer 

Lawrence Flaherty, M.D. 

Lisa Flynn, M.D. 

James Foran, M.D. 

Shirish Gadgeel, M.D. 

Consultant 




Consultant 



Genentech, BMS, Merck, Celgene, GSK 

Genentech 

Boehringer-Ingelheim, Methylgene 

Eli-Lilly, Pfizer, Genentech 

Clovis Oncology, Pfizer, Infinity, Novartis, Genentech, Chugai, Abbott 



David Gandara, M.D. 

Annetine Gelijns, Ph.D. 

Heather Greenlee, N.D., Ph.D. 

Kenneth Grossmann, M.D., 

Ph.D. 

Dawn Hershman, M.D. 

Johanna Horn 

Consultant 







Amgen, AstraZeneca, Biodesix, BI, BMS, ImClone, Genentech, 

Merck, Novartis, Sanofi-Aventis, Array BioPharma, and Response 

Genetics 

BMS, ImClone, Genentech, Lilly, Merck, and Novartis. 

Gabriel Hortobagyi, M.D. Consultant Allergan, Genentech, Novartis, Sanofi-Aventis, and Taivex 

Aly Karsan, M.D., F.R.C.P.C. 


Robert Krouse, M.D. Consultant Novartis 

Razelle Kurzrock, M.D. 

Monika Leja, M.D. 

Bryan Luce, Ph.D., M.B.A. 

Thomas Lynch, Jr., M.D. 


Honoraria 

Consultant 

Other 



Consultant/SAB 

Board of Directors and Stock 

Holder 

Patent Holder 

Amgen, Amplimed, Angiochem, Aronex, AstraZeneca, Callisto, 

Centocor, Concordia, Enzon, Exelixis, Genentech, Genetics, GSK, 

Globomax, GPC Biotech, Hoffman La-Roche, Merck, MGI 

Pharmaceuticals, Myriad, NCCN, Nereus, NIH, Novartis, Otsuka, 

Pfizer, Ziopharm, and Wyeth. 

AACR-MCT, Alfred Mann Foundation, Amgen, ASCO Program 

Committee, Cancer Treatment Centers of America, CTRT-EAB, 

Exelixis, Georgetown University, Merck, MK&A, Myriad, Novartis, 

Optum Heath, Pfizer, Pharmacogenomic Medicine, UTHSCSA, 

Yokohama City University and Yonsei Cancer Center. 

AACR-MCT, Enzon, Health Advances, LLC, Johnson and Johnson, 

Merch, SAIC-Frederick, Inc. 

CTRC-EAB, Novartis, AACR, ASCO, Amgen, CTCA, CTRC, Exelisix, 

IDSC, Georgetown University, Johnson and Johnson, Merck, Mt. 

Sinai School of Medicine, Myriad, Norwegian Radium Hospital, Nova 

Research Company, Novartis, Potum Health Oncology, Palladian 

Partners, Roche, UTHSCSA 

Merck, BI, Astex 

Infinity Pharmaceuticals 

Partners Healthcare 

Frank Meyskens, Jr., M.D. Co-Founder Cancer Prevention Pharmaceuticals 

Carol Moinpour, Ph.D. 

Paul Okunieff, M.D. 

Robert Orlowski, M.D., Ph.D. 

Scott Ramsey, M.D. 



Consultant 



BMS, Onyx, Celgene, Millennium and Abbott 

Celgene, Onyx and BMS 

Antoni Ribas, M.D. Consultant Amgen, Celgene, Millennium, Genentech-Roche and GSK 

Regina Santella, Ph.D. 




Lowell Schnipper, M.D. 

Leonard Sender, M.D. 

Dana Sparks 

Lisa Sparks, Ph.D. 

Ian Thompson, Jr., M.D. 

Joseph Unger 

Courtney Wille 

George Yoo, M.D. 

Jason Zell, D.O., M.P.H. 

Gary Zirpoli, M.A. 












SCHEDULE OF EVENTS 


WEDNESDAY, OCTOBER 17, 2012 

7:00 a.m. – 7:30 a.m. Medidata RAVE & CRA Clinical 

Gold Level 

Trials Training Course Check-In 

Room: Regency S Foyer 

7:30 a.m. – 9:00 a.m. Medidata RAVE Training 

Gold Level 

Room: Regency AB 

7:30 a.m. – 12:30 p.m. CRA Clinical Trials Training 

Gold Level 

Course (Includes Medidata 


RAVE Training) 

1:30 p.m. – 5:00 p.m. CRA Clinical Trials Training 

Gold Level 

Course Practicum 

Room: Regency CD 

1:00 p.m. – 4:00 p.m. SoCRA Certification Exam 

Gold Level 

Room: Acapulco 

4:00 p.m. – 7:00 p.m. Oncology Research Professionals 

Bronze Level 

Executive Meeting (Committee 

Room: Haymarket 

Members Only) 

Note: The Hope Foundation is accredited by the Accreditation 

Council for Continuing Medical Education to provide continuing 

medical education for physicians. 

The Hope Foundation designates this live activity for a 

maximum of 22.00 AMA PRA Category 1 Credits. 

Physicians should only claim credit commensurate with the 

extent of their participation in the activity. 

NOTE: Gray Areas Indicate Workshops 

Bolded Meetings Receive CME Credits 

THURSDAY, OCTOBER 18, 2012 

Group Meeting Registration & Information Desk 

7:00 a.m. - 5:00 p.m. - East Tower Concourse 

Hope Foundation Information Desk 


Exhibits & Complimentary Coffee Service 

8:00 a.m. - 4:00 p.m. - Toronto 

7:00 a.m. – 7:30 a.m. Jeri and Noboru Oishi 

Gold Level 

Symposium Check-In 

Room: Regency S Foyer 

7:30 a.m. – 7:45 a.m. Welcome and Information 

Gold Level 

(Open Session) 


7:45 a.m. – 12:30 p.m. Jeri and Noboru Oishi 


Symposium (Open Session) 

2:00 p.m. – 3:00 p.m. Nursing Committee Special 

Gold Level Session B: QOL Coordinators / 


Disease & Discipline and 

Research Subcommittee 

3:00 p.m. – 4:00 p.m. Nursing Committee Special 

Bronze Level 

Session A: Education & Program 

Room: Gold Coast 

Subcommittee 

8:00 a.m. – 10:00 a.m. Cancer Control and Prevention 

Blue Level 

Executive Council (Committee 

Room: Truffles 

Members Only) 

8:00 a.m. – 11:00 a.m. Advocates Committee Meeting 

Bronze Level 

(Committee Members Only) 





THURSDAY, OCTOBER 18, 2012 






8:00 a.m. - 4:00 p.m. - Toronto 

10:15 a.m. – 12:15 p.m. SYMPTOM CONTROL AND 

Gold Level 

QUALITY OF LIFE 

Room: Regency C 

COMMITTEE 

12:00 p.m. – 2:00 p.m. Quality Initiative Meeting 

Bronze Level 



3:30 p.m. – 4:30 p.m. EARLY THERAPEUTICS 

Gold Level 

COMMITTEE 


4:00 p.m. – 5:30 p.m. Head Clinical Research 

Gold Level 

Associates (Open to Member, 


Affiliate and CCOP Head CRAs 

Only) 

4:00 p.m. – 6:00 p.m. Conflict of Interest 

Bronze Level 

Committee (Committee 

Room: Picasso 

Members Only) 

5:30 p.m. – 7:00 p.m. Hope Foundation Platinum 

Reception (Invitation Only) 

5:30 p.m. – 7:30 p.m. MOLECULAR EPIDEMIOLOGY 

Gold Level 

COMMITTEE 


12:30 p.m. – 2:00 p.m. Clinical Research Associates 

Gold Level 

Open Forum 

Room: Regency D 

12:45 p.m. – 2:45 p.m. OUTCOMES & COMPARATIVE 

Gold Level 

EFFECTIVENESS COMMITTEE 


1:00 p.m. – 2:45 p.m. Translational Medicine 

Gold Level 

Symposium on Circulating 


Tumor Cells 

2:30 p.m. – 4:30 p.m. Hope Foundation Annual Board 

Gold Level 

Meeting (Committee Members 

Room: San Francisco Only) 

3:15 p.m. – 5:15 p.m. PREVENTION COMMITTEE 

Gold Level 


NOTE: Bolded Meetings Receive CME Credits 




FRIDAY, OCTOBER 19, 2012 






7:00 a.m. - 12:00 p.m.; 2:45 p.m. - 4:00 p.m. - Toronto 

7:15 a.m. – 9:45 a.m. CANCER SURVIVORSHIP 

Bronze Level 

COMMITTEE 

Room: Comiskey 

7:30 a.m. – 9:30 a.m. BARLOGIE-SALMON 

Green Level 

MYELOMA COMMITTEE 

Room: Plaza Ballroom 

7:30 a.m. – 9:30 a.m. MELANOMA COMMITTEE 

Green Level 

Room: Crystal A 

8:00 a.m. – 11:30 a.m. Clinical Research Associates 

Green Level 

Continuing Education Workshop 

Room: Crystal B 

9:30 a.m. – 11:00 a.m. Quality Assurance Committee 

Bronze Level 

Meeting (Committee Members 


Only) 

10:00 a.m. – 11:30 a.m. Bone Marrow & Stem Cell 

Bronze Level 

Transplantation Committee 

Room: Gold Coast 

10:00 a.m. – 12:00 p.m. CANCER CONTROL AND 

Gold Level 

PREVENTION OUTREACH 

Room: Regency A 

(HARRY HYNES 

SYMPOSIUM) 

10:00 a.m. – 12:00 p.m. SURGERY COMMITTEE 

Gold Level 


10:00 a.m. – 12:00 p.m. Imaging Committee (Committee 

Blue Level 

Members Only) 


11:30 a.m. – 12:15 p.m. Plenary Reception (Light Hors 

Gold Level 

D’oeuvres) 

Room: Regency Foyer 

12:15 p.m. – 2:45 p.m. PLENARY SESSION 

Gold Level 

Room: Regency B-D 

3:00 p.m. – 5:00 p.m. Nurse/CRA Planning Committee 

Gold Level 


Room: San Francisco 

3:00 p.m. – 7:00 p.m. LEUKEMIA COMMITTEE 

Green Level 

Room: Crystal C 

3:00 p.m. – 7:00 p.m. BREAST COMMITTEE 

Green Level 

Room: Crystal B 

5:00 p.m. – 7:00 p.m. GI COMMITTEE 

Green Level 

Room: Crystal A 

5:00 p.m. – 8:00 p.m. SWOG Data & Safety Monitoring 

Bronze Level 

Committee (Committee Members 


Only) 

6:45 p.m. – 8:00 p.m. Reception 

Gold Level 

Room: Regency CD 





SATURDAY, OCTOBER 20, 2012 



11:30 a.m. – 3:30 p.m. LYMPHOMA COMMITTEE 

Gold Level 




7:00 a.m. – 8:00 a.m. Board of Governors (Board 

Gold Level 

Members Only) 

Room: Regency B 

8:15 a.m. – 9:45 a.m. Committee Chairs (Committee 

Gold Level 

Members Only) 


8:15 a.m. – 9:45 a.m. S0819 Educational Session for 

Gold Level 

PIs and CRAs (Invitation Only) 


10:15 a.m. – 11:45 a.m. Pharmaceutical Sciences 

Gold Level 

Committee 

Room: New Orleans 

10:30 a.m. – 11:30 a.m. Clinical Practices Committee 

Gold Level 


10:30 a.m. – 12:00 p.m. RADIATION THERAPY 

Gold Level 

COMMITTEE 

Room: San Francisco 

11:30 a.m. – 3:30 p.m. GU COMMITTEE 

Gold Level 


11:30 a.m. – 3:30 p.m. LUNG COMMITTEE 

Gold Level 




Roster of Committee Speakers 

Thursday, October 18, 2012 


Outcomes and Comparative Effectiveness Committee, 12:45 p.m. - 2:45 p.m. - Regency C 

Adaptive Trial Design - Bryan Luce, Ph.D., M.B.A., Director of United Biosource Corporation 

The Generalizability of Phase III Cancer Clinical Trial Standard Arm Treatment Outcomes - Joseph M. 

Unger, M.S., SWOG Statistical Center 

Prevention Committee, 3:15 p.m. - 5:15 p.m. - Regency C 

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Prevention 

Committee - Leonard Sender, M.D., Division Chief, Pediatric Oncology, University of California, Irvine 

Molecular Epidemiology Committee, 5:30 p.m. - 7:30 p.m. - Regency C 

Supplement Use During an Intergroup Clinical Trial for Breast Cancer (S0221) - Gary Zirpoli, M.A., 

Roswell Park Cancer Institute and the University of Buffalo 

Friday, October 19, 2012 

Cancer Survivorship Committee, 7:15 a.m. - 9:45 a.m. - Comiskey 

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Cancer 

Survivorship Committee - Leonard Sender, M.D., Division Chief, Pediatric Oncology, University of California, 

Irvine 

Use of Social Media to Recruit into SWOG Studies - Lisa Sparks, Ph.D., Chapman University, University of 

California, Irvine 

Left Ventricular Strain and Serum Troponin to Predict Cardiac Toxicity from Trastuzumab and 

Anthracyclines - Monika Leja, M.D., Division of Cardiovascular Medicine, University of Michigan 

Melanoma Committee, 7:30 a.m. - 9:30 a.m. - Crystal A Ballroom 

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Melanoma 


Discussion on the Imaging Initiative - Kenneth F. Grossmann, M.D., Ph.D., University of Utah 

Harry E. Hynes CCOP Symposium, 10:00 a.m. - 12:00 p.m. - Regency A 

What is Integrative Oncology - Heather Greenlee, N.D., Ph.D., Columbia University Medical Center 

Comparative Effectiveness Research: What is it all about - Scott Ramsey, M.D., Ph.D., Fred Hutchinson 

Cancer Research Center 



Roster of Committee Speakers 

Surgery Committee, 10:00 a.m. - 12:00 p.m. - Acapulco 

Update: New Agents for Melanoma - Lawrence Flaherty, M.D., Professor, Department of Hematology- 

Oncology, Karmanos Cancer Institute, Wayne State University 

Update: S0820, “A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent 

Recurrence of Colorectal Cancers and Adenomas in Patients with Stage I-III Colon Cancer, Phase III” 

- Jason Zell, D.O., M.P.H., Assistant Professor, Division of Hematology/Oncology, Departments of Medicine & 

Epidemiology, University of California, Irvine 

Surgical Quality Overview - Lisa Flynn, M.D., Assistant Professor of Surgery, Director, Surgical ICU Harper 

Hospital, Wayne State University School of Medicine 

Breast Committee, 3:00 p.m. - 7:00 p.m. - Crystal B Ballroom 

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Breast 


SWOG Contributions to Pharmacogenomics - Christine Ambrosone, Ph.D., Professor of Oncology, Chair, 

Department of Cancer Control and Prevention, Roswell Park Cancer Institute 

Leukemia Committee, 3:00 p.m. - 7:00 p.m. - Crystal C Ballroom 

From Genetic to Genomic Testing for Myeloid Malignancy - Aly Karsan, M.D., F.R.C.P.C., Integrative 

Oncology-Radiation Biology Unit, BC Cancer Agency 

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Leukemia 


Saturday, October 20, 2012 

Lung Committee, 11:30 a.m. - 3:30 p.m. - Regency B 

Optimal Therapy for EGFR Mutant NSCLC: Role of Monoclonal Antibodies and Dual Kinase Inhibitors in 

Overcoming Resistance - Thomas Lynch, Jr., M.D., Yale Cancer Center, Yale University 

MEK Inhibition in the Therapy of KRAS Mutant NSCLC - Shirish Gadgeel, M.D., Karmanos Cancer Institute, 

Wayne State University 



SWOG ADMINISTRATIVE COMMITTEES 

Board of Governors 

Chair: Laurence H. Baker, D.O. 

Bone Marrow and Stem Cell Transplantation Committee 

Chair: Stephen J. Forman, M.D. 

Clinical Practices Committee 

Chair: Saul E. Rivkin, M.D. 

Conflict of Interest Committee 

Chair: Vernon K. Sondak, M.D. 

Membership Committee 

Chair: James K. Weick, M.D. 

Pharmaceutical Sciences Committee 

Chair: Siu-Fun Wong, Pharm.D. 

Professional Review Committee 

Chair: Primo N. Lara, Jr., M.D. 

Oncology Research Professionals Committee 

Chair: Rose B. Ermete, R.N., B.S.N. 

Quality Assurance Committee 

Chair: Manuel Valdivieso, M.D. 

Radiation Therapy Committee 

Chair: Paul Okunieff, M.D. 

Surgery Committee 

Chair: George H. Yoo, M.D. 



Your donation 

gives hope. 

We invest because your work is invaluable to 

SWOG and to our common mission of preventing 

and treating cancer. 

All investors will be entered to win up to $10,000 in outstanding 

prizes at the SWOG Reception on Friday, October 19 at 6:45 pm, 

Regency Ballroom C, The Hyatt Regency Chicago. 

Entries must be received by 12:00 pm on October 19, 2012. 

Entrants must be present to win. 

The Hope Foundation, a nonprofit organization, is the philanthropic 

arm of SWOG, and accepts investments from individuals, corporations 

and foundations. In support of SWOG’s mission to eradicate cancer, 

90% of all contributions are directly invested in programming. 

Hope Foundation Information Desk: Foyer, East Tower Concourse, Thursday - Saturday 

Johanna (Jo) Horn, Executive Director | jo@thehopefoundation.org | 734-998-7150 | www.thehopefoundation.org 



Jeri and Noboru Oishi Symposium 

Thursday, October 18, 2012 - 7:45 a.m. - 12:30 p.m. 

Location: Regency AB (Gold Level, West Tower) 

Topic: Consent: More Than Just a Piece of Paper 

Special Symposia 

Featured Speakers: 

• Ethic/Legal Issues of Consent - Michael Roach, J.D. 

• AccrualNet/Recruitment of Underserved Populations - Linda Parreco, R.N., M.S. 

• Communication of Consent/Research - Terry Albrecht, Ph.D. 

• Explain Consent Template Changes - Jeanne Alder, R.N., M.P.H., C.C.R.P. 

• Trials and Tribulation of a Trial Candidate - Susan Steel, B.A. 

This activity has been submitted to the Oncology Nursing Society for approval to award contact hours. ONS is accredited as an approver 

of continuing nursing education by the American Nurses Credentialing Center’s COA. 

Certificates for continuing education credits (CEUs) will be distributed to attendees upon completion and return of their evaluation 

sheets. Certificates of attendance will be given for Society of Clinical Research Associates. 

Clinical Research Associates Open Forum 

Thursday, October 18, 2012 - 12:30 p.m. - 2:00 p.m. 

Location: Regency D (Gold Level, West Tower) 

Topic: This forum offers an opportunity to get answers to your clinical trial questions and address the science and technical 

research issues that challenge us today. 

Featured Topics: 

• Quality Assurance Audits 

• CTCAE/SAE Reporting 

• The Wild World of Regulatory Affairs 

• Data Management Tips & Tools for CRAs 

• Cancer Treatment Modalities 

• Specimen Preparation and Shipment 

• SWOG Federal & CTI Non-Federal Reimbursement 

• Hot Topics in CRA Site Administration 



CRA Continuing Education Workshop 

Friday, October 19, 2012 - 8:00 a.m. - 11:30 a.m. 

Location: Crystal B Ballroom (Green Level, West Tower) 

Title: Lung Cancer 

Special Symposia 

Featured Speakers: 

• Lung Cancer Staging - Jared Acoba, M.D. 

• Lung Cancer Translational Medicine - Philip C. Mack, Ph.D. 

• New Lung Cancer Trials - David R. Gandara, M.D. 

• Roadblocks to Enrollment - Annette Betley, B.S. 

• Drug and Skin Toxicities - Siu-Fun Wong, Pharm.D., F.A.S.H.P., F.C.S.H.P. 

• Helping Patients Transition to Survivorship - Amita Patel, M.D., C.M.D., M.H.A., C.P.E. 

• SWOG Update - Jackie Benedetti, Ph.D. 



Membership Accrual by Institution 

All Credited Registrations* (Excluding Correlatives) 

July 1, 2011 - June 30, 2012 

SWOG Treatment 

SWOG Endorsed/ 

non-SWOG Intergroup 

Cancer Control & 

Prevention** 

MEMBERS/AFFILIATES 

Arizona, U of (3009) 16 15 0 31 

Arkansas, U of (101) 7 21 0 28 

Highlands Onc Group (10885) 0 0 2 2 

MD Anderson, Florida (10955) 7 3 0 10 

Mercy Hosp Ft Smith (8262) 0 1 0 1 

NEA Baptist Clinic (17124) 1 2 0 3 

NEA Baptist Mem Hosp (11728) 2 0 1 3 

Sacred Heart Med Onc (10549) 6 0 9 15 

BC Cancer Agency (14112) 9 6 0 15 

Baylor College (11988) 21 5 0 26 

Baylor Univ Med Ctr (14205) 0 6 0 6 

Brooke Army Med Ctr (10330) 0 1 0 1 

Madigan Army Med Ctr (11460) 15 3 0 18 

S Georgia Med Ctr (10807) 2 7 0 9 

Cedars-Sinai Med Ctr (14111) 31 2 0 33 

Cincinnati MC, U of (10509) 2 4 8 14 

Central Baptist Hosp (11292) 0 0 2 2 

Good Samaritan Hosp (11488) 10 0 0 10 

City of Hope Med Ctr (10082) 35 8 13 56 

Cleveland Clinic OH (301) 42 35 0 77 

Akron Gen Med Ctr (8217) 0 8 7 15 

Mansfield Gen Hosp (10934) 3 1 0 4 

Colorado, U of (10120) 45 31 0 76 

Mem Hosp, Co Springs (10436) 3 4 6 13 

Poudre Valley Hosp (11190) 2 7 11 20 

Columbia University (10769) 0 16 8 24 

Nyack Hospital (11412) 2 1 0 3 

Orange Reg Med Ctr (10889) 2 1 3 6 

St Luke's-Roosevelt (10892) 4 7 0 11 

Valley Hospital (10926) 1 3 0 4 

Winthrop - Univ Hosp (11492) 2 3 0 5 

Davis, U of CA (10176) 53 32 9 94 

California Ca Ctr (10733) 4 0 0 4 

John Muir Med Ctr (10323) 0 1 0 1 

Loma Linda Univ (10682) 10 0 0 10 

NorthBay Med Ctr (10180) 0 0 2 2 

*Registrations used for membership credit. All SWOG studies (excluding correlatives) and SWOG Endorsed registrations count toward SWOG minimum accrual requirements. 

**Includes S0702 and S1105. 

Total 










Prevention** 

Sierra Nevada Mem (10890) 0 0 1 1 

St Elizabeth's MC (11173) 4 7 1 12 

Sutter Hlth CRG-East (10712) 13 0 0 13 

Sutter Hlth Western (10714) 0 10 0 10 

Fox Chase Cancer Ctr (13926) 1 0 0 1 

Galveston, U of TX (601) 1 2 5 8 

H Lee Moffitt CC (11898) 15 21 30 66 

Broward Gen Med Ctr (11938) 0 0 9 9 

Leesburg Reg Med Ctr (14513) 0 0 2 2 

Martin Memorial CC (11941) 1 0 0 1 

Space Coast Med Asso (11930) 0 0 16 16 

St Joseph's/Candler (11980) 3 1 0 4 

Watson Clinic Center (11935) 0 8 0 8 

Harrington CC (11446) 2 5 12 19 

Henry Ford Hosp (501) 17 3 4 24 

Breslin Cancer Ctr (10415) 7 0 5 12 

Irvine, U of CA (10498) 9 5 0 14 

Long Beach Mem MC (10617) 6 0 0 6 

Northridge Hosp (11580) 1 0 0 1 

Presbyterian Hosp (11524) 0 2 0 2 

St Jude Medical Ctr (11553) 2 1 0 3 

KaiserPermanenteNCAL (13655) 11 117 0 128 

KaiserPermanenteCOL (15184) 4 7 0 11 

KaiserPermanenteSCAL (15468) 17 58 0 75 

Kansas, U of (3004) 33 30 1 64 


Stormont-Vail Health (10496) 4 1 6 11 

Kentucky, U of (10012) 36 15 0 51 

Lahey Clinic Med Ctr (16037) 6 8 5 19 

Loyola University (10080) 39 16 39 94 

Edward Hospital (12848) 4 2 1 7 

Hem-Onc Consultants (10616) 0 1 0 1 

Quad Cities/Genesis (10424) 0 1 0 1 

MD Anderson (11439) 80 1 0 81 

MUSC, Hollings CC (11421) 13 8 2 23 

Lexington Med Ctr (12448) 2 0 0 2 

Methodist Hospital (15225) 1 0 1 2 



Total 










Prevention** 

Michigan, U of (4700) 54 31 2 87 

Mississippi, Univ of (3012) 5 2 6 13 

NE Alabama Reg MC (12075) 0 1 0 1 

NE Georgia Med Ctr (11339) 3 8 9 20 

Singing River Hosp (12057) 5 4 5 14 

St Joseph Hospital (11546) 0 3 3 6 

Oregon Hlth Sci Univ (4100) 17 9 0 26 

Asante-Rogue Med Ctr (8290) 2 1 6 9 


Mid-Columbia Med Ctr (15175) 0 2 0 2 

Salem Hospital (8167) 2 1 0 3 

Providence Hosp (3500) 8 6 7 21 

Puget Sound (3007) 19 18 3 40 

Bay Area Hospital (11340) 5 0 6 11 

Columbia Basin Hem (12626) 1 0 4 5 

Harrison Bremerton (11548) 2 2 10 14 

Highline Cancer Ctr (16249) 0 1 0 1 

Minor & James Med (12135) 0 0 1 1 

Rockwood Clinic, PS (11435) 4 0 0 4 

Skagit Valley Hosp (10666) 2 2 2 6 

St Charles Hlth Sys (10359) 7 2 1 10 

St Joseph Hospital (10023) 4 2 0 6 

St Mary Med Ctr (11450) 0 5 0 5 

Wenatchee Valley (8214) 1 0 2 3 

Yakima Valley Mem (10620) 1 0 0 1 

Rochester, Univ of (11400) 61 21 0 82 

Arnot Ogden Med Ctr (13424) 1 0 8 9 

San Antonio, U of TX (2400) 56 9 6 71 

Carolinas Med Ctr (17374) 0 1 0 1 

SW Cancer & Res Ctr (8215) 5 0 0 5 

Sinai Hospital (11184) 12 4 0 16 

TX Oncology-Central (15251) 10 0 0 10 

Thompson Ca Surv Ctr (10427) 2 8 0 10 

So Calif, U of (10138) 40 26 1 67 

Desert Hospital (11205) 4 10 0 14 

St Joseph Med Ctr (10283) 3 3 0 6 

St Louis University (10357) 4 3 5 12 



Total 










Prevention** 

Christian Hosp NE/NW (11878) 0 0 1 1 

Stanford University (12661) 10 5 0 15 

Tennessee, U of (11441) 6 8 0 14 

Cookeville Reg MC (13433) 2 0 1 3 

Tulane University (1801) 3 1 0 4 

Baton Rouge Clinic (15717) 2 1 0 3 

Univ of Chicago MC (13924) 1 0 0 1 

Univ of Chicago MC (15493) 1 0 0 1 

Univ of Maryland (15076) 1 0 0 1 

Utah, U of (2501) 19 34 27 80 

McKay-Dee Hospital (8082) 0 0 11 11 

St Luke's Mt State (8081) 6 6 0 12 

Utah Valley Reg Med (8315) 3 0 3 6 

Wayne State Univ (2701) 37 16 0 53 

MidMichigan Med Ctr (11812) 1 3 0 4 

Mt Clemens Reg MC (10058) 1 0 1 2 

N Michigan Reg Hosp (10697) 1 0 0 1 

Univ of Louisville (11293) 3 0 0 3 

Yale University (17377) 4 1 0 5 

Member & Affiliate Total 1112 834 359 2305 

CCOPS/MBCCOPS 

Atlanta Reg CCOP (10225) 22 14 13 49 

Bay Area CCOP (10706) 4 6 4 14 

Beaumont CCOP (11434) 7 19 5 31 

Boston MC MBCCOP (16686) 2 2 0 4 

Central IL CCOP (10211) 50 35 53 138 

Columbia River CCOP (10251) 6 3 16 25 

Columbus CCOP (9005) 27 4 5 36 

Dayton CCOP (9006) 26 3 16 45 

Grand Rapids CCOP (9007) 15 5 7 27 

Greenville CCOP (10879) 18 6 5 29 

Gulf Coast MBCCOP (11370) 3 1 5 9 

Hawaii MBCCOP, U of (10781) 17 16 5 38 

Kansas City CCOP (9010) 23 10 12 45 

LSU-New Orleans CCOP (10816) 3 6 0 9 

LSU-Shreveport CCOP (13521) 13 3 19 35 

Michigan CRC CCOP (11110) 72 0 16 88 



Total 










Prevention** 

Montana CCOP (10891) 20 4 9 33 

New Mexico MBCCOP (11331) 27 9 4 40 

Northwest CCOP (9016) 17 26 18 61 

Ozarks Reg CCOP (10210) 18 9 2 29 

Scott & White CCOP (10940) 1 2 11 14 

Southeast CCC CCOP (11108) 55 8 21 84 

Southern Nevada CCOP (13500) 17 0 0 17 

St Louis CCOP (9015) 11 17 23 51 

Upstate Carolina (10122) 13 9 4 26 

Virginia Mason CCOP (9011) 13 11 18 42 

Wichita CCOP (9017) 26 20 26 72 

CCOP/MBCCOP Total 526 248 317 1091 

UCOPS 

Baylor College-UCOP (10310) 2 0 0 2 

Henry Ford-UCOP (10703) 7 0 0 7 

LSU-Shreveport UCOP (10704) 4 0 0 4 

Loyola Univ - UCOP (10298) 3 0 0 3 

Michigan, U of-UCOP (11386) 7 0 0 7 

Oklahoma, U of-UCOP (10788) 14 0 0 14 

PSOC UCOP (10300) 8 0 0 8 

So Calif, U of-UCOP (10312) 1 0 0 1 

Urology Ctr of CO (13800) 13 0 0 13 

Utah, U of - UCOP (10313) 25 0 0 25 

UCOP Total 84 0 0 84 

FOREIGN 

INCan (15434) 10 0 32 42 

King Faisal Spec Hos (13697) 0 0 15 15 

National Cancer Ctr (15484) 6 0 0 6 

Foreign Total 16 0 47 63 

Other Groups 

ACOSOG 16 0 0 16 

AMC 3 0 0 3 

CALGB 254 0 40 294 

ECOG 393 0 63 456 

GOG 3 0 0 3 

NCCTG 185 0 67 252 

NCIC 4 0 0 4 



Total 










Prevention** 

NCIC-CTG 22 0 0 22 

NSABP 60 0 2 62 

RTOG 18 0 0 18 

Other Groups Total 958 0 172 1130 

Grand Total 2696 1082 895 4673 



Total 



Membership Accrual by Institution and Committee 



Total 

Breast 

Cancer Survivorship 

GU 

Early Therapeutics 

GI 

Arizona, U of 31 10 - - - - - - 4 10 5 2 - - - 

Arkansas, U of 62 10 - - 10 10 - 3 1 3 13 - - - 12 

Atlanta Reg CCOP 49 22 - - 1 7 - - 5 - - 1 - - 13 

BC Cancer Agency 15 6 - - 3 6 - - - - - - - - - 

Bay Area CCOP 14 9 - - - - - - 1 - - - - - 4 

Baylor College 26 - - - 5 12 - 5 3 - - 1 - - - 

Baylor College-UCOP 2 - - - - 2 - - - - - - - - - 

Baylor Univ Med Ctr 6 - - - - - - - - - 6 - - - - 

Beaumont CCOP 31 21 - - - 4 - - - - 1 - - - 5 

Boston MC MBCCOP 4 - - - 3 - - - - 1 - - - - - 

Brooke Army Med Ctr 28 9 - - 1 16 - - - 2 - - - - - 

Cedars-Sinai Med Ctr 33 1 - - 23 9 - - - - - - - - - 

Central IL CCOP 138 39 - - 13 9 - 1 15 3 - 5 - - 53 

Cincinnati MC, U of 26 6 - - 5 - - - 3 - 2 - - - 10 

City of Hope Med Ctr 56 10 - - 1 15 - 6 2 9 - - - 3 10 

Cleveland Clinic OH 96 46 - - 5 17 - 6 - 4 - 11 - - 7 

Colorado, U of 109 22 - - 11 29 1 3 17 - 8 1 - - 17 

Columbia River CCOP 25 4 - - 3 - - 2 - - - - - - 16 

Columbia University 53 27 - - 3 4 - - 3 2 2 1 2 1 8 

Columbus CCOP 36 24 - - 3 - - 1 2 - 1 - 1 - 4 

Davis, U of CA 147 33 - - 8 45 - 7 27 8 5 1 - - 13 

Dayton CCOP 45 7 - - 4 7 - - 7 2 1 1 - - 16 

Fox Chase Cancer Ctr 1 - - - - - 1 - - - - - - - - 

Galveston, U of TX 8 - - - 2 1 - - - - - - - - 5 

Grand Rapids CCOP 27 4 - - 3 3 - - 8 - 2 - - - 7 

Greenville CCOP 29 6 - - - - - 2 13 - 1 2 3 - 2 

Gulf Coast MBCCOP 9 1 - - 1 2 - - - - - - - - 5 

H Lee Moffitt CC 106 11 - - 3 6 - 7 5 - 10 7 - - 57 

Harrington CC 19 4 - - 1 - - - 1 1 - - - - 12 

Hawaii MBCCOP, U of 38 19 - - 4 - - 1 2 4 1 2 - - 5 

Henry Ford Hosp 43 14 - 3 - 10 - - 6 1 - - - - 9 

INCan 42 9 - - - - - - 1 - - - - - 32 

Irvine, U of CA 26 6 - - 7 1 - 2 7 - 1 2 - - - 

KaiserPermanenteNCAL 214 159 - - 37 1 - 3 8 2 1 3 - - - 

Kansas City CCOP 45 17 - - 1 1 - 2 7 3 - 2 - - 12 

Kansas, U of 78 11 - - 22 12 - 2 21 1 1 - 1 - 7 

Kentucky, U of 51 8 - - 2 9 - 13 13 5 - 1 - - - 

King Faisal Spec Hos 15 - - - - - - - - - - - - - 15 

LSU-New Orleans CCOP 9 - - - 3 1 - - 1 3 - 1 - - - 

LSU-Shreveport CCOP 39 6 - - 1 8 - - 1 1 1 2 - - 19 

Lahey Clinic Med Ctr 19 3 - - - - - 1 6 - 4 - - 5 - 

Loyola University 106 17 1 - 6 19 - 13 6 4 1 - - - 39 

MD Anderson 81 40 - - 5 14 2 3 16 1 - - - - - 

MUSC, Hollings CC 25 9 - - 1 3 - 7 1 2 - - - - 2 

Methodist Hospital 2 1 - - - - - - - - - - - - 1 

Michigan CRC CCOP 88 40 - - 4 7 - - 15 3 - 3 - - 16 

GYN 

Leukemia 

Lung 

Lymphoma 

Melanoma 

Myeloma 

Outcomes 

Prevention 

Symptom Control & QOL 

*Registrations used for membership credit. Affiliate Accrual Reported with Main Member Institution. 



Membership Accrual by Institution and Committee 



Total 

Breast 

Cancer Survivorship 

GU 

Early Therapeutics 

GI 

Michigan, U of 87 38 - - 5 28 - 3 4 5 2 - - - 2 

Michigan, U of-UCOP 7 - - - - 7 - - - - - - - - - 

Mississippi, Univ of 54 18 - - 1 1 1 2 5 2 1 - - - 23 

Montana CCOP 33 9 - - 3 3 - 1 1 1 1 5 - - 9 

National Cancer Ctr 6 6 - - - - - - - - - - - - - 

New Mexico MBCCOP 40 31 - - 2 - - 1 - - - 2 - - 4 

Northwest CCOP 61 31 - - 2 - - - 10 - - - - - 18 

Oklahoma, U of-UCOP 14 - - - - 14 - - - - - - - - - 

Oregon Hlth Sci Univ 56 12 - - 7 17 - - 3 2 3 - - - 12 

Ozarks Reg CCOP 29 10 - - 10 2 1 - 1 - 3 - 1 - 1 

Providence Hosp 21 3 - - 2 - - - 5 - - 4 - - 7 

Puget Sound 115 27 - - 8 24 2 5 5 10 5 - - - 29 

Rochester, Univ of 91 6 - - 5 13 - 18 3 34 2 2 - - 8 

San Antonio, U of TX 113 27 - 2 2 46 - 2 20 - 6 2 - - 6 

Scott & White CCOP 14 - - - 2 1 - - - - - - - - 11 

So Calif, U of 88 36 - 1 24 12 - - 12 1 - 1 - - 1 

Southeast CCC CCOP 84 15 - - 9 10 - 1 14 2 5 7 - - 21 

Southern Nevada CCOP 17 1 - - - 8 - - 5 - - 3 - - - 

St Louis CCOP 51 11 - - - 6 - 2 5 - 2 2 - 1 22 

St Louis University 13 1 - - 1 2 - 1 - 2 - - - - 6 

Stanford University 15 - - - - - - 15 - - - - - - - 

Tennessee, U of 17 9 - - 3 1 - 1 2 - - - - - 1 

Tulane University 7 5 - - 1 - - - 1 - - - - - - 

Univ of Chicago MC 2 - - - - - 1 - - - 1 - - - - 

Univ of Maryland 1 - - - - - 1 - - - - - - - - 

Upstate Carolina 26 12 - - 2 - - - 5 1 1 1 - - 4 

Urology Ctr of CO 13 - - - - 13 - - - - - - - - - 

Utah, U of 134 35 - - 2 39 - 1 11 - 4 1 - 2 39 

Virginia Mason CCOP 42 12 - - - 10 - - 2 - - - - - 18 

Wayne State Univ 63 27 - - 6 13 - 3 9 1 2 1 - - 1 

Wichita CCOP 72 16 - - 9 5 3 3 3 5 1 1 - - 26 

Yale University 5 2 - - 1 - - - 2 - - - - - - 

SWOG Total 3,543 1,091 1 6 312 565 13 149 356 141 106 81 8 12 702 

ACOSOG 16 11 - - 1 - - - 4 - - - - - - 

AMC 3 - - - - - - - - 3 - - - - - 

CALGB 294 102 - - 14 32 - 23 28 52 - 3 - - 40 

ECOG 456 185 - - 16 52 - 11 43 48 - 38 - - 63 

GOG 3 3 - - - - - - - - - - - - - 

NCCTG 252 116 - - 12 15 - - 33 5 - 4 - - 67 

NCIC 4 4 - - - - - - - - - - - - - 

NCIC-CTG 22 22 - - - - - - - - - - - - - 

NSABP 62 54 - - 1 2 - - 2 1 - - - - 2 

RTOG 18 10 - - 5 - - - 2 - - 1 - - - 

Other Group Total 1,130 507 - - 49 101 - 34 112 109 - 46 - - 172 

Grand Total 4,673 1,598 1 6 361 666 13 183 468 250 106 127 8 12 874 

GYN 

Leukemia 

*Registrations used for membership credit. Affiliate Accrual Reported with Main Member Institution. 

Lung 

Lymphoma 

Melanoma 

Myeloma 

Outcomes 

Prevention 

Symptom Control & QOL 



BARLOGIE-SALMON MYELOMA COMMITTEE 

Committee Leadership 

Chair: 

Vice-Chair: 

Executive Officer: 

Statisticians: 

Scientific Leadership 

Translational Medicine: 

Radiation: 

Surgery: 

Pathology: 

Early Therapeutics: 

Designates 

Clinical Research Associates: 

CCOP Representative: 

Data Coordinators: 

Nurses: 

Patient Advocate: 

Pharmaceutical Science: 

Protocol Coordinator: 


Room: Plaza Ballroom 

7:30 a.m. – 9:30 a.m. 

Presentations 

Time/Location 

Agenda 

Robert Z. Orlowski, M.D., Ph.D. 

Brian G.M. Durie, M.D. 

Harry P. Erba, M.D., Ph.D. 

Antje Hoering, Ph.D. 

Rachael Sexton, M.S. 

Joshua Epstein, D.Sc. 

Srinivasan Vijayakumar, M.D. 

J. Sybil Biermann, M.D. 

Robert B. Lorsbach, M.D., Ph.D. 

Frits van Rhee, M.D., Ph.D. 

Ellen Chase, B.S. 

James D. Bearden, III, M.D. 

Jeri Jardine 

Laura Kingsbury 

Tracy Maher, C.C.R.P. 

Steven M. Burt, R.N. 

Deborah A. Halk, R.N. 

Byron Lee 

Lara M. Au, Pharm.D. 

Holly O. Chan, Pharm.D. 

Sandi Fredette 

Active Studies 

■■ 

S0702, “A Prospective Observational Multicenter Cohort Study 

to Assess The Incidence of Osteonecrosis of the Jaw (ONJ) in 

Cancer Patients with Bone Metastases Starting Zoledronic Acid 

Treatment.” Dr. Van Poznak. Activated: 12/15/08. 

■■ 

■■ 

CTSU/CTN0702, “A Trial of Single Autologous Transplant with 

or without Consolidation Therapy versus Tandem Autologous 

Transplant with Lenalidomide Maintenance for Patients with 

Multiple Myeloma.” Dr. Van Rhee. Activated: 3/15/10. 

CTSU/E3A06, Genomic and Immunology Studies for E3A06, 

“Randomized Phase III Trial of Lenalidomide versus Observation 

Alone in Patients with Asymptomatic Smoldering Multiple 

Myeloma.” Dr. Dhodapkar. Activated: 2/1/11. 

Closed Studies 

■■ 

S0777, “A Randomized Phase III Trial of CC-5013 (Lenalidomide, 

NSC-703813) and Low Dose Dexamethasone (LLD) versus 

Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose 

Dexamethasone (BLLD) for Induction, in Patients with Previously 

Untreated Multiple Myeloma without an Intent for Immediate 

Autologous Stem Cell Transplant.” Dr. Durie. Activated: 

2/28/08; Closed: 2/1/12. 

■■ 

■■ 

S0833, “Total Therapy 3 (TT3) for Newly Diagnosed Patients 

with Multiple Myeloma (MM): A Southwest Oncology Group Trial 

for Patients Aged < 65 Years.” Dr. Abidi. Activated: 4/1/11; 

Closed: 5/1/12. 

CTSU/E4A08, “A Randomized Phase III Trial of Melphalan and 

Dexamethasone (MDex) versus Bortezomib, Melphalan and 

Dexamethasone (BMDex) for Untreated Patients with Systemic 

Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell 

Transplantation.” Dr. Zonder. Activated: 12/15/10; Closed: 

9/7/12. 

Proposed Studies 

■■ 

S1211, “A Phase II Study of Optimal Induction Therapy for 

Newly Diagnosed High Risk Multiple Myeloma (HRMM).” Dr. 

Usmani. 

■■ 

■■ 

S1224, “A Phase I/II Study to Evaluate the Safety and Efficacy 

of MK-1775 (NSC-XXXX) (Wee1 Kinase Inhibitor) in Combination 

with Bortezomib and Pegylated Liposomal Doxorubicin in 

Patients with Relapsed and/or Refractory Multiple Myeloma and 

Defined p53 Status.” Dr. Abidi. 

S1304, “A Phase II Randomized Study Comparing Two Doses 

of Carfilzomib (NSC-XXXX) with Dexamethasone for Multiple 

Myeloma Patients with Relapsed or Refractory Disease.” Dr. 

Ailawadhi. 

■■ 

SXXXX, “Phase III Study of Lenalidomide vs. Lenalidomide + 

MLN9708 as Maintenance Therapy Post-Autologous Stem Cell 

Transplant in Patients with Multiple Myeloma.” Dr. Shah. 

Working Groups 

Amyloidosis Working Group update 

Waldenström’s Working Group update 

Myeloma Translational Medicine Subcommittee update 



BARLOGIE-SALMON MYELOMA COMMITTEE 

Publications 

The publications below are those that have been received in 

published, submitted or accepted form by the Group Chair‘s Office 

since the Spring 2012 meeting agenda booklet publication list. 

Published/Accepted Manuscripts 

■■ 

Cure models as a useful statistical tool for analyzing survival. 

M Othus, B Barlogie, ML LeBlanc, JJ Crowley. Clinical Cancer 

Research 18(14):3731-3736, 2012. http://www.ncbi.nlm.nih. 

gov/pubmed/22675175. 

Submitted Manuscripts 

■■ 

S0120 Clinical predictors of malignancy in monoclonal 

gammopathies (SWOG S0120). M Dhodapkar, R Sexton, S 

Waheed, S Usmani, B Nair, N Petty, JD Shaughnessy, A Hoering, 

J Crowley, R Orlowski, B Barlogie. Blood, submitted 8/16/12. 



Barlogie-Salmon Myeloma Committee 

Cumulative Accrual by Institution and Study 

For the Period Ending September 6, 2012 

CTN0702 

E3A06 

S0115 

S0120 

Arizona, U of - - - - 2 

Arkansas, U of - - 22 292 2 

Atlanta Reg CCOP - - - - 1 

Baylor College - - - - 15 

Boston MC MBCCOP - - - - 1 

Boston Univ Med Ctr - - 17 - - 

Brooke Army Med Ctr - - - 12 - 

Central IL CCOP - - - - 8 

City of Hope Med Ctr - - 1 - - 

Cleveland Clinic OH - - 8 2 20 

Colorado, U of - - - - 6 

Columbia River CCOP - - 1 - 3 

Columbia University - - - 2 6 

Davis, U of CA - - 7 2 1 

Dayton CCOP - - 1 - 6 

Grand Rapids CCOP - - - - 2 

Greenville CCOP - 6 - - - 

H Lee Moffitt CC 7 - - - 4 

Harrington CC - - - - 1 

Hawaii MBCCOP, U of - - - - 13 

Henry Ford Hosp - - 3 18 - 

Irvine, U of CA - - - - 6 

KaiserPermanenteNCAL - - - - 13 

Kansas City CCOP - - - 4 6 

Kansas, U of - - 2 15 3 

Kentucky, U of 1 - - - - 

King Faisal Spec Hos - - - - 1 

LSU-New Orleans CCOP - - - - 1 

LSU-Shreveport CCOP 4 - - - - 

Loyola University - - - 9 2 

MD Anderson - - - - 4 

Michigan CRC CCOP - - - - 19 

Michigan, U of - - - 2 - 

Mississippi, Univ of - - - - 2 

Montana CCOP - 1 - - 6 

New Mexico MBCCOP - - - - 7 

Oregon Hlth Sci Univ - - 1 - 1 

S0777 



Barlogie-Salmon Myeloma Committee 



CTN0702 

E3A06 

S0115 

S0120 

Providence Hosp - - - - 6 

Puget Sound - - 9 2 - 

Rochester, Univ of - - - 1 13 

San Antonio, U of TX 2 - 2 - 8 

So Calif, U of - - - 3 7 

Southeast CCC CCOP - - - - 34 

Southern Nevada CCOP - - - - 12 

St Louis CCOP - - - - 7 

St Louis University - - - 7 - 

Tennessee, U of - - - - 4 

Tulane University - - 8 - - 

Upstate Carolina - - - 4 8 

Utah, U of 1 - 4 - - 

Virginia Mason CCOP - - - - 1 

Wayne State Univ - - 6 - 12 

Wichita CCOP 1 - 12 - 17 

CALGB - - - - 22 

CTSU-NOS - - - - 4 

ECOG - - - - 158 

NCCTG - - - - 45 

NSABP - - - - 3 

RTOG - - - - 2 

Total 16 7 104 375 525 

Note: Some studies may not be listed because they were either closed prior to July 1, 2011 or because they are currently 

active but have not had any accrual through September 6, 2012. 

S0777 


BREAST COMMITTEE 



Chair: 

Vice-Chair: 





Radiation Oncology: 

Surgery: 

Pathology: 


Designates 


Cancer Control Liaisons: 



Nurses: 





Room: Crystal B Ballroom 

3:00 p.m. – 7:00 p.m. 

Gabriel N. Hortobagyi, M.D. 

Julie R. Gralow, M.D. 

Anne F. Schott, M.D. 

William E. Barlow, Ph.D. 

Danika Lew, M.A. 

Daniel F. Hayes, M.D. 

TBD 

Christine Lee, M.D. 

Allen M. Gown, M.D. 

Peggy L. Porter, M.D. 

Francisco J. Esteva, M.D., Ph.D. 

Karyn N. Hart, C.C.R.P. 

Pamela A. Williams, R.N., M.S.N. 

Carol J. Fabian, M.D. (Cancer 

Survivorship) 

Dawn L. Hershman, M.D. (Health 

Disparities) 

Melanie R. Palomares, M.D. 

(Prevention) 

Helen K. Chew, M.D. (Symptom 

Control & QOL) 

David A. Decker, M.D. 

Jean Barce 

Jennie Barrett 

Jeri Jardine 

Larry Kaye 

Iris Syquia 

Dorothy Coleman, R.N., M.S. 

Kathy L. Czaplicki, R.N., M.S.N. 

Nancy Singleton 

Jessie Modlin, Pharm.D. 

Megan Hardin 

Time/Location 

Agenda 

3:00 – 3:05 p.m. Welcome and introductions - Gabriel N. 

Hortobagyi, M.D. and Julie R. Gralow, M.D. 

3:05 – 3:15 p.m. Publications update - Bill Barlow, Ph.D. 

3:15 – 3:30 p.m. How young adult research can be embedded 

into studies being developed in the SWOG 

Breast Committee - Adolescent and Young 

Adult Program - Leonard Sender 

3:30 – 3:35 p.m. Q & A 

3:35 – 4:00 p.m. Reports from Committee Liaisons 

Radiotherapy - Reshma Jagsi 

Surgery - J. Gralow/Christine Lee 

Cancer Survivorship - Carol Fabian 

Health Disparities - Dawn Hershman 

S0715 

Prevention - Dawn Hershman for Melanie 

Palomares 

CCOPs - David Decker 

4:00 – 4:35 p.m. Update of open SWOG and CTSU trials - All 

4:35 – 4:45 p.m. Studies in Development - All 

4:45 – 4:50 p.m. Request for endorsing ACOSOG Z11102 - 

Impact of Breast Conservation Surgery on 

Surgical Outcomes and Cosmesis in Patients 

with Multiple Ipsilateral Breast Cancers 

(MIBC). - Gabriel Hortobagyi for Judy 

Boughey 

Translational Medicine Sub-Committee 

Mini-Symposium 

Pharmacogenomics and Breast Cancer: A Decade Later. 

What Have We Learned What Should SWOG Do Next 

4:50 – 4:55 p.m. Introduction - Dan Hayes 

4:55 – 5:15 p.m. SWOG contributions to Pharmacogenomics - 

Christine Ambrosone 

5:15 – 5:20 p.m. CYP2D6 Story - Jimmy Rae 

5:20 – 5:30 p.m. Prospective validation trials in SWOG 

5:30 – 5:35 p.m. Q & A 

5:35 – 7:00 p.m. Translational Medicine Working Group Up 

dates - Daniel F. Hayes 

TM Studies within S0307 - Julie Gralow 

Active Adjuvant Studies 

■■ 

S1007, “A Phase III, Randomized Clinical Trial of Standard 

Adjuvant Endocrine Therapy +/- Chemotherapy in Patients 

with 1-3 Positive Nodes, Hormone-Receptor-Positive and HER2- 

Negative Breast Cancer with Recurrence Score (RS) of 25 or 

Less.” Drs. Gonzalez-Angulo, Meric-Bernstam, Hortobagyi, Albain 

and Barlow. Activated: 1/15/11. 

■■ 

S1207, “Phase III Randomized, Placebo-Controlled Clinical 

Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- 




■■ 

One Year of Everolimus in Patients with High-Risk, Hormone 

Receptor-Positive and HER2/neu Negative Breast Cancer.” Drs. 

Chavez-MacGregor, Gonzalez-Angulo. Planned Activation Date: 

11/15/12. 

CTSU/NSABP B-39, “A Randomized Phase III Study of 

Conventional Whole Breast Irradiation (WBI) Versus Partial 

Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast 

Cancer.” Dr. Pierce. Activated: 3/22/05. 

Treated with Single Agent Tamoxifen.” Dr. Lohrisch. Activated: 

10/08/10. 

Active Cancer Control Studies 

■■ 


to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) 

in Cancer Patients with Bone Metastases Starting Zoledronic 

Acid Treatment.” Drs. Van Poznak, Gralow, Schubert, and 

Bagramian, Lisa Hansen, R.N. Activated: 12/15/08. 

■■ 

■■ 

■■ 

■■ 

CTSU/NSABP B-43, “A Phase III Clinical Trial Comparing 

Trastuzumab Given Concurrently with Radiation Therapy and 

Radiation Therapy Alone for Women with HER 2-Positive Ductal 

Carcinoma in Situ Resected by Lumpectomy.” Dr. Chung. 

Activated: 11/22/08. 

CTSU/NSABP B-47, “A Randomized Phase III Trial of Adjuvant 

Therapy Comparing Chemotherapy Alone (Six Cycles of TC or 

Four Cycles of AC followed by Four Cycles of Weekly Paclitaxel) 

to Chemotherapy Plus Trastuzumab in Women with Node- 

Positive or High-Risk Node-Negative HER2-Normal Invasive 

Breast Cancer.” Dr. Albain. Activated: 1/7/11. 

CTSU/NSABP B-49, “A Phase III Clinical Trial Comparing 

the Combination of Docetaxel Plus Cyclophosphamide to 

Anthracycline-Based Chemotherapy Regimens for Women with 

Node-Positive or High-Risk Node-Negative, HER 2-Negative 

Breast Cancer.” Dr. Decker. Activated: 4/9/12. 

CTSU/NCIC MA.32, “A Phase III Randomized Trial of Metformin 

Versus Placebo on Recurrence and Survival in Early Stage Breast 

Cancer.” Dr. Hershman. Activated: 7/8/10. 

Active Advanced Disease Studies 

■■ 

S0800, “A Randomized Phase II Trial of Weekly Nanoparticle 

Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) 

with or without Bevacizumab, either Preceded by or Followed 

by Q2 Week Doxorubicin (A) and Cyclophosphamide (C) plus 

Pegfilgrastim (PEG-G) as Neoadjuvant Therapy for Inflammatory 

and Locally Advanced HER-2/NEU Negative Breast Cancer.” Drs. 

Nahleh, Schott and Hayes. Activated: 4/1/10. 

■■ 

CTSU/E2108, “A Randomized Phase III Trial of Early Local 

Therapy for the Intact Primary Tumor in Women with Metastatic 

Breast Cancer.” Dr. Christine Lee. Activated: 2/28/11. 

■■ 

■■ 

■■ 

■■ 

S0812, “A Randomized Double-Blind Placebo-Controlled 

Biomarker Modulation Study of Vitamin D in Premenopausal 

Women at High Risk for Breast Cancer, Phase IIB.” Drs. Crew 

and Hershman. Activated: 11/01/11. 

S0927, “A Randomized Placebo-Controlled Trial of Omega- 

3-Fatty Acid for the Control of Aromatase Inhibitor-Induced 

Musculoskeletal Pain and Stiffness in Women with Early Stage 

Breast Cancer, Phase III.” Drs. Hershman, Crew and Moinpour. 


S1008, “Feasibility Study of a Physical Activity and Dietary 

Change Weight Loss Intervention in Breast and Colorectal Cancer 

Survivors Phase II.” Drs. Greenlee and Hershman. Activated: 

3/1/12. 

S1105, “Randomized Trial of Text-Messaging Intervention to 

Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor 

Therapy in Women With Early Stage Breast Cancer.” Drs. 

Neugut, Hershman and Ramsey. Activated: 3/27/12. 


■■ 

S0221, “Phase III Trial of Continuous Schedule AC + G Vs. Q 

2 Week Schedule AC, Followed by Paclitaxel Given Either Every 

2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant 

Therapy in Node-Positive or High -Risk Node-Negative Breast 

Cancer.” Drs. Budd and Moore. Activated: 11/1/03; Closed: 

1/15/12. 

■■ 

S0500, “A Randomized Phase III Trial to Test the Strategy of 

Changing Therapy Versus Maintaining Therapy for Metastatic 

Breast Cancer Patients Who Have Elevated Circulating Tumor 

Cell Levels at First Follow-Up Assessment.” Drs. Smerage 

and Hayes. Activated: 10/1/06; Closed: 3/15/12 (initial 

registration). 

■■ 

CTSU/E3108, “A Phase II Prospective Trial Correlating PFS with 

CYP2D6 Activity in Patients with Metastatic Breast Cancer 

■■ 

S0715, “A Randomized Placebo-Controlled Trial of Acetyl 

L-Carnitine (ALC) for the Prevention of Taxane Induced 




Neuropathy – Phase III.” Drs. Hershman, Albain, Gotay and Lisa 

Hansen, R.N., M.S. Activated: 9/15/09; Closed: 2/1/11. 

■ ■ 

”Omega-3 Plus Metformin for Breast Cancer Prevention.” Dr. 

Crew. 

■■ 

■■ 

■■ 

■■ 

CTSU/CALGB 40601, “Randomized Phase III Trial of Paclitaxel 

Combined With Trastuzumab, Lapatinib, or Both as Neoadjuvant 

Treatment of HER2-Positive Primary Breast Cancer.” Dr. Henry. 

Activated: 12/08/08; Closed: 2/29/12. 

CTSU/NCCTG N0733, “Randomized Phase II Trial of 

Capecitabine and Lapatinib With or Without IMC-A12 in Patients 

with HER2 Positive Breast Cancer Previously Treated with 

Trastuzumab and an Anthracycline and/or a Taxane.” Dr. Linden. 


CTSU/ACOSOG Z1071, “A Phase II Study Evaluating the Role 

of Sentinel Lymph Node Surgery and Axillary Lymph Node 

Dissection Following Preoperative Chemotherapy in Women 

with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial 

Diagnosis.” Dr. Byrd. Activated: 7/22/09; Closed: 5/29/12. 

CTSU/C40603, “Randomized Phase II 2 X 2 Factorial Trial of the 

Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly 

Paclitaxel Followed by Dose-Dense AC in Hormone Receptor- 

Poor/HER2-Negative Resectable Breast Cancer.” Dr. Somlo. 


Studies in Development 

■■ 

S1202, “Phase III Study of Duloxetine for Treatment of 

Aromatase Inhibitor-Associated Musculoskeletal Symptoms in 

Women with Early Stage Breast Cancer.” Dr. Henry. 

New Proposals 

■ ■ “Randomization to Endocrine Therapy Alone Versus Endocrine 

Therapy Plus RAD-001 in the Neoadjuvant Setting for ER+ 

Breast Cancers Based Upon On-Therapy Biologic Response.” Dr. 

Sachdev and Massarweh. 

■ ■ 

■ ■ 

■ ■ 

“Phase III Trial of Armodafinil for Chemotherapy-Associated 

Fatigue and Cognitive Dysfunction.” Dr. Chew. 

“Phase II: T-DM1 plus Pertuzumab +/- Paclitaxel in HER 

2-Positive Metastatic Breast Cancer.” Dr. Elias. 

“PI3K-targeted Therapy in Metastatic Metaplastic/Myoepithelial 

Breast cancer- Who DAT” Dr. Moulder. 

■ ■ 

■ ■ 

“A Randomized Trial of High vs. Standard Dose Vitamin D and 

Adherence with Use of Aromatase Inhibitors in the Adjuvant 

Setting.” Dr. Khan. 

“Combined Diet, Exercise and Behavioral Modification 

Intervention in Breast Cancer Survivors.” Dr. Klemp. 

Publications 

The publications listed below are those that have been received in 

published, submitted or accepted form by the Group Chair’s Office 



■■ 

S0226 Combination anastrozole and fulvestrant in metastatic 

breast cancer: SWOG S0226. R Mehta, W Barlow, K Albain, 

T Vandenberg, S Dakhil, N Tirumali, DL Lew, DF Hayes, JR 

Gralow, R Livingston, GH Hortobagyi. New England Journal of 

Medicine 367(5):435-444, 2012. http://www.ncbi.nlm.nih.gov/ 

pubmed/22853014 

■■ 

■■ 

B-34 (NSABP) Oral clodronate for adjuvant treatment of 

operable breast cancer (National Surgical Adjuvant Breast and 

Bowel Project protocol B-34: a multicenter, placebo-controlled, 

randomized trial. AH Paterson, SJ Anderson, BC Lembersky, 

L Fehrenbacher, CI Falkson, KM King, LM Weir, AM Brufsky, S 

Dakhil, T Lad, L Baez-Diaz, JR Gralow, A Robidoux, EA Perez, 

P Zheng, CE Geyer, SM Swain, JP Costantino, EP Mamounas. 

Lancet Oncology,13(7):734-742, 2012 . http://www.ncbi.nlm. 

nih.gov/pubmed/22704583 

E2197 Prognostic value of biologic subtype and the 21-gene 

recurrence score relative to local recurrence after breast 

conservation treatment with radiation for early stage breast 

carcinoma: results from the Eastern Cooperative Oncology 

Group E2197 study. L Solin , R Gray, L Goldstein, A Recht, F 

Baehner, S Shak, S Badve, EA Perez, L Shulman S Martino, NE 

Davidson, GW Sledge, J Sparano. Breast Cancer Research and 

Treatment 134(2):683-692, 2012. http://www.ncbi.nlm.nih.gov/ 

pubmedterm=solin%20l%20E2197 





■■ 

S0221 First analysis of SWOG S0221: a phase III trial 

comparing chemotherapy schedules in high-risk early breast 

cancer. GT Budd, W Barlow, HCF Moore, T Hobday, JA 

Stewart, C Isaacs, M Salim, J Cho, K Rinn, K Albain, H Chew, 

GV Burton, TD Moore, G Srkalovic, BA McGregor, LE Flaherty, 

RB Livingston, DL Lew, JR Gralow, GN Hortobagyi. Journal of 

Clinical Oncology, pending resubmission in response to reviewers’ 

comments 8/30/12. 

■■ 

■■ 

S0715 Randomized double-blind placebo-controlled trial 

of acetyl-l-carnitine for the prevention of taxane induced 

neuropathy in women undergoing adjuvant breast cancer 

therapy. D Hershman, J Unger, K Crew, L Minasian, C 

Moinpour, L Hansen, D Lew, L Fehrenbacher, J Wade, S Wong, G 

Hortobagyi, F Meyskens, K Albain. Journal of Clinical Oncology, 

re-submitted 8/12 (also listed under Symptom Control and 

Quality of Life Committee). 

MA.27 (NCIC) Exemestane versus anastrozole in postmenopausal 

women with early breast cancer. PE Goss, JN Ingle, JW 

Chapman, MJ Ellis, GW Sledge, GT Budd, DB Johnson, M 

Rabaglio, KI Pritchard, C Elliott, KA Gelmon, LE Shepherd. 

Journal of Clinical Oncology, under review, 8/12. 



Breast Committee 



B39 

B43 

B47 

C40101 

Arizona, U of - - - 20 - - 3 - - - - - - 

Arkansas, U of - - 2 10 - - - - - - - - - 

Atlanta Reg CCOP - - 4 - - - - 13 - 1 - - 14 

BC Cancer Agency - - - - - - - - - - - 6 - 

Bay Area CCOP - - - 1 - - - - - - - - 1 

Beaumont CCOP - - - 2 - - - - - - - - 12 

Boston Univ Med Ctr - - - - - - - - - - - - - 

Brooke Army Med Ctr - - - 12 - - - - - - - - 3 

Cedars-Sinai Med Ctr - - - - - - - - - - - - - 

Central IL CCOP - - - 50 6 8 - - - - - - 8 

Cincinnati MC, U of - - - - - - - - - - - - 1 

City of Hope Med Ctr - - - 1 - - - 3 - - - - - 

Cleveland Clinic OH - - - 19 - - 1 - - - - - 9 

Colorado, U of - - - 3 2 - - 3 - - - - 1 

Columbia River CCOP - - - 2 - 1 - - - - - - 3 

Columbia University - - 4 43 - 6 1 - - - 2 - - 

Columbus CCOP - - - 93 - 3 - - 10 - - - 3 

Davis, U of CA 2 2 1 69 3 - 3 - 7 - 1 - 13 

Dayton CCOP - - - 3 - - - 3 - - - - - 

Galveston, U of TX - - - 37 - - - - - - - - - 

Grand Rapids CCOP - - - - - - - - - - - - 3 

Greenville CCOP - - - - - - - - - - - - - 

Gulf Coast MBCCOP - - - 2 - - - - - 1 - - - 

H Lee Moffitt CC - 2 5 4 - - - - - 1 1 - 5 

Harrington CC - 4 - 1 - - - - - - - - - 

Hawaii MBCCOP, U of - - - 5 - - - 5 - 1 - 1 1 

Henry Ford Hosp - - - - - - - - - - - - - 

INCan - - - - - - - - - - - - - 

Irvine, U of CA - - - - - - - - - - - - - 

KaiserPermanenteNCAL - - 1 - - - - - - - - - 9 

Kansas City CCOP - - - - - - - - - - - - 1 

Kansas, U of - - - 15 - 6 2 - - 1 - - - 

Kentucky, U of - - - - - - - - - - - - - 

King Faisal Spec Hos - - - - - - - - - - - - - 

LSU-New Orleans CCOP - - - 8 1 - - - - - - - - 

LSU-Shreveport - - - - - - - - - - - - 3 

LSU-Shreveport CCOP 1 - - - - - - - - - - - 4 

Lahey Clinic Med Ctr - - - - - - - - - - - - - 

Los Angeles, U of CA - - - - - - - - - - - - 2 

Loyola University 9 - 1 7 - 3 2 - - - - - 10 

MD Anderson - - - - - - - - - - - - 26 

MUSC, Hollings CC - - - 11 - - - - - - 1 - - 

Methodist Hospital - - - - - - - - - - - - - 

C40302 

C40503 

C40601 

C40603 

C70301 

E1105 

E2108 

E3108 

IBC24-02 






B39 

B43 

B47 

C40101 

Michigan CRC CCOP - - - - - - - - - - - - - 

Michigan, U of - - 2 25 12 - - - - - - - 14 

Mississippi, Univ of 3 - 1 20 - 2 - - 7 - - - - 

Montana CCOP - - - 6 1 - - 1 - 1 - - - 

National Cancer Ctr - - - - - - - - - - - - - 

New Mexico MBCCOP - - - - - - - - - - - - - 

Northwest CCOP - - - 8 - - 2 1 - - - - 1 

Oklahoma, Univ of - - - 8 - - - - - - - - - 

Oregon Hlth Sci Univ - - 1 1 - - - - - - - - - 

Ozarks Reg CCOP - - - 11 - 3 - - - 1 - - - 

Providence Hosp - - - 7 - - - - - - - - - 

Puget Sound - - 6 32 1 6 5 4 - 1 2 - 6 

Rochester, Univ of - - 3 45 - - - - - - 1 - - 

San Antonio, U of TX - - - 45 - - - - 1 - - - 8 

Santa Rosa CCOP - - - 3 - - - - - - - - 3 

Scott & White CCOP - - - - - - - - - - - - 1 

So Calif, U of - - 2 17 - - 11 4 - - - - 4 

Southeast CCC CCOP - - - - - - - - - 2 - - 3 

Southern Nevada CCOP - - - - - - - - - - - - - 

St Louis CCOP - - - 6 - - - - 3 - - - - 

St Louis University - - - - - - - - - - - - - 

Tennessee, U of - - - - 1 - - - - 3 - - - 

Tulane University - - - - - - - - - - 1 - - 

Upstate Carolina - - - - - - - 3 - - - - 2 

Utah, U of - - - 12 1 - - 2 - - - - - 

Virginia Mason CCOP - - - - - - 1 - - - - - 2 

Wayne State Univ - - 7 14 - 1 - 1 7 2 - - 6 

Western Reg CCOP - - - - - - - - - - - - - 

Wichita CCOP - - - 55 - - - 5 - - - - 5 

Yale University - - - - - - - - - - - - - 

ACOSOG - - - - - - - - - - - - - 

ANZ BCTG/ IBCSG - - - - - - - - - - - - - 

CALGB - - - - - - - - - - - - - 

CTSU-NOS - - - - - - - - - - - - - 

ECOG - - - - - - - - - - - - - 

FSS/ IBCSG - - - - - - - - - - - - - 

GOG - - - - - - - - - - - - - 

NCCTG - - - - - - - - - - - - - 

NCIC - - - - - - - - - - - - - 

NCIC-CTG - - - - - - - - - - - - - 

NSABP - - - - - - - - - - - - - 

RTOG - - - - - - - - - - - - - 

Total 15 8 40 733 28 39 31 48 35 15 9 7 187 

C40302 

C40503 

C40601 

C40603 

C70301 

E1105 

E2108 

E3108 

IBC24-02 



JMA20 




MA32 

N063D 

N0733 

PACCT-1 

Arizona, U of - 10 - - 5 38 - - - - - - 

Arkansas, U of - - 4 - 93 56 - 7 8 3 6 - 

Atlanta Reg CCOP - - 7 - 34 3 - - - - 11 3 

BC Cancer Agency - - - - - - - - - - - - 

Bay Area CCOP - 5 - - - 4 - - 1 4 1 - 

Beaumont CCOP - 17 - - 3 41 - 17 1 - 2 9 

Boston Univ Med Ctr - - - - - - - - 2 - - - 

Brooke Army Med Ctr - 7 2 - 29 65 1 2 1 - 1 - 

Cedars-Sinai Med Ctr - - - - - - - - - 2 - - 

Central IL CCOP - 26 10 - - 39 - 8 8 - 3 - 

Cincinnati MC, U of - - - - 16 8 - 1 - - 4 - 

City of Hope Med Ctr - - 2 - 23 36 2 2 - - 8 - 

Cleveland Clinic OH - 19 - - 35 61 3 15 2 5 10 - 

Colorado, U of - 15 4 - 16 35 - 8 7 3 2 - 

Columbia River CCOP - 3 - - 16 8 - 4 - - - - 

Columbia University - 19 3 - 70 29 2 - - - 4 6 

Columbus CCOP 2 - - - 2 77 1 - 3 21 6 14 

Davis, U of CA 3 12 10 - 71 90 2 7 5 16 5 - 

Dayton CCOP - - - - 2 5 1 - - 2 4 - 

Galveston, U of TX - - - - 6 - - 7 - - - - 

Grand Rapids CCOP - - - - 24 27 - 6 - - 2 - 

Greenville CCOP - - - - 26 22 1 25 - - 1 - 

Gulf Coast MBCCOP - - 1 - 11 5 - - - 2 2 - 

H Lee Moffitt CC - 9 - - 68 - - 2 - - - - 

Harrington CC - - - - - - - - - - 1 - 

Hawaii MBCCOP, U of - 9 7 - 155 107 - 13 - 2 3 - 

Henry Ford Hosp - - - - 14 23 1 24 - 2 - - 

INCan - - - - - - - - - - 12 - 

Irvine, U of CA - - - - 51 6 - 1 - - 6 - 

KaiserPermanenteNCAL - 144 - 2 37 - - - - - 21 - 

Kansas City CCOP - 10 2 - 29 30 - - - - 2 6 

Kansas, U of - - 8 - 24 24 1 4 - - 2 - 

Kentucky, U of - - - - - - - - - - 8 - 

King Faisal Spec Hos - - - - - - 3 - - - - - 

LSU-New Orleans CCOP - 2 1 - - 16 - - - - - - 

LSU-Shreveport - - - - 12 66 - - - - - - 

LSU-Shreveport CCOP - - - - 53 64 - - - - - - 

Lahey Clinic Med Ctr - 2 - - - - - - - - 2 - 

Los Angeles, U of CA - - - - - - - - - - - - 

Loyola University - 5 7 - 33 102 2 - 2 - 8 1 

MD Anderson - - - - 96 - 2 1 - - 44 - 

MUSC, Hollings CC - 7 3 - 11 - - - - - 4 6 

Methodist Hospital - - - - - - - - - - 1 - 

S0221 

S0230 

S0500 

S0622 

S0800 

S1007 

Z1071 



JMA20 

SWOG • Leading Cancer Research. Together. 




MA32 

N063D 

N0733 

PACCT-1 

Michigan CRC CCOP - - - - - 92 - 39 9 13 12 - 

Michigan, U of - 24 - - 3 37 3 28 13 3 8 3 

Mississippi, Univ of - 10 3 - 66 12 - 14 1 3 1 - 

Montana CCOP - - - - 13 67 2 7 6 2 1 - 

National Cancer Ctr - - - - - - - - - - 10 - 

New Mexico MBCCOP - 9 - - - 32 - 5 2 14 4 - 

Northwest CCOP - 22 4 1 23 49 - 3 1 7 6 - 

Oklahoma, Univ of - - - - - - - - - - - - 

Oregon Hlth Sci Univ - 11 - - 31 3 3 1 - - - - 

Ozarks Reg CCOP - - - - 7 44 2 4 - 8 3 - 

Providence Hosp - - 3 - 4 18 - 9 - 6 - - 

Puget Sound - 10 3 3 73 101 2 10 - 1 5 3 

Rochester, Univ of - - 1 - 49 10 1 - 3 - - - 

San Antonio, U of TX 1 - 4 - 59 52 - 20 1 7 2 - 

Santa Rosa CCOP - - - - 6 - - - - - - - 

Scott & White CCOP - - - - - 27 - 8 - - - - 

So Calif, U of - 5 - - 68 47 6 10 - 17 7 5 

Southeast CCC CCOP 1 4 1 1 25 43 2 15 2 3 9 - 

Southern Nevada CCOP - - - - - - - - 1 - 1 - 

St Louis CCOP - 10 1 - 12 7 - - - - 2 - 

St Louis University 1 - - - 12 - - - - - 1 - 

Tennessee, U of - 3 3 - 59 13 2 3 - - 2 - 

Tulane University - - 3 - - 3 - - - - 3 - 

Upstate Carolina - 4 - - 6 1 - - 5 13 - - 

Utah, U of - 22 8 - 61 42 - 5 - - 3 - 

Virginia Mason CCOP - 1 - - 2 20 - 9 1 - 10 - 

Wayne State Univ - 7 14 - 66 76 - 9 - 6 7 2 

Western Reg CCOP - - - - 2 6 - - - - - - 

Wichita CCOP - 10 - - - 16 8 4 - - 12 9 

Yale University - - - - - - - - - - 2 - 

ACOSOG - - - - - 20 - 13 - 1 13 - 

ANZ BCTG/ IBCSG - - - - - - 58 - - - - - 

CALGB - - - - - 324 14 57 - 6 75 - 

CTSU-NOS - - - - - 43 - - - - - - 

ECOG - - - - - 419 86 88 - 9 92 - 

FSS/ IBCSG - - - - - - 46 - - - - - 

GOG - - - - - 1 - - - - 3 - 

NCCTG - - - - - 431 - 62 - 10 29 - 

NCIC - - - - - - - - - - 10 - 

NCIC-CTG - - - - - 96 - - - - - - 

NSABP - - - - - 32 - 45 - 1 48 - 

RTOG - - - - - 23 - 2 - - 1 - 

Total 8 473 119 7 1,712 3,294 257 624 85 192 568 67 

S0221 

S0230 

S0500 

S0622 

S0800 

S1007 

Note: Some studies may not be listed because they were either closed prior to July 1, 2011 or 

because they are currently active but have not had any accrual through September 6, 2012. 

Z1071


CANCER CONTROL & PREVENTION COMMITTEES 


Assoc. Chair for Cancer 

Control & Prevention: 

Frank L. Meyskens, Jr., M.D. 

CC&P Executive Council Co-Chair: Powel Brown, M.D., Ph.D. 


Garnet Anderson, Ph.D. 

William E. Barlow, Ph.D. 

Joseph M. Unger, M.S. 

Danika Lew, M.A. 

Kathryn B. Arnold, M.S. 



Mark A. O’Rourke, M.D. 

Radiation Therapy Committee: Louis “Sandy” Constine, M.D. 

Surgery Committee: 

Robert S. Krouse, M.D., F.A.C.S. 


Liaisons: 

Breast Cancer Committee: 

James (Jimmy) Rae, Ph.D. 

Carol J. Fabian, M.D. 

(Survivorship) 

Helen Chew, M.D. (Symptom 

Control & QOL) 

Dawn Hershman, M.D., M.S. 

(Outcomes) 

Melanie Palomares, M.D. 

(Prevention) 

Gastrointestinal Committee Colon: Jason, Zell, D.O. 

Genitourinary Committee: Peter J. Van Veldhuizen, Jr., M.D. 

International Liaison: 

Kathy S. Albain, M.D. 

Lung Committee: 

Gary E. Goodman, M.D. 

Lymphoma Committee: 

John W. Hayslip, M.D. 

Melanoma Committee: 

TBD 

Designates 


Nursing Committee: 


Statistical Center Support: 

Patient Advocates: 

Connie Szczepanek, R.N., B.S.N. 

Susan Majeski, C.C.R.P. 

Joyce N. Tull, R.N., B.S.N. 

Micheal F. Stephens, C.C.R.A. 

Lisa Hansen, R.N., M.S. 

Siu-Fun Wong, Pharm.D. 

Stephanie Edwards 

Jeri Jardine 


Monica Yee 

Dona Marrah 

Diane Liggett 

Roxanne Topacio 

Amy Johnson 

Daniel M. Moore, Jr., J.D. 

Anna Gottlieb 

Protocol Coordinator - 

(Outcomes and Comparative 

Effectiveness, Prevention, and 

Molecular Epidemiology): 

Protocol Coordinator - 

(Cancer Survivorship; Symptom 

Control and Quality of Life): 

Patricia O’Kane 

Kimberly Kaberle 

Cancer Control and Prevention Executive Council 




8:00 a.m. – 10:00 a.m. 

Time/Location 

Agenda 

8:00 – 8:15 a.m. Associate Chair Report - F. Meyskens, Jr. 

8:15 – 8:25 a.m. Questions 

8:25 – 8:35 a.m. SWOG and AYA - L. Sender 


8:40 – 8:50 a.m. Statistical Update - G. Anderson & B. Barlow 


COMMITTEE REPORTS 

9:00 – 9:10 a.m. Prevention Committee 

P. Brown/G. Goodman 

9:10 – 9:20 a.m. Cancer Survivorship Committee 

C. Fabian/R. Krouse 

9:20 – 9:30 a.m. Symptom Control and QOL Committee 

C. Moinpour/J. Wade 

9:30 – 9:40 a.m. Outcomes and Comparative Effectiveness 

Committee - D. Hershman/S. Ramsey 

9:40 – 9:50 a.m. Molecular Epidemiology Committee 

R. Santella 

9:50 – 10:00 a.m. Pharmacy Update - SF. Wong 



CANCER CONTROL & PREVENTION COMMITTEES 

Harry E. Hynes CCOP Symposium (Joint Session) 



10:00 a.m. – 12:00 p.m. 

Time/Location 

Agenda 

10:00 – 10:05 a.m. WELCOME - Mark O’Rourke, M.D. 

10:05 – 10:15 a.m. Associate Chair Report 

Frank L. Meyskens, Jr., M.D. 

10:15 – 10:45 a.m. What is integrative oncology 

Heather Greenlee, N.D., Ph.D. 

10:45 – 10:50 a.m. Questions 

10:50 – 11:10 a.m. Comparative Effectiveness Research: 

What is it all about 

Scott Ramsey, M.D., Ph.D. 

11:10 – 11:15 a.m. Questions 

11:15 – 11:40 a.m. CC&P Committee Updates to 

CCOPs 

11:40 a.m. – 12:00 p.m. Open Forum for CCOP Investigators 



CANCER SURVIVORSHIP COMMITTEE 

Cancer Survivorship Committee Co-Chairs: 

Carol J. Fabian, M.D. 

Robert S. Krouse, M.D. 


Room: Comiskey 

7: 15 a.m. – 9:45 a.m. 

Introductions and Updates 

7:15 - 7:20 a.m. Welcome 

Time/Location 

Agenda 

Presentations: 

7:20 - 7:35 a.m. Dr. Leonard Sender: How young adult research 

can be embedded into studies being developed in 

the SWOG Cancer Survivorship Committee 

7:35 - 7:50 a.m. Dr. Lisa Sparks: Use of Social Media to recruit 

into SWOG studies 

7:50 - 8:00 a.m. Dr. Monika Leja: Left ventricular strain and 

serum troponin to predict cardiac toxicity from 

trastuzumab and anthracyclines. 

■■ 

■■ 

■■ 

■■ 

6/11/11. Cancer Control Credits: 0.2 ($400) at pre-registration; 

0.8($1,600) at enrollment. Accrual Update 

S1008, “Pilot and Feasibility Study of a Physical Activity 

and Dietary Change Weight Loss Intervention in Breast and 

Colorectal Cancer Patients.” Dr. Greenlee. Activated: 3/1/12. 

Cancer Control Credits: 1.0 ($2,000). Update on accrual – Need 

for Eligibility Amendment 

Moderate Dose Vitamin D vs Placebo to Prevent AI Associated 

Musculoskeletal Symptoms. Dr. Khan. Study Submitted to 

Triage. Update Schema. (Secondary Committee Symptom 

Control /QOL). 

Change in Impaired Cardiopulmonary Fitness with Graded 

Intensity Exercise vs Usual Care in Overweight and Obese Breast 

Cancer Survivors. Drs. Klemp, Porter, and Floyd. (Secondary 

Committee Breast). Update on Schema and Time Table to 

Triage. 

Proposed Intergroup A Randomized Controlled Trial of the Impact 

of a Telephone-Based Weight Loss Intervention Plus Health 

Education Materials versus Health Education Materials Only 

upon Invasive Disease Free Survival in Overweight and Obese 

Women with Early Stage Breast Cancer. Dr. Korde. (Secondary 

Committee Breast ) Update Progress. 

8:00 - 8:10 a.m. Discussion 

New Concepts Proposed (at April Meeting) - 10 minutes each 

■■ 

Effect of Everolimus vs Placebo on Intermediate Markers of 

Health and Lifespan in Renal Cell Carcinoma Survivors. Drs. 

Nicolas Musi and Peter Van Veldhuizen (Secondary Committee 

Genitourinary). Update Concept and Probable Funding Source. 

■■ 

■■ 

Long term effects of Urinary Diversion in Bladder Cancer 

Survivors. Dr. Scott Gilbert (Secondary Committee Genitourinary) 

Update Concept. 

Bowel obstruction from Metastatic Cancer: Dr. Robert Krouse. 

Update Concept. 

Newly Activated Studies and Update of Concepts Previously 

Proposed - 5 minutes each 

■■ 

The Men’s Eating and Living (MEAL) Study: A Randomized 

Trial of Diet to Alter Disease Progression in Prostate Cancer 

Patients on Active Surveillance. Dr. Van Veldhuizen. Activated: 

Special Projects/ Presentations - 10 minutes each 

■■ 

Rick Bangs: Advocate Update. 

■■ 

■■ 

Update on SWOG Survivorship Care Plan : Klemp, Lackey, Cook, 

Crowley, Anderson ( Secondary Committee is Breast) Present 

Design and Source of Support. 

International Survivorship Update: Report from the meeting. Dr. 

Kathy Albain. 

Other Business 


■■ 

Ancillary to S0221 (R01), Antioxidant and CAM Use and 

Survival. Drs. Ambrosone and Albain. 

■■ 


to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in 

Cancer Patients with Bone Metastasis Starting Zoledronic Acid 

Treatment.” Drs. Van Poznak and Gralow. Activated: 12/15/08. 

(Primary Committee Symptom Control). 



CANCER SURVIVORSHIP COMMITTEE 

■■ 

■■ 

S1008, “Pilot and Feasibility Study of a Physical Activity 

and Dietary Change Weight Loss Intervention in Breast and 

Colorectal Cancer Patients.” Dr. Greenlee. Activated: 3/1/12. 

CTSU/C70807, “The Men’s Eating and Living (MEAL) Study: A 

Randomized Trial of Diet to Alter Disease Progression in Prostate 

Cancer Patients on Active Surveillance.” Dr. Parsons. Activated: 

6/1/11. (Primary Committee Genitourinary) 


■■ 

S0230, “Phase III Trial of LHRH Analog Administration 

During Chemotherapy to Reduce Ovarian Failure Following 

Chemotherapy in Early Stage, Hormone-Receptor Negative 

Breast Cancer.” Drs. Moore, Albain, and Martino. Activated: 

10/1/03; Closed: 6/1/11. 

■■ 

S0715, “Randomized Placebo-Controlled Trial of Acetyl 

L-Carnitine For The Prevention Of Taxane-Induced Neuropathy.” 

Drs. Hershman, Albain, Gotay and Lisa Hansen, R.N., M.S. (Coassignment 

to Symptom Control/OOL Committee). Activated: 

9/15/09; Closed: 2/1/11. 

9:45 Adjourn 

Publications 





■■ 

S0316 A prospective analysis of the influence of older age on 

physician decision-making when considering enrollment to breast 

cancer clinical trials (SWOG S0316). SH Javid, JM Unger, JR 

Gralow, CM Moinpour, AJ Wozniak, JW Goodwin, PN Lara, PA 

Williams, LF Hutchins, CC Gotay, KS Albain. The Oncologist 

2012 June 20 [Epub ahead of print]. http://www.ncbi.nlm.nih. 

gov/pubmed/22723506 


No publication information for this cycle. 



MOLECULAR EPIDEMIOLOGY COMMITTEE 

Molecular Epidemiology Committee Co-Chairs: 

Regina M. Santella, Ph.D. 




5:30 – 7:30 p.m. 

Time/Location 

Agenda 

Presentation 

Supplement Use During an Intergroup Clinical Trial for Breast Cancer 

(S0221) - Gary Zirpoli, MA Roswell Park Cancer Institute and the 

University at Buffalo 

Discussion 


S0424, “Molecular Epidemiology Case-Series Study of Non-Small 

Cell Lung Cancer in Smoking and Non-Smoking Women and Men.” 

Drs. Ambrosone, Santella, Albain, Gumerlock and Reid. Activated: 

10/1/05 Closed: 3/15/11. (Santella or Redman report) 


■■ 

S8897 papers – Song Yao 

■■ 

■■ 

■■ 

■■ 

■■ 

■■ 

S8897 Grant to examine SNPs in microRNAs in relation to 

toxicity and survival. Dr. Yao. 

Update on collaboration with Margaret Briehl, Lisa Rimsza 

(Translational Medicine) on Variants in Oxidative Stress 

Pathways and Lymphoma Outcomes (funded by Hope 

Foundation). Dr. Yao. 

S0221 Antioxidant study, status of papers (Ambrosone). 

S0221 Grant to perform a genome wide scan in relation to 

toxicities. Dr. Ambrosone. 

PCPT P01Status of studies/papers. 

SELECT and PCPT biorepository use requests. 

New Business 

■■ 

Examine genetic variants in relation to cisplatin-related toxicities 

among patients with colorectal cancer. Drs. Zell and Ambrosone. 



OUTCOMES AND COMPARATIVE EFFECTIVENESS 

COMMITTEE 

Outcomes and Comparative Effectiveness Committee Co-Chairs: 

Dawn L. Hershman, M.D., M.S. 

Scott D. Ramsey, M.D., Ph.D. 



12:45 p.m. – 2:45 p.m. 

Time/Location 

Agenda 

■ ■ 

■■ 

■■ 

“A Sero-Epidemiology Survey and Cost-Effectiveness Study of 

Screening for HIV, Hepatitis B and Hepatitis C Among Newly 

Diagnosed Cancer Patients Among SWOG Affiliated Oncology 

Clinics.” Dr. Ramsey. 

Grants Submitted 

Aligning Genomic Testing with Patient and Physician Preferences 

in NSCLC (AGENT-P). Dr. Carlson. 

Publications 

Presentations 

“Adaptive Trial Design” - Bryan Luce, Ph.D., M.B.A., Director of 

United Biosource Corporation. 

”The Generalizability of Phase III Cancer Clinical Trial Standard Arm 

Treatment Outcomes” - Joseph M. Unger, M.S. 


■■ 

S1007, “Update on Quality of Life and Economic Analysis Substudy 

of Breast protocol S1007.” Bill Barlow, Ph.D. 

■■ 

S1105, “Randomized Controlled Trial of a Behavioral 

Intervention to Improve Adherence to Adjuvant Aromatase 

Inhibitor Therapy in Women with Early Stage Breast Cancer.” 

Drs. Neugut and Hershman. Activated: 3/27/12. 


■■ 

NexCura Barriers Survey 

Ongoing Database projects 

■■ 

Toxicity and survival analysis by gender in Southwest Oncology 

Group Trials. Dr. Albain, Joseph M. Unger, M.S. and Carolyn 

Gotay, Ph.D. Endpoint/Demographic Factor: Gender – Update on 

manuscript status. 

Disease type: Multiple 





■■ 

The automatic clinical trial: leveraging the electronic medical 

record in multisite cancer clinical trials. K Goodman, J 

Krueger, J Crowley. Current Oncology Reports 2012 Aug 

21 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/ 

pubmedterm=goodman%20k%20automatic 

■■ 

When progressive disease does not mean treatment failure: 

reconsidering criteria for progression. G Oxnard, M Morris, S 

Hodi, L Baker, A Venook, L Schwartz. Journal of the National 

Cancer Institute 2012 Aug 27 [Epub ahead of print]. http://www. 

ncbi.nlm.nih.gov/pubmed/22927506 


■■ 

Patient income level and cancer clinical trial participation. J 

Unger, D Hershman, K Albain, C Moinpour, J Petersen, K Burg, J 

Crowley. Journal of Clinical Oncology, resubmitted 8/31/12. 

■■ 

■■ 

Medicare claims data as a core resource for comparative 

effectiveness studies. Dr. Hershman, Joseph M. Unger, M.S. 

Disease type: Multiple 

Proposed Letter of Intent: Pending CTEP Review 


PREVENTION COMMITTEE 


Prevention Committee Co-Chairs: 

Powel Brown, M.D., Ph.D. 




3:15 p.m. – 5:15 p.m. 

Time/Location 


■■ 

S0000, “Selenium and Vitamin E Cancer Prevention Trial 

(SELECT).” Drs. Klein, Lippman, Thompson and Lucia. 


■■ 

S0000A, “Prevention of Alzheimer’s Disease with Vitamin E and 

Selenium (PREADVISE), Phase III Ancillary to S0000 – SELECT.” 

Drs. Markesbery and Schmitt. Activated: 5/17/02; Closed: 

9/30/09. 

Introduction 

Agenda 

■■ 

S0000C, “Prevention of Lung Function Decline with Vitamin E 

and Selenium – Respiratory Ancillary Study (RAS) to SELECT.” 

Drs. Cassano and Kristal. Activated: 6/4/04; Closed: 5/1/07. 

Presentation: “How Young Adult Research Can Be Embedded Into 

Studies Being Developed in the SWOG Prevention Committee.” Dr. 

Leonard Sender, Division Chief, Pediatric Oncology, University of 

California, Irvine. 

■■ 

E5597, “Phase III Chemoprevention Trial of Selenium 

Supplementation in Persons with Resected Stage I Non-Small 

Cell Lung Cancer.” Dr. Kucuk. Activated: 12/1/00; Closed: 

11/5/09. 

Panel Discussion: Cancer prevention studies in the adolescent and 

young adult population. 


■■ 

S0812, “A Randomized Double-Blind Placebo-Controlled 

Biomarker Modulation Study of Vitamin D in Premenopausal 

Women at High-Risk For Breast Cancer, Phase IIB.” Dr. Crew. 


■■ 

■■ 

■■ 

S00002, “Centralized Follow-up to Selenium and Vitamin 

E Cancer Prevention Trial (SELECT).“ Drs. Klein, Lippman, 

Thompson and Lucia. Activated: 11/01/09. 

S0000B, “Prevention of Cataract and Age-Related Macular 

Degeneration with Vitamin E and Selenium – SELECT Eye 

Endpoints (SEE) Phase III Ancillary to S0000 – SELECT.” Drs. 

Christen, Glynn and Gaziano. Activated: 7/1/04. 

S0000D, “A Study of the Effect of Vitamin E and/or Selenium on 

Adenomatous Colorectal Polyps (ACP) in Participants Enrolled 

in SELECT, Phase III Ancillary to S0000-SELECT.” Drs. Lance, 

Alberts, Battacharyya, Green, and Martinez. Activated: 6/3/08. 

■■ 

S0701, “A Phase III Randomized Trial of Three Antibiotic 

Regimens to Eradicate Helicbacter Pylori.” Dr. Greenberg. 


Proposed Studies (on website) 

■■ 

S0820, “A Double-Blind Placebo-Controlled Trial of Eflornithine 

and Sulindac to Prevent Recurrence of High Risk Adenomas and 

Second Primary Colorectal Cancers in Patients With Stage 0-III 

Colon Cancer, Phase III.” Drs. Zell, Brown, Lance, Krouse and 

Lipkin. Posted for IRB review: 4/15/11. 

New Business 

1. Committee re-organization of Molecular Epidemiology and 

Prevention Committees (P. Brown, F. Meyskens) 

2. Discussion of future prostate cancer prevention trials (P. Brown, 

G. Goodman, I. Thompson) 

Publications 


published, submitted or accepted form by the Group Chair’s Office since 

the Spring 2012 meeting agenda booklet publication list. 

■■ 

S1119, “Gastric Cancer and Helicobacter Pylori Infection in 

Lima, Peru: The Role of Water Contamination.” Dr. Valdivieso. 



■■ 

S0000A Age expanded normative data for the Ruff 2 & 7 

Selective Attention test: evaluating cognition in older males. A 

Caban-Holt, E Abner, RJ Kryscio, J Crowley, FA Schmitt. The 

Clinical Neuropsychologist 26(5):751-768, 2012. http://www. 




PREVENTION COMMITTEE 

■■ 

S0000A A randomized controlled Alzheimer’s disease prevention 

trial’s evolution into an exposure trial. RJ Kryscio, EL Abner, FA 

Schmitt, PJ Goodman, M Mendiondo, A Caban-Holt, BC Dennis, 

EA Klein, JJ Crowley. Journal of Nutrition, Health and Aging, 

accepted 4/4/12. 

■■ 

S9217 Projecting prostate cancer mortality in the PCPT and 

REDUCE chemoprevention trials. PF Pinsky, A Black, R Grubb, 

ED Crawford, G Andriole, I Thompson, H Parnes. Cancer 2012 

Aug 14 [Epub ahead of print] http://www.ncbi.nlm.nih.gov/ 

pubmed/22893105 

■■ 

■■ 

■■ 

■■ 

■■ 

■■ 

S0000 Evaluation of selenium supplementation on the prevention 

of bladder cancer in SWOG-coordinated SELECT. Y Lotan, 

P Goodman, R Youssef, R Svatek, S Shariat, C Tangen, IM 

Thompson, E Klein. Journal of Urology 187(6):2005-2010, 

2012. http://www.ncbi.nlm.nih.gov/pubmedterm=lotan%20 

y%20selenium 

S0000 Moving a randomized clinical trial into an observational 

cohort. PJ Goodman, JA Hartline, CM Tangen, JJ Crowley, LM 

Minasian, EA Klein, ED Cook, K Anderson, M Yee, FL Meyskens, 

LH Baker. Clinical Trials, accepted 8/13/12. 

S9217 Associations of serum sex steroid hormones and 

5a-androstane-3a,17ß-diol glucuronide concentrations with 

prostate cancer risk among men treated with finasteride. AR 

Kristal, CA Till, CM Tangen, PJ Goodman, ML Neuhouser, FZ 

Stanczyk, LW Chu, SK Patel, IM Thomspon, J Reichardt, AM 

Hoque, EA Platz, WD Figg, A van Bokhoven, SM Lippman, AW 

Hsing. Cancer Epidemiology Biomarkers and Prevention 2012 

Aug 9 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/ 

pubmed/22879203 

S9217 Prospective study of cytomegalovirus serostatus and 

prostate cancer risk in the prostate cancer prevention trial. S 

Sutcliffe, C Till, CA Gaydos, FJ Jenkins, P Goodman, A Hoque, 

AW Hsing, IM Thompson, JM Zenilman, WG Nelson, AM 

DeMarzo, EA Platz. Cancer Causes and Control, 23(9):1511- 

1518, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22810146 

S9217 Indications for and use of nonsteroidal anti-inflammatory 

drugs and the risk of incident, symptomatic benign prostatic 

hyperplasia: results from the prostate cancer prevention trial. 

JM Schenk, GS Calip, CM Tangen, P Goodman, JK Parsons, 

IM Thompson, Kristal AR. American Journal of Epidemiology 

176(2):156-1663, 2012. http://www.ncbi.nlm.nih.gov/ 

pubmed/22759721 

S9217 Finasteride reduces the risk of incident symptomatic 

benign prostatic hyperplasia. JK Parsons, JM Schenk, KB 

Arnold, K Messer, C Till, IM Thompson, A Kristal. European 

Urology, 61(6):1263-1270, 2012. http://www.ncbi.nlm.nih.gov/ 

pubmed/22459892 



■■ 

S0701 Risk of recurrence and probability of successful 

eradication of Helicobacter pylori: one-year results of a 

randomized trial in seven Latin American sites (SWOG S0701). 

DR Morgan, J Torres, R Sexton, R Herrero, E Salazar-Martinez, 

ER Greenberg, LE Bravo, RL Dominguez, C Ferreccio, E Lazcano- 

Ponce, MM Meza-Montenegro, EM Pena, R Pena, P Correa, ME 

Martinez, WD Chey, M Valdivieso, GL Anderson, GE Goodman, 

JJ Crowley, LH Baker. Journal of the American Medical 

Association, submitted 8/21/12. 

■■ 

S0701 Epidemiology of Helicobacter pylori infection in six Latin 

American countries (SWOG trial S0701). C Porras, J Nodora, 

R Sexton, R Ferreccio, S Jimenez, RL Dominguez, MP Cook, 

GL Anderson, DR Morgan, LH Baker, ER Greenberg, H Herrero. 

Cancer Causes and Control, submitted 8/22/12.


SYMPTOM CONTROL & QUALITY OF LIFE COMMITTEE 

Symptom Control and QOL Committee Co-Chairs: 

James L. Wade, III, M.D. 

Carol M. Moinpour, Ph.D. 



10:15 a.m. - 12:15 p.m. 

Time/Location 

Agenda 

Introductions and Presentations 


■■ 



Cancer Patients with Bone Metastasis Starting Zoledronic Acid 

Treatment.” Drs. Gralow and Van Poznak. Activated: 12/15/08. 

■■ 

■■ 

■■ 

S0927, “Randomized Placebo-Controlled Trial of Omega-3- 

Fatty Acid for the Control of Aromatase Inhibitor-Induced 

Musculoskeletal Pain in Women with Early Stage Breast Cancer, 

Phase III.” Drs. Hershman and Crew. Activated: 2/1/12. 

S1013, “A Phase II Prospective Study of Epidermal Growth 

Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic 

Toxicity: Validation of the Functional Assessment of Cancer 

Therapy – EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRIinduced 

Skin Toxicities.” Dr. Wong. Activated: 11/15/11. 

S1200, “Randomized Blinded Sham- and Waitlist-Controlled 

Trial of Acupuncture for Joint Symptoms Related to Aromatase 

Inhibitors in Women with Early Stage Breast Cancer.” Drs. 

Hershman and Crew. Activated: 4/1/12. 


■■ 

S0715, “Randomized Placebo-Controlled Trial of Acetyl 

L-Carnitine for the Prevention of Taxane-Induced Neuropathy.” 

Drs. Hershman and Albain. (Co-assignment to Survivorship 

Committee) Activated: 9/15/09; Closed 2/1/11. 


■■ 

S1202, “Phase III Study of Duloxetine for Treatment of 

Aromatase Inhibitor-Associated Musculoskeletal Symptoms in 

Women with Early Stage Breast Cancer.” Drs. Henry and Schott. 

Protocol approved by DCP: 4/10/12, will open once S0927 has 

closed to accrual. 

Concepts in Development 

■ ■ “A Phase II Randomized Placebo-Controlled Study to Evaluate 

the Use of Menadione Topical Lotion in Patients with Cutaneous 

Toxicity Caused by Epidermal Growth Factor Receptor (HER1/ 

EGFR) Inhibitors.” Drs. Wong, Ryan, Wade, & Moinpour. Seeking 

Industry funding. Examining other potential agents. 

■■ 

■■ 

GWAS analysis for oxaliplatin-associated neurotoxicity. Drs. 

Zell/Ambrosone. 

—— 

R01 submitted with letters of support from both NSABP 

and the Alliance. 

Two surveys: 

—— 

Dr. Wong: Knowledge and Attitudes Re: Safe Handling of 

Oral Chemotherapy Agents 

—— 

Dr. Anne Jeffres: Role of Acupuncture in Oncology 

Committee Process 

■■ 

Sign meeting attendance list 

■■ 

Committee communication between Group Meetings 

■■ 

Monthly/bimonthly conference call Participants 

■■ 

Cancer Control and Prevention Committee Reorganization 

■■ 

Local Initiatives of interest and potentially feasible in SWOG 

Announcements 

Other Studies with Symptom Control and QOL Component 

■■ 

S1007, “A Phase III, Randomized Clinical Trial of Standard 

Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 

1-3 Positive Nodes, Hormone-responsive and Her2-Negative 

Breast Cancer according to Recurrence Score (RS).” Drs. 

Gonzales-Angulo, Meric-Bernstam, Hortobagyi, and Albain. 


■■ 

■■ 

■■ 

CTSU/C30610, “Phase III Comparison of Thoracic Radiotherapy 

Regimens in Patients with Limited Small Cell Lung Cancer Also 

Receiving Cisplatin and Etoposide.” Drs. Gadgeel and Gaspar. 


CTSU/C90203, “A Randomized Phase III Study of Neo- 

Adjuvant Docetaxel and Androgen Deprivation Prior to Radical 

Prostatectomy Versus Immediate Radical Prostatectomy in 

Patients with High-Risk, Clinically Localized Prostate Cancer.” 

Dr. Kim. Activated: 7/1/07. 

CTSU/E1411, “Intergroup Randomized Phase 2 Four Arm Study 

in Patients >/= 60 with Previously Untreated Mantle Cell 



SYMPTOM CONTROL & QUALITY OF LIFE COMMITTEE 

■■ 

Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine 

Followed by Rituximab Consolidation (RB -->R); Arm B = Ri 

tuximab+Bendamustine+Bortezomib Followed By Rituximab 

Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine 

Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) 

or Arm D = Rituximab+Bendamustine+Bortezomib Followed by 

Lenalidomide+Rituximab Consolidation (RBV --> LR).” Dr. Till. 


CTSU/E1609, “A Phase III Randomized Study of Adjuvant 

Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon 

a-2b for Resected High-Risk Melanoma.” Dr. Flaherty. Activated: 

7/15/11. 

■■ 

■■ 

and an Anthracycline and/or a Taxane.” Dr. Hannah M. Liden. 


CTSU/R0848, “A Phase III Trial Evaluating Both Erlotinib 

and Chemoradiation as Adjuvant Treatment for Patients with 

Resected Head of Pancreas Adenocarcinoma.” Dr. Philip. 


CTSU/R1010, “A Phase III Trial Evaluating the Addition of 

Trastuzumab to Trimodality Treatment Of HER2-Overexpressing 

Esophageal Adenocarcinoma.” Dr. Leichman. Activated: 9/1/11. 

Publications 

■■ 

■■ 

■■ 

■■ 

■■ 

■■ 

■■ 

CTSU/E2108, “A Randomized Phase III Trial of the Value of 

Early Local Therapy for the Intact Primary Tumor in Women with 

Metastatic Breast Cancer.” Dr. Lee. Activated: 3/15/11. 

CTSU/E3805, “CHAARTED: ChemoHormonal Therapy versus 

Androgen Ablation Randomized Trial for Extensive Disease in 

Prostate Cancer.” Dr. Garcia. Activated: 9/1/08. 

CTSU/E3A06, “Randomized Phase III Trial of Lenalidomide 

Versus Observation Alone in Patients with Asymptomatic 

Smoldering Multiple Myeloma.” Drs. Dhodapkar and 

Shaughnessy. Activated: 2/1/11. 

CTSU/MA32, “A Phase III Randomized Trial of Metformin 

versus Placebo on Recurrence and Survival in Early Stage Breast 

Cancer.” Dr. Hershman. Activated: 9/15/10. 

CTSU/N1048, “A Phase II/III trial of Neoadjuvant FOLFOX, with 

Selective Use of Combined Modality Chemoradiation versus 

Preoperative Combined ModalityChemoradiation for Locally 

Advanced Rectal Cancer Patients Undergoing Low Anterior 

Resection with Total Mesorectal Excision.” Dr. Eng. Activated: 

4/15/12. 

CTSU/N107C, “A Phase III Trial of Post-Surgical Stereotactic 

Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) 

for Resected Metastatic Brain Disease.” Dr. Gaspar. Activated: 

12/1/11. 

CTSU/N0733, “Randomized Phase II Trial of Capecitabine and 

Lapatinib with or without IMC-A12 in Patients with HER2 

Positive Breast Cancer Previously Treated with Trastuzumab 



since the Spring 2012 meeting agenda booklet publcation list. 


■■ 

S0715 Randomized double-blind placebo-controlled trial 

of acetyl-l-carnitine for the prevention of taxane induced 

neuropathy in women undergoing adjuvant breast cancer 

therapy. D Hershman, J Unger, K Crew, L Minasian, C 

Moinpour, L Hansen, D Lew, L Fehrenbacher, J Wade, S Wong, G 

Hortobagyi, F Meyskens, K Albain. Journal of Clinical Oncology, 

resubmitted 8/12 (also listed under Breast Committee) . 

■■ 

S9217 Health-related quality of life findings for the Prostate 

Cancer Prevention Trial. CM Moinpour, AK Darke, GW 

Donaldson, D Cespedes, CR Johnson, PA Ganz, DL Patrick, JE 

Ware, SA Shumaker, FL Meyskens, IM Thompson. Journal of the 

National Cancer Institute, accepted 8/21/12. 





Cancer Control and Prevention Committees 



Outcomes & 

Comparative 

Effectiveness Prevention 

Cancer 

Survivorship 

Symptom Control & Quality of Life 

S1007 S1105 S00002 S0000B S0000D S0812 C70807 S0230 S1008 C30610 C70301 C90203 CTN0701 

Abramson Cancer Ctr - - 174 13 23 - - - - - - - - 

Altamira Family Med - - 73 - - - - - - - - - - 

Anne Arundel Med Ctr - - 33 5 - - - - - - - - - 

Arizona Cancer Ctr - - 218 - 100 - - - - - - - - 

Arizona, U of - - - - - - - - - - - - - 

Arkansas, U of 6 1 - - - - - - - 1 - - - 

Arkansas, Univ of - - 20 - - - - - - - - - - 

Atlanta Reg CCOP 11 - 87 - - - 1 - - - - - - 

Aultman Hospital - - 22 - - - - - - - - - - 

Baptist Hosp East - - 151 - - - - - - - - - - 

Baptist Regional - - 90 10 - - - - - - - - - 

Bassett Research Ins - - 35 6 - - - - - - - - - 

Bay Area CCOP 1 - 114 18 1 - - - - - - - - 

Baylor Univ Med Ctr - - 47 - - - - - - - - - - 

Beaumont CCOP 2 - - - - - 4 - - - - - - 

Berkshire Hem/Onc - - 42 - - - - - - - - - - 

Beth Israel Deacones - - 8 - - - - - - - - - - 

Boston MC MBCCOP - - - - - - - - - - - - - 

Boston Medical Ctr - - 20 - - - - - - - - - - 

Boston Univ Med Ctr - - - - - - - - - - - - - 

Brooke Army Med Ctr 1 - - - - - - 1 - - - 3 - 

Camcare Health - - 12 - - - - - - - - - - 

Capital Region PC - - 271 - - - - - - - - - - 

Carle Cancer Center - - 205 2 5 - - - - - - - - 

Cascadia Cancer Prev - - 125 95 165 - - - - - - - - 

Cedar Rapids CCOP - - 79 15 30 - - - - - - - - 

Cedars-Sinai Med Ctr - - - - - - 1 - - - - - - 

Central Baptist Hosp - - 19 - - - - - - - - - - 

Central IL CCOP 3 - 111 - - - - - - 5 - - - 

Central PA Hem & Med - - 5 - - - - - - - - - - 

Centro Clinico - - 23 - - - - - - - - - - 

Chicago Hospitals, U - - 16 - - - - - - - - - - 

Christiana Care Hlth - - 47 7 - - - - - - - - - 

Cincinnati MC, U of 4 - - - - - - - - - - - - 

Cincinnati, Univ of - - 9 - - - - - - - - - - 

City of Hope Med Ctr 8 - 56 - - 6 - 2 - - - 10 - 

Cleveland Clinic - - 69 - - - - - - - - - - 

Cleveland Clinic OH 10 - - - - - 1 3 - - - - - 

Colorado Ca Res Prog - - 112 8 52 - - - - - - - - 

Colorado, U of 2 - - - - - 1 - - - - 12 - 

Colorado, Univ of - - 569 56 - - - - - - - - - 

Columbia River CCOP - - 67 - - - - - - - - - - 

Columbia University 4 7 13 - - 1 - 2 - - - - - 

Columbus CCOP 6 1 37 - - - - 1 - - 10 - - 

Conemaugh Mem MC - - 3 - - - - - - - - - - 

Connecticut, Univ of - - 38 - - - - - - - - - - 

DC United - - 42 - - - - - - - - - - 






Outcomes & 

Comparative 


Cancer 

Survivorship 



Dartmouth Hitchcock - - 1 - - - - - - - - - - 

Davis, U of CA 5 - - - - - - 2 - 7 7 13 2 

Dayton CCOP 4 1 183 - - - - 1 - - - - - 

Dickstein CTC - - 23 - - - - - - - - - - 

Downstate Med Ctr - - 80 - - - - - - - - - - 

Duluth CCOP - - 94 42 80 - - - - - - - - 

Faxton-St Luke's - - 46 - - - - - - - - - - 

Fox Chase Cancer Ctr - - 176 26 37 - - - - - - - - 

Galveston, U of TX - - - - - - - - - - - - - 

Geisinger Clinic - - 91 - 77 - - - - - - - - 

George Washington U - - 282 74 208 - - - - - - - - 

Glendale Mem Hosp - - 40 - - - - - - - - - - 

Good Samaritan Hosp - - 72 22 - - - - - - - - - 

Good Samaritan MC - - 15 - - - - - - - - - - 

Grand Rapids CCOP 2 4 241 - 167 - - - - - - - - 

Greenville CCOP 1 4 107 - 68 - - 1 - - - - - 

Gulf Coast MBCCOP 2 - 3 - - - - - - - - - - 

H Lee Moffitt CC - - 77 - - - - - - - - 2 1 

Harbor-UCLA - - 448 - 54 - - - - - - - - 

Harrington CC 1 - 34 10 - - - - - - - - - 

Harris Methodist - - 24 - - - - - - - - - - 

Harrison Peeples HCC - - 41 - - - - - - - - - - 

Hawaii CCOP - - 61 15 - - - - - - - - - 

Hawaii MBCCOP, U of 3 - - - - - - - - - - - - 

Hem-Onc Assoc of CNY - - 51 5 41 - - - - - - - - 

Henry Ford Hosp - - 88 10 51 - - 1 - - - 1 - 

Huntington Mem Hosp - - 13 5 - - - - - - - - - 

INCan 12 - - - - - - - - - - - - 

INTEGRIS Oncology - - 99 - - - - - - - - - - 

Illinois, Univ of - - 389 350 420 - - - - - - - - 

Indiana University - - 17 - - - - - - - - - - 

Iowa Hosp, Univ of - - 136 - - - - - - - - - - 

Iowa Oncology CCOP - - 174 48 70 - - - - - - - - 

Ireland Cancer Ctr - - 28 7 - - - - - - - - - 

Irvine, U of CA 6 - - - - - - - - - - - - 

Irvine, Univ of CA - - 26 - - - - - - - - - - 

Johns Hopkins Univ - - 13 - - - - - - - - - - 

Johnson City Med Ctr - - 24 - - - - - - - - - - 

Kaiser Permanente-GA - - 49 3 - - - - - - - - - 

Kaiser-Oakland - - 26 5 - - - - - - - - - 

KaiserPermanenteNCAL 21 - - - - - - - - 1 - - - 

Kalamazoo CCOP - - 128 - 70 - - - - - - - - 

Kansas City CCOP 2 - 53 - 26 - - - - - - - - 

Kansas, U of 2 1 - - - - 2 1 - - - 11 - 

Kentucky, U of 8 - - - - - 1 - - - - - - 

Kentucky, Univ of - - 23 - - - - - - - - - - 

Kimmel Cancer Ctr - - 29 5 - - - - - - - - - 






Outcomes & 

Comparative 


Cancer 

Survivorship 



King Faisal Spec Hos - - - - - - - 3 - - - - - 

Knoxville, U of TN - - 53 19 47 - - - - - - - - 

Kootenai Cancer Ctr - - 14 6 - - - - - - - - - 

LDS Hospital - - 106 - - - - - - - - - - 

LSU-New Orleans - - 15 - - - - - - - - - - 

LSU-New Orleans CCOP - - - - - - 1 - - - - 2 - 

LSU-Shreveport - - 91 - - - - - - - - - - 

LSU-Shreveport CCOP - - - - - - - - - - - 1 - 

Lahey Clinic Med Ctr 2 - 54 - - 5 - - - - - - - 

Lawrence & Mem Hosp - - 30 7 - - - - - - - - - 

Lehigh Valley Hosp - - 91 5 - - - - - - - - - 

Lionel B. Katchem - - - 6 - - - - - - - - - 

Los Angeles, U of CA - - 40 11 - - - - - - - - - 

Loyola University 8 - 31 7 - - - 2 2 - - 11 - 

MD Anderson 44 - 272 96 225 - - 2 - - - 3 - 

MUSC, Hollings CC 4 - - - - - - - - 1 - - - 

Main Line/Lankenau - - 19 1 - - - - - - - - - 

MaineGeneral MC - - 9 - - - - - - - - - - 

Marquette Gen Hosp - - 19 - - - - - - - - - - 

Marshfield Clinic - - 99 - - - - - - - - - - 

Martin Memorial CC - - 16 3 - - - - - - - - - 

Maryland, Univ of - - 9 - - - - - - - - - - 

Mayo Clinic - - 4 - - - - - - - - - - 

Med Col of Wisconsin - - 83 - - - - - - - - - - 

Meharry Med College - - 5 - - - - - - - - - - 

MeritCare Hosp CCOP - - 104 39 88 - - - - - - - - 

Methodist Cancer Ctr - - 23 - - - - - - - - - - 

Methodist Hospital 1 - - - - - - - - - - - - 

Methodist, Dallas - - 52 1 10 - - - - - - - - 

Metro-Minnesota CCOP - - 155 19 102 - - - - - - - - 

Miami, Univ of - - 6 - - - - - - - - - - 

Michigan CRC CCOP 12 3 171 - - - - - - - - 2 - 

Michigan, U of 8 - - - - - - 3 - 1 - - - 

Midtown Urology PC - - 15 - - - - - - - - - - 

Miguel Sosa Padilla - - 31 - - - - - - - - - - 

Mississippi, Univ of 1 - 154 36 88 - - - - - 7 - - 

Missouri Baptist MC - - 105 - - - - - - - - - - 

Missouri Valley CCOP - - 86 - - - - - - - - - - 

Montana CCOP 1 - 30 6 - - - 2 - - - - - 

Montefiore MC, N Div - - 3 - - - - - - - - - - 

Mount Sinai CCOP - - 130 - 54 - - - - - - - - 

Mt Zion Cancer Ctr - - 9 - - - - - - - - - - 

NY Methodist Hosp - - 11 4 - - - - - - - - - 

National Cancer Ctr 10 - - - - - - - - - - - - 

Nebraska, Univ of - - 65 - - - - - - - - - - 

Nevada Cancer Inst - - - - - - - - - - - - - 

New Mexico MBCCOP 4 1 - - - - - - - - - 1 - 






Outcomes & 

Comparative 


Cancer 

Survivorship 



New Mexico, Univ of - - 12 - - - - - - - - - - 

North Shore CCOP - - 16 - - - - - - - - - - 

NorthShore Univ - - 31 - - - - - - - - - - 

Northern Indiana CRC - - 110 37 25 - - - - - - - - 

Northern NJ Ca Assoc - - 15 - - - - - - - - - - 

Northwest CCOP 6 - 161 - - - - - - - - - - 

Northwestern Univ - - 91 21 18 - - - - - - - - 

Ochsner CCOP - - 11 - - - - - - - - - - 

Ohio State Univ - - 20 2 - - - - - - - - - 

Oklahoma, Univ of - - 56 - - - - - - - - - - 

Oregon Hlth Sci Univ - - 48 19 - - - 3 - - - 1 - 

Orocovis Med Ctr - - 52 - - - - - - - - - - 

Ottawa General Hosp - - 54 - - - - - - - - - - 

Our Lady, Bellefonte - - 25 - - - - - - - - - - 

Ozarks CCOP - - 27 - - - - - - - - - - 

Ozarks Reg CCOP 3 2 - - - - - 2 - - - - - 

Pittsburgh Ca Inst - - 18 - - - - - - - - - - 

Princess Margaret - - 33 - - - - - - - - - - 

Prostate Cancer Ctr - - 49 - - - - - - - - - - 

Providence Hosp - - - - - - - - - 2 - - - 

Puget Sound 5 - - - - - 1 2 1 - - 1 - 

Queens Hospital Ctr - - 3 - - - - - - - - - - 

Regional CC-Waukesha - - 33 - - - - - - - - - - 

Regional Cancer Ctr - - 15 - - - - - - - - - - 

Rochester, Univ of - - 16 - - - - 1 - - - 2 - 

Roswell Park - - 43 - - - - - - - - - - 

Rush Univ Med Ctr - - 214 - - - - - - - - - - 

SELECT Coord Center - - 495 - 3,219 - - - - - - - - 

SUNY Stony Brook - - 256 45 - - - - - - - - - 

SW Cancer & Res Ctr - - 16 3 - - - - - - - - - 

San Antonio, U of TX 2 - 68 - 49 - 3 - - 3 1 - - 

San Diego, U of CA - - 1,162 - 306 - - - - - - - - 

San Juan MBCCOP - - 55 - - - - - - - - - - 

Sanford Cancer Ctr - - 109 27 37 - - - - - - - - 

Santa Rosa Mem Hosp - - 31 - - - - - - - - - - 

Schiffler Cancer Ctr - - 58 - 49 - - - - - - - - 

Scott & White CCOP - - 98 25 - - - - - - - - - 

Sentara Cancer Inst - - 69 - - - - - - - - - - 

Sierra Nevada Mem - - 49 - - - - - - - - - - 

So Calif, U of 7 - 22 - - - - 6 - - - 4 - 

Somerset Med Ctr - - 10 - - - - - - - - - - 

Southeast CCC CCOP 9 - 366 80 238 - - 2 - - - - - 

Southern Nevada CCOP 1 - 115 16 50 - - - - - - - - 

St Francis Hospital - - 28 - - - - - - - - - - 

St Louis CCOP 2 - - - - 1 - - - - 3 - - 

St Louis University 1 - - - - - - - - - - - - 

St Luke's Mt State - - 87 29 - - - - - - - - - 






Outcomes & 

Comparative 


Cancer 

Survivorship 



St Vincent Hospital - - 71 - 68 - - - - - - - - 

Stanford University - - 63 - - - - - - - - - - 

Stormont-Vail Health - - 97 26 75 - - - - - - - - 

Summa Health System - - 27 8 - - - - - - - - - 

Sunnybrook Hlth SC - - 99 - - - - - - - - - - 

Sutter Hlth CRG-East - - 126 - - - - - - - - - - 

Swedish Medical Ctr - - 559 150 263 - - - - - - - - 

Tennessee, U of 2 - - - - - - 2 - - - - - 

Thompson Ca Surv Ctr - - 75 18 - - - - - - - - - 

Thunder Bay Reg HSC - - 24 - - - - - - - - - - 

Toledo CCOP - - 116 44 68 - - - - - - - - 

Trinitas Hospital - - 21 - 16 - - - - - - - - 

Tulane University 3 - 23 - 3 - - - - - - - - 

Tyler, U of TX - - 32 - - - - - - - - - - 

UAB Div of Prev Med - - 63 9 14 - - - - - - - - 

US Oncology - - 84 - - - - - - - - - - 

Upstate Carolina - 2 871 154 568 - - - - - - 1 - 

Utah, U of 3 - - - - 3 10 - - - - - - 

VAMC Asheville - - 1 - - - - - - - - - - 

VAMC Boston - - 67 41 - - - - - - - - - 

VAMC Cleveland - - 78 - - - - - - - - - - 

VAMC Dallas - - 69 - - - - - - - - - - 

VAMC Durham - - 13 - - - - - - - - - - 

VAMC Fargo - - 83 71 109 - - - - - - - - 

VAMC Gainesville - - 25 - - - - - - - - - - 

VAMC Hines - - 51 28 50 - - - - - - - - 

VAMC Houston - - 20 - - - - - - - - - - 

VAMC James A. Haley - - 4 - - - - - - - - - - 

VAMC Kansas City - - 74 22 - - - - - - - - - 

VAMC Loma Linda - - 28 8 - - - - - - - - - 

VAMC Long Beach - - 21 - - - - - - - - - - 

VAMC Louisville - - 31 - - - - - - - - - - 

VAMC McGuire - - 6 - - - - - - - - - - 

VAMC Minneapolis - - 137 84 3 - - - - - - - - 

VAMC New Jersey - - 18 - - - - - - - - - - 

VAMC Northport - - 14 - - - - - - - - - - 

VAMC Pittsburgh - - 16 - - - - - - - - - - 

VAMC Puget Sound - - 30 - - - - - - - - - - 

VAMC So Arizona - - 46 - - - - - - - - - - 

VAMC St Louis - - 16 - - - - - - - - - - 

VAMC Stratton - - 8 - - - - - - - - - - 

VAMC Syracuse - - 19 8 - - - - - - - - - 

VAMC Tuscaloosa - - 2 - - - - - - - - - - 

VAMC Washington DC - - 36 19 25 - - - - - - - - 

VAMC Western NY - - 5 - - - - - - - - - - 

VCU Massey CC - - 63 - - - - - - - - - - 

Valley Hospital - - 10 - - - - - - - - - - 






Outcomes & 

Comparative 


Cancer 

Survivorship 



Vancouver Hospital - - 241 47 - - - - - - - - - 

Vanderbilt Univ - - 86 - - - - - - - - - - 

Vermont Cancer Ctr - - 55 1 - - - - - - - - - 

Virginia Mason CCOP 10 - 24 4 - - 5 - - - - 10 - 

WNY Urology Assoc - - - 3 - - - - - - - - - 

WVU-Morgantown - - 14 - - - - - - - - - - 

Wake Forest Univ - - 12 - - - - - - - - - - 

Walter Reed AMC - - 94 42 - - - - - - - - - 

Washington Univ - - 70 18 - - - - - - - - - 

Wayne State Univ 7 - - - - - - - - 1 7 4 - 

Wayne State/Karmanos - - 7 - - - - - - - - - - 

West Clinic - - 13 - - - - - - - - - - 

Western Reg CCOP - - 44 - - - - - - - - - - 

Wichita CCOP 12 9 162 82 143 - - 8 - 12 - - - 

Wilford Hall Med Ctr - - 250 78 150 - - - - - - - - 

William Beau Hosp - - 215 26 108 - - - - - - - - 

Wisconsin, Univ of - - 91 - - - - - - - - - - 

Yale University 2 - - - - - - - - - - - - 

York Cancer Center - - 36 13 - - - - - - - - - 

ACOSOG 13 - - - - - - - - - - - - 

ANZ BCTG/ IBCSG - - - - - - - 58 - - - - - 

CALGB 75 - - - - - - 14 - - - - - 

ECOG 92 - - - - - - 86 - - - - - 

FSS/ IBCSG - - - - - - - 46 - - - - - 

GOG 3 - - - - - - - - - - - - 

NCCTG 29 - - - - - - - - - - - - 

NCIC 10 - - - - - - - - - - - - 

NSABP 48 - - - - - - - - - - - - 

RTOG 1 - - - - - - - - - - - - 

Total 568 36 17,780 2,436 8,013 16 31 257 3 34 35 95 3 

Note: Some studies may not be listed because they were either closed prior to July 1, 2011 or because they are currently active but have not had any accrual through September 6, 2012. 







E1609 E2108 E2906 E3805 E3A06 MA32 N0733 PR11 R04 R0848 R1010 S0622 S0702 S0715 S0927 S1013 S1200 

Abramson Cancer Ctr - - - - - - - - - - - - - - - - - 

Altamira Family Med - - - - - - - - - - - - - - - - - 

Anne Arundel Med Ctr - - - - - - - - - - - - - - - - - 

Arizona Cancer Ctr - - - - - - - - - - - - - - - - - 

Arizona, U of 5 - - - - 10 - - - - - - - - - - - 

Arkansas, U of 17 - - 1 - - - - - - - 8 11 6 3 - - 

Arkansas, Univ of - - - - - - - - - - - - - - - - - 

Atlanta Reg CCOP - - - - - - - - - - - - 14 7 - - - 

Aultman Hospital - - - - - - - - - - - - - - - - - 

Baptist Hosp East - - - - - - - - - - - - - - - - - 

Baptist Regional - - - - - - - - - - - - - - - - - 

Bassett Research Ins - - - - - - - - - - - - - - - - - 

Bay Area CCOP - - - - - 5 - - - - - 1 5 5 3 - - 

Baylor Univ Med Ctr 8 - - - - - - - - - - - - - - - - 

Beaumont CCOP - - - - - 17 - 1 - - - 1 29 7 - - - 

Berkshire Hem/Onc - - - - - - - - - - - - - - - - - 

Beth Israel Deacones - - - - - - - - - - - - - - - - - 

Boston MC MBCCOP - - - 1 - - - - - - - - - 1 - - - 

Boston Medical Ctr - - - - - - - - - - - - - - - - - 

Boston Univ Med Ctr - - - 1 - - - - - - - 2 - - - - - 

Brooke Army Med Ctr - - - - - 7 - - 4 - - 1 6 1 - - - 

Camcare Health - - - - - - - - - - - - - - - - - 

Capital Region PC - - - - - - - - - - - - - - - - - 

Carle Cancer Center - - - - - - - - - - - - - - - - - 

Cascadia Cancer Prev - - - - - - - - - - - - - - - - - 

Cedar Rapids CCOP - - - - - - - - - - - - - - - - - 

Cedars-Sinai Med Ctr - - - - - - - - - - - - - - - - - 

Central Baptist Hosp - - - - - - - - - - - - - - - - - 

Central IL CCOP - - - - - 26 - - - - 1 8 133 4 3 4 - 

Central PA Hem & Med - - - - - - - - - - - - - - - - - 

Centro Clinico - - - - - - - - - - - - - - - - - 

Chicago Hospitals, U - - - - - - - - - - - - - - - - - 

Christiana Care Hlth - - - - - - - - - - - - - - - - - 

Cincinnati MC, U of 2 - - - - - - - - - - - 9 - 2 - - 

Cincinnati, Univ of - - - - - - - - - - - - - - - - - 

City of Hope Med Ctr - - - - - - - - - - - - 15 - - - - 

Cleveland Clinic - - - - - - - - - - - - - - - - - 

Cleveland Clinic OH 1 - - 45 - 19 - - - - - 2 15 18 - - - 

Colorado Ca Res Prog - - - - - - - - - - - - - - - - - 

Colorado, U of 12 - - 11 - 15 - 3 - - - 7 26 12 - - - 

Colorado, Univ of - - - - - - - - - - - - - - - - - 

Columbia River CCOP - - - - - 3 - - - - - - 49 3 - - - 

Columbia University 1 2 - 5 - 19 - - 4 1 - - 15 8 3 - 1 

Columbus CCOP - - - - - - - - - - - 3 16 1 2 - - 

Conemaugh Mem MC - - - - - - - - - - - - - - - - - 

Connecticut, Univ of - - - - - - - - - - - - - - - - - 

DC United - - - - - - - - - - - - - - - - - 








Dartmouth Hitchcock - - - - - - - - - - - - - - - - - 

Davis, U of CA 6 1 - 10 - 12 - - 3 - - 5 23 26 7 1 - 

Dayton CCOP 1 - - - - - - - - - - - 20 1 5 - - 

Dickstein CTC - - - - - - - - - - - - - - - - - 

Downstate Med Ctr - - - - - - - - - - - - - - - - - 

Duluth CCOP - - - - - - - - - - - - - - - - - 

Faxton-St Luke's - - - - - - - - - - - - - - - - - 

Fox Chase Cancer Ctr - - - - - - - - - - - - - - - - - 

Galveston, U of TX - - - - - - - - - - - - 5 - - - - 

Geisinger Clinic - - - - - - - - - - - - - - - - - 

George Washington U - - - - - - - - - - - - - - - - - 

Glendale Mem Hosp - - - - - - - - - - - - - - - - - 

Good Samaritan Hosp - - - - - - - - - - - - - - - - - 

Good Samaritan MC - - - - - - - - - - - - - - - - - 

Grand Rapids CCOP 3 - - - - - - - - - - - 18 9 6 - - 

Greenville CCOP 1 - - - 6 - - - - 1 - - 16 9 6 - - 

Gulf Coast MBCCOP - - - 1 - - - - - - - - 11 - 1 - - 

H Lee Moffitt CC 15 1 - - - 9 - - 6 - - - 113 4 - - - 

Harbor-UCLA - - - - - - - - - - - - - - - - - 

Harrington CC - - - - - - - - 3 - - - 14 6 - - - 

Harris Methodist - - - - - - - - - - - - - - - - - 

Harrison Peeples HCC - - - - - - - - - - - - - - - - - 

Hawaii CCOP - - - - - - - - - - - - - - - - - 

Hawaii MBCCOP, U of - - - - - 9 - - - - - - 32 3 - - - 

Hem-Onc Assoc of CNY - - - - - - - - - - - - - - - - - 

Henry Ford Hosp - - - - - - - - - - - - 26 6 - - - 

Huntington Mem Hosp - - - - - - - - - - - - - - - - - 

INCan - - - - - - - - - - - - 40 - - - - 

INTEGRIS Oncology - - - - - - - - - - - - - - - - - 

Illinois, Univ of - - - - - - - - - - - - - - - - - 

Indiana University - - - - - - - - - - - - - - - - - 

Iowa Hosp, Univ of - - - - - - - - - - - - - - - - - 

Iowa Oncology CCOP - - - - - - - - - - - - - - - - - 

Ireland Cancer Ctr - - - - - - - - - - - - - - - - - 

Irvine, U of CA 1 - - - - - - - 1 1 - - 4 1 - - - 

Irvine, Univ of CA - - - - - - - - - - - - - - - - - 

Johns Hopkins Univ - - - - - - - - - - - - - - - - - 

Johnson City Med Ctr - - - - - - - - - - - - - - - - - 

Kaiser Permanente-GA - - - - - - - - - - - - - - - - - 

Kaiser-Oakland - - - - - - - - - - - - - - - - - 

KaiserPermanenteNCAL 2 - - - - 144 2 - - - - - - 69 5 - - 

Kalamazoo CCOP - - - - - - - - - - - - - - - - - 

Kansas City CCOP - - - - - 10 - - - - - - 31 - - - - 

Kansas, U of 2 - - 2 - - - - 11 1 - - 25 1 - - - 

Kentucky, U of - - 1 8 - - - - - - - - - - - - - 

Kentucky, Univ of - - - - - - - - - - - - - - - - - 

Kimmel Cancer Ctr - - - - - - - - - - - - - - - - - 








King Faisal Spec Hos - - - - - - - - - - - - 17 - - - - 

Knoxville, U of TN - - - - - - - - - - - - - - - - - 

Kootenai Cancer Ctr - - - - - - - - - - - - - - - - - 

LDS Hospital - - - - - - - - - - - - - - - - - 

LSU-New Orleans - - - - - - - - - - - - - - - - - 

LSU-New Orleans CCOP - - - - - 2 - - - - - - - 1 - - - 

LSU-Shreveport - - - - - - - - - - - - - - - - - 

LSU-Shreveport CCOP - - - - - - - - 2 - - - 17 7 2 - - 

Lahey Clinic Med Ctr 4 - - - - 2 - - - - - - - - - - - 

Lawrence & Mem Hosp - - - - - - - - - - - - - - - - - 

Lehigh Valley Hosp - - - - - - - - - - - - - - - - - 

Lionel B. Katchem - - - - - - - - - - - - - - - - - 

Los Angeles, U of CA - - - - - - - - - - - - - - - - - 

Loyola University 1 - 1 6 - 5 - - - 3 - 2 77 10 9 - - 

MD Anderson - - - - - - - - - - - - - - - - - 

MUSC, Hollings CC - 1 - - - 7 - - - - - - 7 - - - - 

Main Line/Lankenau - - - - - - - - - - - - - - - - - 

MaineGeneral MC - - - - - - - - - - - - - - - - - 

Marquette Gen Hosp - - - - - - - - - - - - - - - - - 

Marshfield Clinic - - - - - - - - - - - - - - - - - 

Martin Memorial CC - - - - - - - - - - - - - - - - - 

Maryland, Univ of - - - - - - - - - - - - - - - - - 

Mayo Clinic - - - - - - - - - - - - - - - - - 

Med Col of Wisconsin - - - - - - - - - - - - - - - - - 

Meharry Med College - - - - - - - - - - - - - - - - - 

MeritCare Hosp CCOP - - - - - - - - - - - - - - - - - 

Methodist Cancer Ctr - - - - - - - - - - - - - - - - - 

Methodist Hospital - - - - - - - - - - - - - - 1 - - 

Methodist, Dallas - - - - - - - - - - - - - - - - - 

Metro-Minnesota CCOP - - - - - - - - - - - - - - - - - 

Miami, Univ of - - - - - - - - - - - - - - - - - 

Michigan CRC CCOP - - - - - - - - - - - 9 30 29 10 - - 

Michigan, U of 2 - - 8 - 24 - - - - - 13 18 21 - - - 

Midtown Urology PC - - - - - - - - - - - - - - - - - 

Miguel Sosa Padilla - - - - - - - - - - - - - - - - - 

Mississippi, Univ of 1 - - 3 - 10 - - - - - 1 46 3 7 - - 

Missouri Baptist MC - - - - - - - - - - - - - - - - - 

Missouri Valley CCOP - - - - - - - - - - - - - - - - - 

Montana CCOP 1 - - 1 1 - - - - - - 6 17 2 5 - - 

Montefiore MC, N Div - - - - - - - - - - - - - - - - - 

Mount Sinai CCOP - - - - - - - - - - - - - - - - - 

Mt Zion Cancer Ctr - - - - - - - - - - - - - - - - - 

NY Methodist Hosp - - - - - - - - - - - - - - - - - 

National Cancer Ctr - - - - - - - - - - - - - - - - - 

Nebraska, Univ of - - - - - - - - - - - - - - - - - 

Nevada Cancer Inst - - - - - - - - - - - - 2 - - - - 

New Mexico MBCCOP - - - - - 9 - - - - - 2 7 11 1 - - 








New Mexico, Univ of - - - - - - - - - - - - - - - - - 

North Shore CCOP - - - - - - - - - - - - - - - - - 

NorthShore Univ - - - - - - - - - - - - - - - - - 

Northern Indiana CRC - - - - - - - - - - - - - - - - - 

Northern NJ Ca Assoc - - - - - - - - - - - - - - - - - 

Northwest CCOP 1 - - - - 22 1 - - 1 - 1 36 12 4 - - 

Northwestern Univ - - - - - - - - - - - - - - - - - 

Ochsner CCOP - - - - - - - - - - - - - - - - - 

Ohio State Univ 1 - - - - - - - - - - - - - - - - 

Oklahoma, Univ of - - - - - - - - - - - - - - - - - 

Oregon Hlth Sci Univ 5 - - - - 11 - - 3 - - - 22 1 - - - 

Orocovis Med Ctr - - - - - - - - - - - - - - - - - 

Ottawa General Hosp - - - - - - - - - - - - - - - - - 

Our Lady, Bellefonte - - - - - - - - - - - - - - - - - 

Ozarks CCOP - - - - - - - - - - - - - - - - - 

Ozarks Reg CCOP 3 - - 2 - - - - - - - - - 10 1 - - 

Pittsburgh Ca Inst - - - - - - - - - - - - - - - - - 

Princess Margaret - - - - - - - - - - - - - - - - - 

Prostate Cancer Ctr - - - - - - - - - - - - - - - - - 

Providence Hosp - - - - - - - - - - - - 9 4 1 - - 

Puget Sound 6 2 - - - 10 3 - - - - - 58 16 3 - - 

Queens Hospital Ctr - - - - - - - - - - - - - - - - - 

Regional CC-Waukesha - - - - - - - - - - - - - - - - - 

Regional Cancer Ctr - - - - - - - - - - - - - - - - - 

Rochester, Univ of 1 1 - 1 - - - - - - - 3 9 - 1 - - 

Roswell Park - - - - - - - - - - - - - - - - - 

Rush Univ Med Ctr - - - - - - - - - - - - - - - - - 

SELECT Coord Center - - - - - - - - - - - - - - - - - 

SUNY Stony Brook - - - - - - - - - - - - - - - - - 

SW Cancer & Res Ctr - - - - - - - - - - - - - - - - - 

San Antonio, U of TX 6 - - 16 - - - - - - - 1 17 - - - - 

San Diego, U of CA - - - - - - - - - - - - - - - - - 

San Juan MBCCOP - - - - - - - - - - - - - - - - - 

Sanford Cancer Ctr - - - - - - - - - - - - - - - - - 

Santa Rosa Mem Hosp - - - - - - - - - - - - - - - - - 

Schiffler Cancer Ctr - - - - - - - - - - - - - - - - - 

Scott & White CCOP - - - - - - - - - - - - 13 - - - - 

Sentara Cancer Inst - - - - - - - - - - - - - - - - - 

Sierra Nevada Mem - - - - - - - - - - - - - - - - - 

So Calif, U of - - - 11 - 5 - - - - - - - 21 - 3 - 

Somerset Med Ctr - - - - - - - - - - - - - - - - - 

Southeast CCC CCOP 3 - - 3 - 4 1 - - - - 2 66 25 4 2 - 

Southern Nevada CCOP - - - - - - - - - - - 1 4 1 - - - 

St Francis Hospital - - - - - - - - - - - - - - - - - 

St Louis CCOP 1 - - 6 - 10 - - - - - - 38 12 6 - - 

St Louis University - - - 4 - - - - - - - - 9 - - - - 

St Luke's Mt State - - - - - - - - - - - - - - - - - 








St Vincent Hospital - - - - - - - - - - - - - - - - - 

Stanford University - - - - - - - - - - - - - - - - - 

Stormont-Vail Health - - - - - - - - - - - - - - - - - 

Summa Health System - - - - - - - - - - - - - - - - - 

Sunnybrook Hlth SC - - - - - - - - - - - - - - - - - 

Sutter Hlth CRG-East - - - - - - - - - - - - - - - - - 

Swedish Medical Ctr - - - - - - - - - - - - - - - - - 

Tennessee, U of - - - - - 3 - - 6 - - - 3 - - - - 

Thompson Ca Surv Ctr - - - - - - - - - - - - - - - - - 

Thunder Bay Reg HSC - - - - - - - - - - - - - - - - - 

Toledo CCOP - - - - - - - - - - - - - - - - - 

Trinitas Hospital - - - - - - - - - - - - - - - - - 

Tulane University - 1 - - - - - - - - - - - - - - - 

Tyler, U of TX - - - - - - - - - - - - - - - - - 

UAB Div of Prev Med - - - - - - - - - - - - - - - - - 

US Oncology - - - - - - - - - - - - - - - - - 

Upstate Carolina - - - - - 4 - - - - - 5 8 3 4 - - 

Utah, U of 6 - - - - 22 - - 3 - - - 51 - 4 - - 

VAMC Asheville - - - - - - - - - - - - - - - - - 

VAMC Boston - - - - - - - - - - - - - - - - - 

VAMC Cleveland - - - - - - - - - - - - - - - - - 

VAMC Dallas - - - - - - - - - - - - - - - - - 

VAMC Durham - - - - - - - - - - - - - - - - - 

VAMC Fargo - - - - - - - - - - - - - - - - - 

VAMC Gainesville - - - - - - - - - - - - - - - - - 

VAMC Hines - - - - - - - - - - - - - - - - - 

VAMC Houston - - - - - - - - - - - - - - - - - 

VAMC James A. Haley - - - - - - - - - - - - - - - - - 

VAMC Kansas City - - - - - - - - - - - - - - - - - 

VAMC Loma Linda - - - - - - - - - - - - - - - - - 

VAMC Long Beach - - - - - - - - - - - - - - - - - 

VAMC Louisville - - - - - - - - - - - - - - - - - 

VAMC McGuire - - - - - - - - - - - - - - - - - 

VAMC Minneapolis - - - - - - - - - - - - - - - - - 

VAMC New Jersey - - - - - - - - - - - - - - - - - 

VAMC Northport - - - - - - - - - - - - - - - - - 

VAMC Pittsburgh - - - - - - - - - - - - - - - - - 

VAMC Puget Sound - - - - - - - - - - - - - - - - - 

VAMC So Arizona - - - - - - - - - - - - - - - - - 

VAMC St Louis - - - - - - - - - - - - - - - - - 

VAMC Stratton - - - - - - - - - - - - - - - - - 

VAMC Syracuse - - - - - - - - - - - - - - - - - 

VAMC Tuscaloosa - - - - - - - - - - - - - - - - - 

VAMC Washington DC - - - - - - - - - - - - - - - - - 

VAMC Western NY - - - - - - - - - - - - - - - - - 

VCU Massey CC - - - - - - - - - - - - - - - - - 

Valley Hospital - - - - - - - - - - - - - - - - - 








Vancouver Hospital - - - - - - - - - - - - - - - - - 

Vanderbilt Univ - - - - - - - - - - - - - - - - - 

Vermont Cancer Ctr - - - - - - - - - - - - - - - - - 

Virginia Mason CCOP - - - 3 - 1 - 4 - - - 1 55 11 - - - 

WNY Urology Assoc - - - - - - - - - - - - - - - - - 

WVU-Morgantown - - - - - - - - - - - - - - - - - 

Wake Forest Univ - - - - - - - - - - - - - - - - - 

Walter Reed AMC - - - - - - - - - - - - - - - - - 

Washington Univ - - - - - - - - - - - - - - - - - 

Wayne State Univ 2 - - - - 7 - - 3 - - - 7 - - - - 

Wayne State/Karmanos - - - - - - - - - - - - - - - - - 

West Clinic - - - - - - - - - - - - - - - - - 

Western Reg CCOP - - - - - - - - - - - - - - - - - 

Wichita CCOP - - - - - 10 - - - - - - 156 29 8 1 - 

Wilford Hall Med Ctr - - - - - - - - - - - - - - - - - 

William Beau Hosp - - - - - - - - - - - - - - - - - 

Wisconsin, Univ of - - - - - - - - - - - - - - - - - 

Yale University - - - - - - - - - - - - - - - - - 

York Cancer Center - - - - - - - - - - - - - - - - - 

ACOSOG - - - - - - - - - - - - - - - - - 

ANZ BCTG/ IBCSG - - - - - - - - - - - - - - - - - 

CALGB - - - - - - - - - - - - 135 - - - - 

ECOG - - - - - - - - - - - - 154 - - - - 

FSS/ IBCSG - - - - - - - - - - - - - - - - - 

GOG - - - - - - - - - - - - - - - - - 

NCCTG - - - - - - - - - - - - 188 - - - - 

NCIC - - - - - - - - - - - - - - - - - 

NSABP - - - - - - - - - - - - 9 - - - - 

RTOG - - - - - - - - - - - - 3 - - - - 

Total 121 9 2 149 7 473 7 8 49 8 1 85 2,009 437 117 11 1 



EARLY THERAPEUTICS COMMITTEE 



Chair: 



Designates 

Clinical Research Associate: 


Nurse: 

Pharmacologist: 


Early Therapeutics Liaisons 

Breast Committee: 

Genitourinary Committee: 

Lung Committee: 

Lymphoma Committee: 

Melanoma Committee: 

Myeloma Committee: 



3:30 p.m. – 4:30 p.m. 

Introduction to Early Therapeutics 

Time/Location 

Agenda 

Razelle Kurzrock, M.D. 

Bruce Redman, D.O. 

Antje Hoering, Ph.D. 

Rachael Sexton, M.S. 

Corrine Turrell, C.C.R.P. 


Christine McLeod 

Margaret Ward, R.N., B.S.N 

Siu-Fun Wong, Pharm.D. 


Fransisco Esteva, M.D. 

Neeraj Agarwal, M.D. 

Shirish M. Gadgeel, M.D. 

Daruka Mahadevan, M.D., Ph.D. 

TBD 

Frits van Rhee, M.D., Ph.D. 


■■ 

S0711, “A Phase I Trial of Dasatinib (BMS-354825) in Patients 

with Advanced Malignancies and Varying Levels of Liver 

Dysfunction.” Dr. Sarantopoulos. Activated: 10/15/08. 

Open Discussion 


■■ 

S0528 Phase I study evaluating the combination of lapatinib 

and everolimus in patients with advanced cancers: SWOG study 

S0528. SM Gadgeel, D Lew, TW Synold, P LoRusso, V Chung, 

SD Christensen, DC Smith, L Kingsbury, A Hoering, R Kurzrock. 

Journal of Clinical Oncology, submitted 9/12. 

Early Therapeutics Committee 



S0711 

City of Hope Med Ctr 1 - 

Davis, U of CA 1 - 

Henry Ford Hosp 10 - 

Kansas, U of 3 - 

Kentucky, U of - 5 

MUSC, Hollings CC - 2 

Michigan, U of - 10 

New Mexico MBCCOP - 5 

San Antonio, U of TX 38 1 

Scott & White CCOP 2 - 

So Calif, U of 8 - 

Wichita CCOP - 21 

Total 63 44 

S0916 

Note: Some studies may not be listed because they were either closed prior 

to July 1, 2011 or because they are currently active but have not had any 

accrual through September 6, 2012. 

Publications 








GASTROINTESTINAL COMMITTEE 


Chair: 

Vice-Chair: 




Gastroesophageal: 

Pancreatic: 

Hepatobiliary: 

Colon: 

Rectal: 


Drug Development: 


Designates 

Cancer Control Liaison: 



Nurses: 




Charles D. Blanke, M.D. 

Heinz-Josef Lenz, M.D. 


Jacqueline K. Benedetti, Ph.D. 

Shannon McDonough, M.S. 

Cathryn Rankin, M.S. 

Syma Iqbal, M.D. 

Lawrence P. Leichman, M.D. 

Scott A. Hundahl, M.D. (Surgical 

representative) 

Philip A. Philip, M.D., Ph.D. 

Andrew M. Lowy, M.D. (Surgical 


Anthony B. El-Khoueiry, M.D. 

Abby B. Siegel, M.D. 

Syed Ahmad, M.D. (Surgical 


Philip J. Gold, M.D. 

Anthony F. Shields, M.D., Ph.D. 

Kevin G. Billingsley, M.D. 

(Surgical representative) 

Lisa A. Kachnic, M.D. 

Cathy Eng, M.D. 

Christopher L. Corless, M.D., Ph.D. 

Heinz-Josef Lenz, M.D. 

Ramesh Ramanathan, M.D. 

Sunil Sharma, M.D. 

Lisa A. Kachnic, M.D. 

Jason A. Zell, D.O. 

TBD 

Stephanie Edwards 


Rodney Sutter 

Rita Kaul, R.N., B.S.N. 

Valerie A. Parks, R.N. 

Mortimer Brown, Ph.D. 

Porsha James, M.P.H. 


Kimberly Kaberle 

Time/Location 

Agenda 

Gastroesophageal 


■■ 

S1005, “A Phase II Study of MK-2206 (NSC-749607) as Second 

Line Therapy for Advanced Gastric and Gastroesophageal 

Junction Cancer.” Drs. Ramanathan and Kennecke. Activated: 

1/1/11. 

■■ 

■■ 

S1201, “A Randomized Phase II Pilot Study Prospectively 

Assigning Treatment for Patients Based on ERCC1 (Excision 

Repair Cross-Complementing 1) for Advanced/Metastatic 

Esophageal, Gastric or Gastroesophageal Junction (GEJ) 

Cancer.” Drs. Iqbal and Lenz. Activated: 2/8/12. 

CTSU/RTOG 1010, “A Phase II Trial Evaluating the Addition of 

Trastuzumab to Trimodality Treatment of HER2-Overexpressing 

Esophageal Adenocarcinoma.” Dr. L. Leichman. Activated: 

9/1/11. 

Proposed 

■■ 

S1302, “A Phase II Study of Trastuzumab and mFOLFOX6 

as First Line Therapy of HER2-positive Advanced Gastric or 

Gastroesophageal Cancer.” Dr. Lenz. 

Pancreatic 


■■ 

S1115, “Randomized Phase II Clinical Trial of AZD-6244 (NSC- 

741078) and MK-2206 (NSC-749607) vs mFOLFOX in Patients 

with Metastatic Pancreatic Cancer After Prior Chemotherapy.” 

Drs. Chung and Philip. Activated: 8/15/12. 

■■ 

■■ 

CTSU/C80701, “Randomized Phase II Study of Everolimus Alone 

Versus Everolimus Plus Bevacizumab in Patients with Locally 

Advanced or Metastatic Pancreatic Neuroendocrine Tumors.” Dr. 

Wolin. Activated: 3/1/12. 

CTSU/RTOG 0848, “A Phase III Trial Evaluating Both Erlotinib 

and Chemoradiation as Adjuvant Treatment for Patients with 

Resected Head of Pancreas Adenocarcinoma.” Dr. Philip. 



Room: Crystal A Ballroom 

5:00 p.m. – 7:00 p.m. 




Hepatobiliary 


■■ 

CTSU/C80802, “Phase III Randomized Study of Sorafenib 

Plus Doxorubicin Versus Sorafenib in Patients with Advanced 

Hepatocellular Carcinoma (HCC).” Activated: 6/1/11. 

■■ 

CTSU/E1208, “A Phase III Randomized, Double-Blind Trial of 

Chemoembolization with or without Sorafenib in Unresectable 

Hepatocellular Carcinoma (HCC) in Patients with and without 

Vascular Invasion.” Dr. El-Khoueiry. Activated: 7/15/10. 


■■ 

S0809, “A Phase II Trial of Adjuvant Capecitabine / Gemcitabine 

Chemotherapy Followed by Concurrent Capecitabine and 

Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC).” Drs. 

Ben-Josef, Zalupski, Lowy and Corless. Activated: 12/1/08; 

Closed: 10/1/12. 


■■ 

S1214, “A Randomized Open-Label Multi-Institution Phase II 

Study of Cabozantinib (NSC-761968) + Best Supportive Care 

(BSC) Compared to BSC + Placebo in the Second-Line Treatment 

of Patients with Advanced Hepatocellular Carcinoma (HCC).” 

Drs. El-Khoueiry and Thomas. 

■■ 

S1218, “Randomized Phase II Trial of Single Agent MEK Inhibitor 

GSK11200212 vs. 5-Fluorouracil or Capecitabine in Refractory 

Advanced Biliary Cancer.” Dr. Kim. 

Colon 


■■ 

CTSU/C80702, “A Phase III Trial of 6 versus 12 Treatments 

of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients 

with Resected Stage III Colon Cancer.” Dr. Shields. Activated: 

8/15/10. 


■■ 

S0820, “A Double Blind Placebo-Controlled Trial of Eflornithine 

and Sulindac to Prevent Recurrence of High Risk Adenomas and 

Second Primary Colorectal Cancers in Patients with Stage 0-III 

Colon Cancer, Phase III.” Dr. Zell. 

■■ 

S-C80405-A, “Analysis of EGFR and ERCC1 Markers and 

Progression-Free Survival in Patients with Advanced Colorectal 

Cancer Enrolled on C80405.” Drs. Shields and Lenz. 

Rectal 


■■ 

S0713, “A Phase II Study of Oxaliplatin, Capecitabine, 

Cetuximab and Radiation in Pre-Operative Therapy of Rectal 

Cancer.” Drs. G. Leichman, Smalley, Billingsley and Lenz. 


■■ 

CTSU/N1048, “A Phase II/III Trial of Neoadjuvant FOLFOX with 

Selective Use of Combined Modality Chemoradiation versus 

Preoperative Combined Modality Chemoradiation for Locally 

Advanced Rectal Cancer Patients Undergoing Low Anterior 

Resection with Total Mesorectal Excision.” Dr. Eng. Activated: 

4/15/12. 

Other 


■■ 


Facto Receptor (Her01/EGFR) Inhibitor-Induced Dermatologic 


Therapy – EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRI- 

Induced Skin Toxicities.” Drs. Wong, Moinpour, and Wade. 



■■ 

S0518, “Phase III Prospective Randomized Comparison of Depot 

Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus 

Bevacizumab (NSC #704865) in Advanced, Poor Prognosis 

Carcinoid Patients.” Drs. Yao, Kvols and Moran. Activated: 

12/1/07; Closed: 9/1/12. 

Correlative Studies 

■■ 

S0205A-ICSC, “Predictive and Prognostic Value of Tumor 

K-ras Mutation Status, Amphiregulin and Epiregulin and Gene 

Expression Levels and Germline Polymorphisms Involved in the 

EGFR and Gemcitabine Pathway in Advanced Pancreas Cancer: 

A Pilot Study of Tissues from Southwest Oncology Group Study 

S0205.” Dr. Lenz. 


■ ■ “A Randomized Phase II International Study Assessing Adjuvant 

Standard and High-Dose Imatinib Mesylate Treatment in Fully 

Resected Intermediate and High-Risk GIST Patients with KIT 

Exon 9 Mutations.” Dr. Blanke. 




■■ 

■ ■ 

■■ 

■■ 

■■ 

Pilot esophageal study assessing treatment based on ERCC-1 

data. Dr. L. Leichman. 

“A Phase II Randomized Study of FOLFIRINOX + Pegylate 

Recombinant Human Hyaluronidase (PEGPH20) versus 

FOLFIRINOX Alone in Patients with Metastatic Pancreatic 

Adenocarcinoma”. Dr. Ramanathan. 

Borderline unresectable locally advanced pancreas. Drs. Esnaola 

and Ahmad. 

Phase II NCCTG Cholangiocarcinoma: Concept for metatstatic 

disease involving IMC112 and PARP inhibitor. 

Randomized Phase II Study Comparing Dual BRAF and PI3k 

Inhibition to Standard of Care Chemotherapy in BRAF Mutant 

Metastatic Colorectal Cancer. Dr. Kopetz. 

■■ 

■■ 

R9704 Failure to adhere to protocol specified radiation 

therapy guidelines was associated with decreased survival in 

RTOG 9704 - a phase III trial of adjuvant chemotherapy and 

chemoradiotherapy for patients with resected adenocarcinoma 

of the pancreas. RA Abrams, KA Winter, WF Regine, H Safran, 

JP Hoffman, R Lustig, AA Konski, AB Benson, JS Macdonald, TA 

Rich, CG Willett. International Journal of Radiation Oncology, 

Biology & Physics, 82(2):809-816, 2012. http://www.ncbi.nlm. 

nih.gov/pubmed/21277694 

R9704 Five year results of US Intergroup/RTOG 9704 with 

postoperative CA 19-9 < 90 U/mL and comparison to the 

CONKO-001 trial. AC Berger, K Winter, JP Hoffman, WF Regine, 

RA Abrams, H Safran, GM Freedman, AB Benson, J Macdonald, 

CG Willett. International Journal of Radiation Oncology, Biology 

& Physics 2012 June 9 [Epub ahead of print]. http://www.ncbi. 

nlm.nih.gov/pubmed/22682806 

■■ 

A Randomized Phase II Study Comparing The Novel MEK 

Inhibitor TAK-733 to Standard of Care Chemotherapy in Patients 

with KRAS Mutant, PI3K Wild-type Metastatic Colorectal 

Cancer. Dr. Lieu. 

Publications 


■■ 

S0030 Higher AUC and reduced capecitabine clearance in elderly 

patients with advanced colorectal cancer (SWOG 0030). S 

Louie, B Ely, H Lenz, K Albain, C Gotay, D Coleman, D Raghavan, 

A Shields, P Gold, CD Blanke. British Journal of Cancer, under 

review 8/12 





■■ 

S0414 Cetuximab plus cisplatin, irinotecan, and thoracic 

radiotherapy as definitive treatment for locally advanced, 

unresectable esophageal cancer: a phase II study of the SWOG 

(S0414). M Tomblyn, B Goldman, C Thomas, J Benedetti, H 

Lenz, V Mehta, T Beeker, P Gold, J Abbruzzese, C Blanke. 

Journal of Thoracic Oncology 7(5):906-992, 2012. http://www. 


■■ 

S9304 SWOG S9304 phase III intergroup trial’s 

pharmacogenetic analysis: association of polymorphisms with 

survival and toxicity in stage II/III rectal cancer patients treated 

with 5-fluorouracil and pelvic radiation. P Bohanes, CJ Rankin, 

CD Blanke, T Winder, CM Ulrich, SR Smalley, K Danenberg, KW 

Makar, W Zhang, JK Benedetti, H-J Lenz. Journal of Clinical 

Oncology, submitted 9/12 

■■ 

S9008 Updated analysis of SWOG-directed intergroup study 

0116: a phase III trial of adjuvant radiochemotherapy versus 

observation following curative gastric cancer resection 

(CALGB-9195; ECOG-6290; NCCTG-90-41-51; RTOG 9018 and 

SWOG 9008. S Smalley, J Benedetti, D Haller, S Hundahl, N 

Estes, J Ajani, L Gunderson, B Goldman, J Martenson, J Jessup, 

G Stemmermann, C Blanke, J Macdonald. Journal of Clinical 

Oncology 30(19):2327-2333, 2012. http://www.ncbi.nlm.nih. 

gov/pubmed/22585691 



Gastrointestinal Committee 



C80405 

C80701 

C80702 

C80802 

E1208 

E5202 

R04 

R0848 

R1010 

S0518 

S0600 

S0713 

S0727 

S0809 

S0941 

S1005 

S1201 

Arizona, U of - - - - - - - - - - - 1 - - 1 - - 

Arkansas, U of 9 - 1 1 11 12 - - - 3 - - 1 1 4 3 - 

Atlanta Reg CCOP 30 - - - - 43 - - - - - - 2 2 - - - 

BC Cancer Agency - - - - - - - - - - - - - - - 3 - 

Bay Area CCOP - - - - - - - - - - - - 1 - - - - 

Baylor College 4 - 5 - - 3 - - - - - 5 2 - - 2 - 

Beaumont CCOP 10 1 - - - 7 - - - - - - 1 - - - - 

Boston MC MBCCOP 3 - 1 2 - - - - - 1 - - 1 3 1 - - 

Boston Univ Med Ctr 3 - - - - - - - - - 1 - 7 - - - - 

Brooke Army Med Ctr 8 - 1 - - 18 4 - - - - - 1 - - - - 

Cedars-Sinai Med Ctr - 4 - - - - - - - 22 - - - - - - - 

Central IL CCOP 17 - 6 - - - - - 1 10 2 11 8 - 2 - - 

Cincinnati MC, U of - - - - 2 - - - - 8 - - - 2 - 2 - 

City of Hope Med Ctr 26 - 1 - - - - - - - 3 - 5 - - - - 

Cleveland Clinic OH 11 - 5 - - 4 - - - 1 - - - - - - - 

Colorado, U of 6 - 4 - 2 16 - - - 5 - - 4 1 - 1 - 

Columbia River CCOP 7 - - - - 2 - - - 6 - - - 4 - - - 

Columbia University 1 - 1 - 1 9 4 1 - 4 - 3 - - - - - 

Columbus CCOP 13 - 4 1 - - - - - 4 4 - - - - - - 

Davis, U of CA 51 - 8 - - 6 3 - - 9 1 1 6 1 9 - - 

Dayton CCOP 8 - - - - 2 - - - - 3 4 - 1 1 - 1 

Galveston, U of TX 13 - - - 2 - - - - - - - - - - - - 

Grand Rapids CCOP - - - - - 5 - - - - 1 1 8 - - 3 - 

Greenville CCOP - - - - - 28 - 1 - 5 - - - - - - - 

Gulf Coast MBCCOP - - - - - 1 - - - - - 1 4 - - - - 

H Lee Moffitt CC 11 - 1 - - 12 6 - - 22 - - 4 - - - - 

Harrington CC 3 - - - - 6 3 - - 1 - - - - - - - 

Hawaii MBCCOP, U of 30 - 8 - - 15 - - - - - - - - 1 - - 

Henry Ford Hosp - - - - - - - - - - - 1 - - - - - 

Irvine, U of CA 8 - 8 - - 11 1 1 - - 3 - 1 1 3 4 - 

KaiserPermanenteNCAL 11 - 37 2 - - - - - 3 - - - - - - - 

Kansas City CCOP - - - - 1 - - - - - - - 14 - 2 - - 

Kansas, U of 37 - 15 - 2 12 11 1 - 5 - 4 - 2 - 3 - 

Kentucky, U of 2 - 1 - - - - - - - - - - - - - - 

LSU-New Orleans CCOP 14 - 3 - - - - - - 1 - - - - - - - 

LSU-Shreveport 1 - - - - - - - - - - - - - - - - 

LSU-Shreveport CCOP 6 - 1 - - 4 2 - - - - - 1 - - - - 

Lahey Clinic Med Ctr - - - - 1 - - - - - - - - - - - - 



Gastrointestinal Committee 



C80405 

C80701 

C80702 

C80802 

E1208 

E5202 

R04 

R0848 

R1010 

S0518 

S0600 

S0713 

S0727 

S0809 

S0941 

S1005 

S1201 

Loyola University 5 - 4 - - 23 - 3 - - - - - 4 5 - - 

MD Anderson 18 - - - - 5 - - - 44 - - - - - - - 

MUSC, Hollings CC - - - - - - - - - - 1 - 8 4 2 - - 

Michigan CRC CCOP 1 - - - - - - - - 6 1 - - - 1 2 - 

Michigan, U of - - - - 3 1 - - - 8 - 2 5 6 - - - 

Mississippi, Univ of 11 - 1 - - 25 - - - 7 2 - - - 1 - - 

Montana CCOP 2 - 1 - - 5 - - - 3 3 - 1 - 1 2 - 

Nevada Cancer Inst 2 - - - - - - - - - - - - - - - - 

New Mexico MBCCOP - - - - - - - - - 14 - - 5 - - - - 

Northwest CCOP 13 - 1 1 - 8 - 1 - 2 - - - - - - - 

Oregon Hlth Sci Univ 7 - 3 - - 3 3 - - - - - 2 - - 4 - 

Ozarks Reg CCOP 7 - 5 - - 5 - - - 10 1 - - - - 4 - 

Providence Hosp 11 - 2 - 1 12 - - - - - - - - - - - 

Puget Sound 28 - 8 1 - 20 - - - 6 6 1 4 2 1 1 2 

Rochester, Univ of 15 - 3 - - 5 - - - 2 - 10 3 - - 5 1 

San Antonio, U of TX 20 - 1 - - 8 - - - - - - 1 - - - - 

Santa Rosa CCOP 1 - - - - 2 - - - - - - - - - - - 

Scott & White CCOP 7 - 1 - - - - - - - 2 - 2 - - - - 

So Calif, U of 65 - 14 - 5 30 - - - 9 9 11 9 3 4 - 2 

Southeast CCC CCOP - - - - - 20 - - - 7 - 7 10 1 - 2 1 

Southern Nevada CCOP - - - - - - - - - 3 - - - - - - - 

St Louis CCOP 1 - - - - 8 - - - 8 - - - - - - - 

St Louis University 4 - - - - 1 - - - 3 - - 3 - - 1 - 

Tennessee, U of 26 - - 3 - 5 6 - - 2 1 - - - - - - 

Tulane University - - - - - - - - - 1 - - - - - - - 

Upstate Carolina 8 - 1 - - 5 - - - - 1 1 - 1 - - - 

Utah, U of 18 - 3 - - 17 3 - - - - - 2 - - - - 

Virginia Mason CCOP 4 - - - - 1 - - - 1 - - - - - 1 - 

Wayne State Univ 30 - 10 - - 12 3 - - - 2 - 8 3 - - - 

Wichita CCOP - - 5 2 - - - - - 16 1 5 - 4 1 - - 

Yale University - - - 1 - - - - - - - - - - - - - 

ACOSOG - - - - - - - - - - - - - 3 - - - 

CALGB - - - - - - - - - 73 2 - - 15 - - - 

ECOG - - - - - - - - - 44 7 - - 15 - - 1 

NCCTG - - - - - - - - - 39 12 - - 5 - - 1 

NSABP - - - - - - - - - 4 3 - - 1 - - - 

RTOG - - - - - - - - - - - - - 19 - - - 

Total 647 5 174 14 31 437 49 8 1 422 72 69 134 104 40 43 9 



GENITOURINARY COMMITTEE 



Chair: 

Vice-Chair: 






Surgery: 

Medical Oncology: 

Pathology: 

Liaison to the SPORES: 


Designates 


Cancer Control: 


Nurses: 






11:30 a.m. – 3:30 p.m. 

Time/Location 

Agenda 

Ian M. Thompson, Jr., M.D. 

Nicholas J. Vogelzang, M.D. 


Cathy M. Tangen, Dr.P.H. 

Hongli Li, M.S. 

David J. McConkey, Ph.D. 

David Raben, M.D. 

Daniel J. Culkin, M.D. 

Celestia S. Higano, M.D. 

M. Scott Lucia, M.D. 

Colin P.N. Dinney, M.D. 

Neeraj Agarwal, M.D. 

Debra W. Christie, M.B.A. 

Peter J. Van Veldhuizen, M.D. 

Jean Barce 

Austin Hamm 

Brian Zeller 

Deborah A. Halk, R.N. 

Rick Bangs (Bladder) 

Tony Crispino (Prostate) 

Gilland Dea, Pharm.D. 

Jessie Modlin, Pharm.D. 

Jennifer I. Scott 

Priority Studies 

■■ 

S1216, “A Phase III Randomized Trial Comparing Androgen 

Deprivation Therapy + TAK-700 With Androgen Deprivation 

Therapy + Bicalutamide In Patients With Newly Diagnosed 

Metastatic Hormone Sensitive Prostate Cancer.” 

Bladder 

Organ Site Chairs: Drs. Daniel P. Petrylak (Advanced) and Seth P. 

Lerner (Local) 


■■ 

S1011, “A Phase III Surgical Trial to Evaluate the Benefit 

of a Standard Versus an Extended Pelvic Lymphadenectomy 

Performed at Time of Radical Cystectomy for Muscle Invasive 

Urothelial Cancer.” Drs. Lerner, Koppie, Alva and Svatek and R. 

Bangs. Activated: 8/1/11. 

■■ 

■■ 

CTSU/C90601, “A Randomized Double-Blinded, Phase III 

Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to 

Gemcitabine, Cisplatin, and Placebo in Patients with Advanced 

Transitional Cell Carcinoma.” Dr. Flaig. Activated: 8/15/09. 

CTSU/R0524, “A Phase I/II Trial of a Combination of Paclitaxel 

and Trastuzumab with Daily Irradiation or Paclitaxel Alone 

with Daily Irradiation Following Transurethral Surgery for Non- 

Cystectomy Candidates with Muscle-Invasive Bladder Cancer.” 

Dr. Swanson. Activated: 12/15/06. 


■■ 

S0337, “A Phase III Blinded Study of Immediate Post-TURBT 

Instillation of Gemcitabine versus Saline in Patients with Newly 

Diagnosed or Occasionally Recurring Grade I/II Superficial 

Bladder Cancer.” Drs. Messing, Sahasrabudhe, Koppie, Wood 

and Mack. Activated: 7/15/07; Closed: 8/15/12. 

Prostate 

Organ Site Chairs: Drs. David I. Quinn (Advanced) and Martin E. 

Gleave and David Raben (Local) 


■■ 

S0925, “A Phase II Randomized Study of Androgen Deprivation 

Combined with IMC-A12 Versus Androgen Deprivation Alone 

for Patients with New Hormone-Sensitive Metastatic Prostate 

Cancer.” Drs. Yu and Higano. Activated: 12/15/10. 

■■ 

■■ 

S13XX, “COXEN (Coexpression Extrapolation) Directed 

Neoadjuvant Chemotherapy for Bladder Cancer.” 

Mims/Heath Transformative Renal Trial 

■■ 

S1014, “Abiraterone Acetate Treatment for Prostate Cancer 

Patients with a PSA of More Than Four Following Initial 

Androgen Deprivation Therapy, Phase II.” Drs. Flaig and 

Hussain. Activated: 8/9/11. 

■■ 

CTSU/C90203, “A Randomized Phase III Study of Neo- 

Adjuvant Docetaxel and Androgen Deprivation Prior to Radical 



GENITOURINARY COMMITTEE 

■■ 

Prostatectomy Versus Immediate Radical Prostatectomy in 

Patients with High-Risk, Clinically Localized Prostate Cancer.” 

Dr. Kim. Activated: 7/1/07. 

CTSU/E3805, “CHAARTED: ChemoHormonal Therapy versus 

Androgen Ablation Randomized Trial for Extensive Disease in 

Prostate Cancer.” Dr. Garcia. Activated: 9/1/08. 


■■ 

CTSU/C90202, “A Randomized Double-Blind, Placebo-Controlled 

Phase III Study of Early versus Standard Zoledronic Acid to 

Prevent Skeletal Related Events in Men with Prostate Cancer 

Metastatic to Bone.” Dr. Bhoopalam. Activated: 8/1/04; 

Closed: 4/4/12. 


■■ 

S1216, “A Phase III Randomized Trial Comparing Androgen 

Deprivation Therapy + TAK-700 With Androgen Deprivation 

Therapy + Bicalutamide In Patients With Newly Diagnosed 

Metastatic Hormone Sensitive Prostate Cancer.” Dr. Agarwal. 

Renal Cell 

Organ Site Chairs: Drs. Primo N. Lara, Jr. (Advanced) and Edward M. 

Messing (Local) 


■■ 

S0931, “EVEREST: EVErolimus for Renal Cancer Ensuing 

Surgical Therapy, A Phase III Study.” Drs. Ryan, Heath, Lara, 

Palapattu and Mack. Activated: 4/1/11. 

■■ 

S1107, “Parallel (Randomized) Phase II Evaluation of ARQ 197 

and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell 

Carcinoma.” Drs. Twardowski and Lara. Activated: 8/20/12. 

Cancer Control 

Organ Site Chair: Dr. Peter J. Van Veldhuizen 


■■ 


to Asses the Incidence of Osteonecrosis of the Jaw (ONJ) in 

Cancer Patients with Bone Metastases Starting Zoledronic 

Acid Treatment.” Drs. Van Poznak, Gralow, Bagramian, and 

Schubert, and Lisa Hansen, R.N. Activated: 12/15/08. 

■■ 

CTSU/C70807, “The Men’s Eating and Living (MEAL) Study: A 

Randomized Trial of Diet to Alter Disease Progression in Prostate 

Cancer Patients on Active Surveillance.” Dr. Van Veldhuizen. 


Publications 




All PCPT and SELECT publications are listed under Cancer Control & 

Prevention Committees. 


■■ 

S8894/9346 Has survival prognosis of men with newly 

diagnosed M1 prostate cancer changed over time A SWOG 

phase III trial experience (S8894 & S9346). CM Tangen, MHA 

Hussain, CS Higano, MA Eisenberger, EJ Small, G Wilding, BJ 

Donnelly, DG McLeod, PF Schellhammer, ED Crawford, NJ 

Vogelzang, IJ Powell, IM Thompson. Journal of Urology 2012 

Aug 22 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/ 

pubmed/22921015 

■■ 

■■ 

CTSU/C90802, “Randomized Phase III Trial Comparing 

Everolimus Versus Everolimus Plus Bevacizumab for Advanced 

Renal Cell Carcinoma Progressing After Treatment with Tyrosine 

Kinase Inhibitors.” Dr. Vaishampayan. Activated: 5/15/12. 

CTSU/E2810, “Randomized Double-Blind Phase III Study of 

Pazopanib vs. Placebo in Patients with Metastatic Renal 

Cell Carcinoma Who Have No Evidence of Disease Following 

Metastatectomy.” Dr. Pal. Activated: 9/1/12. 


■■ 

NCIC PR7 Intermittent androgen suppression for rising PSA 

level after radiotherapy. J Crook, CJ O’Callaghan, G Duncan, 

DP Dearnaley, CS Higano, EM Horwitz, E Frymire, S Malone, J 

Chin, A Nabid, P Warde, T Corbett, S Angyalfi, SL Goldenberg, 

Gospodarowicz, F Saad, JP Logue, E Hall, PF Schellhammer, K 

Ding, L Klotz. New England Journal of Medicine, 367(10):895- 

903, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22931259 


■■ 

S9917 Incidence of Prostate Cancer after HGPIN diagnosis: 

results from SWOG S9917. W Sakr, M Ray, CM Tangen, IM 

Thompson, EA Klein, K Kasza, L Minasian, H Parnes, DP Wood, 

JR Marshall. Journal of Clinical Oncology, submitted 9/12.


Genitourinary Committee 



C70807 

C90202 

C90203 

C90601 

C90802 

E2804 

E2805 

E3805 

MDA3410 

Arizona, U of - - - - - - 5 - - - - - - - - - 

Arkansas, U of - 5 - 3 1 3 11 1 1 - - 4 4 2 - 1 

Atlanta Reg CCOP 1 - - 2 - - 20 - - - - - - 6 - - 

BC Cancer Agency - - - - - - - - - - - - 6 - - - 

Baylor College - 29 - 2 - 1 4 - - - - 5 - - 7 - 

Baylor College-UCOP - - - - - - 13 - - - - 36 - - - - 

Beaumont CCOP 4 - - - - - 8 - - 1 - - - - - - 

Boston MC MBCCOP - - - - - - - 1 - - - - - - - - 

Boston Univ Med Ctr - - - - - - - 1 - - - - - - - - 

Brooke Army Med Ctr - - 3 - - - 11 - - - - 22 - - - - 

Cedars-Sinai Med Ctr 1 - - - - - - - - - - 9 1 - - - 

Central IL CCOP - - - 1 - - - - - - - - 3 8 - - 

Cincinnati MC, U of - 1 - - - - 5 - - - - - - - - - 

City of Hope Med Ctr - - 10 - - - 9 - - - - - 14 5 - - 

Cleveland Clinic OH 1 - - 3 - 1 24 45 - - - 1 - - 1 - 

Colorado, U of 1 1 12 8 - - 12 11 - 3 - 21 8 6 - - 

Columbia River CCOP - - - - - - 1 - - - - - - - - - 

Columbia University - - - 3 - 1 12 5 - - - 8 - 3 - - 

Columbus CCOP - - - 1 - - - - - - - - - - - - 

Davis, U of CA - - 13 2 - 1 28 10 3 - - 39 4 12 - - 

Dayton CCOP - - - - - - 2 - - - - - 5 3 - - 

E Virginia UCOP - 1 - - - - 9 - - - - - - - - - 

Galveston, U of TX - - - - - - - - 1 - - - - 1 - - 

Grand Rapids CCOP - - - - - 4 14 - - - - - 1 3 - - 

Greenville CCOP - - - - - - 5 - - - - - - - - - 

Gulf Coast MBCCOP - - - - - - 1 1 - - - - - 1 - - 

H Lee Moffitt CC - 8 2 - - - 52 - 1 - - - 6 - - - 

Hawaii MBCCOP, U of - 2 - - - - 3 - - - - - 1 - - - 

Henry Ford Hosp - 1 1 2 - - 3 - - - - 7 3 3 - - 

Irvine, U of CA - - - - - 1 8 - - - - - - 1 - - 

KaiserPermanenteNCAL - - - - 1 - 9 - - - - - - 1 - - 

Kansas City CCOP - - - - - - 7 - - - - - - 2 - - 

Kansas, U of 2 4 11 1 - 2 19 2 - - 3 22 2 3 - - 

Kentucky, U of 1 - - 4 - - 3 8 - - - - - - - - 

LSU-New Orleans CCOP 1 - 2 - - - - - - - - - - - - - 

LSU-Shreveport CCOP - 2 1 - - - 3 - - - - 20 - 1 - - 

Loyola University - 14 11 - - - 10 6 3 - - 7 3 8 1 - 

MD Anderson - - 3 - - - 59 - - - - 17 - - 5 - 

PR11 

R0524 

S0337 

S0925 

S0931 

S1011 

S1014 



Genitourinary Committee 



C70807 

C90202 

C90203 

C90601 

C90802 

E2804 

E2805 

E3805 

MDA3410 

MUSC, Hollings CC - - - 3 - - 6 - - - - - 5 - - - 

Michigan CRC CCOP - - 2 1 - - - - - - - - 2 5 - - 

Michigan, U of - - - - - - 13 8 - - - 7 15 9 - - 

Michigan, U of-UCOP - - - - - - - - - - - 27 - - - - 

Mississippi, Univ of - - - 1 - 1 12 3 - - - - - 1 - - 

Montana CCOP - - - - - - 1 1 - - - - 1 1 - - 

New Mexico MBCCOP - - 1 - - - - - - - - - - - - - 

Northwest CCOP - 1 - - - - 6 - - - - - 3 - - - 

Oklahoma, U of-UCOP - - - - - - - - - - - 25 - - - - 

Oregon Hlth Sci Univ - - 1 - - - 11 - - - - 6 - 10 1 - 

Ozarks Reg CCOP - - - - - 2 2 2 - - - - - 2 - - 

Providence Hosp - - - - - 1 - - - - - - - - - - 

Puget Sound 1 4 1 2 - 4 30 - - - - 5 23 10 - - 

Rochester, Univ of - - 2 1 - 1 9 1 - - - 45 2 3 - - 

San Antonio, U of TX 3 - - - - 3 18 16 4 - - 53 - 1 7 1 

Scott & White CCOP - - - - - - - - - - - - - 1 - - 

So Calif, U of - 1 4 2 - 2 10 11 - - - 3 1 - 8 - 

Southeast CCC CCOP - - - - - 1 24 3 6 - - - - 10 - - 

Southern Nevada CCOP - - - - - - - - - - - - 10 2 - - 

St Louis CCOP - - - 2 - 3 16 6 - - - - - 3 - - 

St Louis University - - - - - - 2 4 - - - - - 1 - - 

Tennessee, U of - - - - - 11 7 - 3 - - - - 1 - - 

Upstate Carolina - - 1 1 - 1 5 - - - - - - - - - 

Urology Ctr of CO - - - - - - - - - - - 22 - - - - 

Utah, U of 10 3 - 1 - - 11 - - - - 5 26 7 - - 

Virginia Mason CCOP 5 - 10 - - - 14 3 - 4 - - - 2 - - 

Wayne State Univ - - 4 - - - 16 - - - - - 10 3 - - 

Wichita CCOP - - - 4 - - - - - - 2 - 4 3 - - 

CALGB - - - - - - - - - - - - - 13 22 - 

ECOG - - - - - - - - - - - - - 51 11 - 

NCCTG - - - - - - - - - - - - - 18 - - 

NSABP - - - - - - - - - - - - - 4 - - 

Total 31 77 95 50 2 44 583 149 22 8 5 416 163 230 63 2 

PR11 

R0524 

S0337 

S0925 

S0931 

S1011 

S1014 


Accrual to Cancer Control Studies is listed in the Cancer Control Sections. 


GYNECOLOGIC COMMITTEE 


The Gynecologic Committee was formally closed as of 

September 1, 2010. 


■■ 

NCIC CTG OV.21, “A Phase II/III Study of Intraperitoneal (IP) 

Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus 

Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally 

Debulked at Surgery Following Neoadjuvant Intravenous 

Chemotherapy.” Dr. Armstrong. Activated: 2/1/12. 


■■ 

S0904, “Randomized Phase II Study of Docetaxel Followed by 

Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients 

with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, 

or Primary Peritoneal Carcinoma.” Drs. Coleman and Sood. 

Activated: 3/15/10; Closed 8/1/11. 


Gynecologic Committee 



Arizona, U of 7 

Arkansas, U of 2 

Bay Area CCOP 3 

Colorado, U of 1 

Davis, U of CA 6 

Fox Chase Cancer Ctr 4 

Irvine, U of CA 1 

Loyola University 1 

MD Anderson 36 

Mississippi, Univ of 1 

Montana CCOP 3 

Ozarks Reg CCOP 19 

Puget Sound 10 

So Calif, U of 3 

Southeast CCC CCOP 4 

Southern Nevada CCOP 1 

St Louis CCOP 2 

Tulane University 1 

Univ of Chicago MC 5 

Univ of Maryland 2 

Wichita CCOP 19 

Total 131 

S0904 

Note: Some studies may not be listed because they were either closed prior 

to July 1, 2011 or because they are currently active but have not had any 

accrual through September 6, 2012. 



LEUKEMIA COMMITTEE 


Chair: 

Vice-Chair: 





Pathology: 

Cytogenetics Liaison: 

Designates 



Nurse: 





Room: Crystal C Ballroom 

3:00 p.m. – 7:00 p.m. 


Alan F. List, M.D. 

Laurence H. Baker, D.O. 

Megan Othus, Ph.D. 

Shannon McDonough, M.S. 

Jerald P. Radich, M.D. 

David R. Head, M.D. 

Diane Roulston, Ph.D. 

Min Fang, M.D., Ph.D. 

Emilia G. Cantu 

Gaye L. Winakur, C.C.R.A. 

Jean Barce 


Tracy Maher, C.C.R.P. 

Keisha C. Humphries, R.N., B.S.N. 

Michelle J. Worman, L.V.N. 



Time/Location 

Agenda 

Introduction 

Current Status of the Leukemia Committee 

Presentations 

From Genetic to Genomic Testing for Myeloid Malignancy - Aly 

Karsan, M.D., F.R.C.P.C., Integrative Oncology-Radiation Biology 

Unit, BC Cancer Agency. 

High-Risk Acute Promyelocytic Leukemia.” Dr. Lancet. 


AML/MDS Studies 


■■ 

S0919, “A Phase II Study of Idarubicin and Ara-C in Combination 

with Pravastatin for Relapsed Acute Myelogenous Leukemia 

(AML).” Dr. Advani. Activated: 8/15/09. 

■■ 

■■ 

■■ 

S1117, “A Randomized Phase II Study of Azacitidine in 

Combination with Lenalidomide (NSC-703813) vs. Azacitidine 

Alone vs. Azacitidine in Combination with Vorinostat (NSC- 

701852) for Higher-Risk Myelodysplastic Syndromes (MDS).” 

Dr. Sekeres. Activated: 3/1/12. 

CTSU/E2905, “Randomized Phase III Trial Comparing the 

Frequency of Major Erythroid Response (MER) to Treatment with 

Lenalidomide (Revlimid) Alone and in Combination with Epoetin 

Alpha (Procrit®) in Subjects with Low-or Intermediate-1 Risk 

MDS and Symptomatic Anemia.” Dr. Schiffer. Activated by 

ECOG: 1/29/09; Endorsed by SWOG: 2/15/09. 

CTSU/E2906, “Phase III Randomized Trial of Clofarabine as 

Induction and Post-Remission Therapy vs. Standard Daunorubicin 

& Cytarabine Induction and Intermediate Dose Cytarabine Post- 

Remission Therapy, Followed by Decitabine Maintenance vs. 

Observation in Newly-Diagnosed Acute Myeloid Leukemia in 

Older Adults (Age ≥ 60 Years.” Activated by ECOG: 12/28/10; 

Endorsed by SWOG: 7/20/12. 


■■ 

S0703, “A Phase II Trial of Azacitidine (NSC-102816) Plus 

Gemtuzumab Ozogamicin as Induction and Post-Remission 

Therapy in Patients of Age 60 and Older with Previously 

Untreated Non-M3 Acute Myeloid Leukemia.” Dr. Nand. 


How Young Adult Research Can Be Embedded Into Studies 

Being Developed in the SWOG Leukemia Committee - Leonard 

Sender, M.D., Division Chief, Pediatric Oncology, University of 

California, Irvine. 

APL Studies 


■■ 

S0535, “A Phase II Study of ATRA, Arsenic Trioxide and 

Gemtuzumab Ozogamicin in Patients with Previously Untreated 


■■ 

CTSU/C10603, “A Phase III Randomized, Double-Blind Study 

of Induction (Daunorubicin/Cytarabine) and Consolidation (High- 

Dose Cytarabine) Chemotherapy + Midostaurin (PKC 412) 

(IND#101261) or Placebo in Newly Diagnosed Patients < 60 

Years of Age with Flt3 Mutated Acute Myeloid Leukemia (AML).” 

Dr. Medeiros. Activated by CALGB: 4/1/08; Endorsed by SWOG: 

2/1/09; Closed: 10/15/11.




■■ 

S1203, “A Randomized Phase III Study of Standard Cytarabine 

plus Daunomycin (7+3) Therapy versus Idarubicin with High 

Dose Cytarabine (IA) with or without Vorinostat in Younger 

Patients with Previously Untreated Acute Myeloid Leukemia 

(AML).” Dr. Garcia-Manero. 

ALL Studies 


■■ 

S0805, “Phase II Study of Combination of Hyper-CVAD and 

Dasatinib (NSC-732517) with or without allogenic stem cell 

transplant in Patients with Philadelphia (Ph) Chromosome 

Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia 

(ALL) (A BMT Study).” Dr. Ravandi. Activated: 9/1/09. 

■■ 

CTSU/C10701, “A Phase II Study of Dasatinib (Sprycel®) 

(IND #73969, NSC #732517) as Primary Therapy Followed by 

Transplantation for Adults >= 50 Years with Newly Diagnosed 

Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG 

and NCIC CTG(CALGB 10701).” Dr. Liedtke. Activated: 6/1/12. 


■■ 

S0910, “A Phase II Study of Epratuzumab (NSC-716711) in 

Combination with Cytarabine and Clofarabine for Patients with 

Relapsed or Refractory PH-Negative Precursor B-cell Acute 

Lymphoblastic Leukemia (ALL).” Dr. Advani. Activated: 8/15/10; 

Closed 7/1/12. 

■■ 

C10403, “An Intergroup Phase II Clinical Trial for Adolescents 

and Young Adults with Untreated Acute Lymphoblastic Leukemia 

(ALL).” Dr. Advani. Activated by CALGB: 11/15/07; Activated by 

SWOG: 1/15/08; Closed 9/14/12. 

CLL Studies 


■■ 

CTSU/E1908, “A Phase II Randomized Trial Comparing Standard 

and Low Dose Rituximab: Initial Treatment of Progressive 

Chronic Lymphocytic Leukemia in Elderly Patients Using 

Alemtuzumab and Rituximab.” Dr. Libby. Activated by ECOG: 

10/8/10; Endorsed by SWOG: 11/15/10. 


■■ 

C10404, “A Genetic Risk-Stratified Randomized Phase II Study 

of Four Fludarabine/Antibody Combinations for Patients with 

Symptomatic, Previously Untreated Chronic Lymphocytic 

Leukemia.” Dr. Godwin. Activated by CALGB: 1/15/08; 

Activated by SWOG: 3/15/09; Closed: 8/17/12. 

Publications 





■■ 

S0325 A randomized trial of dasatinib 100 mg vs imatinib 400 

mg in newly diagnosed chronic phase chronic myeloid leukemia. 

JP Radich, KJ Kopecky, FR Appelbaum, S Kamel-Reid, W Stock, 

G Mainassy, E Paietta, M Wadleigh, R Larson, P Emmanuel, M 

Tallman, J Lipton, R Turner, B Druker. Blood 2012 Aug 22 [Epub 

ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/22915637 

■■ 

■■ 

■■ 

■■ 

S9031/S9033 DNMT3A-Mut independently predict poor 

outcome in older AML patients: a SWOG report. F Ostronoff, M 

Othus, P Ho, DE Geraghty, SH Petersdorf, J Anderson, J Godwin, 

C Willman, J Radich, F Appelbaum, K Kopecky, DL Stirewalt, S 

Meshinchi. Leukemia 2012 June 22 [Epub ahead of print]. http:// 

www.ncbi.nlm.nih.gov/pubmed/22722750 

C9011 The impact of initial fludarabine therapy on 

transformation to richter’s syndrome or prolymphocytic leukemia 

in patients with chronic lymphocytics leukemia: analysis of 

an intergroup trial (CALGB 9011). M Solh, BL Peterson, F 

Appelbaum, M Tallman, A Belch, RA Larson, VA Morrison. 

Leukemia & Lymphoma 2012 Aug 17 [Epub ahead of print]. 

http://www.ncbi.nlm.nih.gov/pubmed/22897733 

C9710 Treatment influenced associations of PML-RARa 

mutations, FLT3 mutations and additional chromosome 

abnormalities in relapse acute promyelocytic leukemia. RE 

Gallagher, BK Moser, J Racevskis, X Poire, CD Bloomfield, AJ 

Karroll, RP Ketterling, D Roulston, E Schachter-Tokarz, DC Zhou, 

IM Chen, R Harvey, G Koval, DA Sher, J Feusner, M Tallman, 

RA Larson, BL Powell, F Appelbaum, E Paietta, CL Willman, W 

Stock. Blood 2012 June 25 [Epub ahead of print]. http://www. 


Multiple Studies Failed diagnostic cytogenetics is a poor 

prognostic feature in acute myeloid leukemia. B Medeiros, M 

Othus, M Fang, E Estey, F Appelbaum. Leukemia, accepted 

5/21/12. 





■■ 

S0521 A phase III randomized trial (SWOG S0521) of 

maintenance vs. observation for patients with previously 

untreated low and intermediate risk acute promyelocytic 

leukemia (APL). SE Coutre, M Othus, B Powell, CL Willman, W 

Stock, E Paietta, D Levitan, M Wetzler, EC Attar, JK Altman, 

SD Gore, T Maher, KJ Kopecky, MS Tallman, RA Larson, FR 

Appelbaum. Blood, submitted 9/12. 

■■ 

■■ 

■■ 

■■ 

Multiple Studies Prognostic Significance of the French- 

American-British (FAB) Morphologic Subclassification of “Acute 

Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO 

Classification: Analysis of 5,848 Newly Diagnosed Patients from 

HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. 

R Walter, M Othus, A Burnett, B Lowenberg, H Kantarjian, G 

Ossenkoppele, R Hills, K van Montfort, F Ravandi, A Evans, S 

Pierce, F Appelbaum, E Estey. Journal of Clinical Oncology, 

submitted 8/8/12. [studies: S0106, S0112, S8600, S9031, 

S9034, S9333,S9500, S9617]. 

Multiple Studies Age and karyotype changes in acute (nonpromyelocytic) 

myeloid leukemia. T Norwood, H Gundacker, 

ML Slovak, FR Appelbaum, C Willman. Genes, Chromsomes 

& Cancer, submitted 6/13/12 [studies: S8600, S9031, 

S9034,S9126, S9333, S9500,S9617, S9918, S0112, S0432] 

Multiple Studies Outcome of adolescents and young adults 

with acute myeloid leukemia treated on COG trials compared 

to CALGB and SWOG trials. W Woods, A Franklin, T Alonzo, R 

Gerbing, K Donohue, M Othus, J Horan, F Appelbaum, E Estey, C 

Bloomfield, R Larson. Blood, submitted 9/12. [studies: C19808, 

C8525, C9022, C9222, C9621, S0106, S8600, S9500] 

Multiple Studies Expression of novel IRF8 splice variants is 

associated with a significant decrease in relapse-free survival 

in adult AML patients. E Pogosova-Agadjanyan, K Kopecky, 

S Meshinchi, F Appelbaum, J Anderson, J Godwin, H Lee, A 

List, V Oehler, S Petersdorf, J Radich, C Willman, D Stirewalt. 

Leukemia, submitted 9/12. [studies S9031, S9126, S9333 and 

S9500] 



Leukemia Committee 



C10403 

C10404 

C10603 

E1905 

E1908 

Arkansas, U of - 3 - 1 - - - 2 - - - - - - 

Atlanta Reg CCOP - - 1 - - - - - - - - - - - 

Baylor College - - 1 - - - - - - - - 6 1 - 

Boston Univ Med Ctr - - 1 1 - - - - - - - - - - 

Central IL CCOP - - - - - - - - 1 6 - - - - 

Cincinnati MC, U of - - 1 - - - - - 1 - - - - - 

City of Hope Med Ctr 2 - - - - - - - - - 1 4 - - 

Cleveland Clinic OH 15 - - 1 - - - - 7 - - 3 11 5 

Colorado, U of - - - 1 - - - - 3 - - 2 1 - 

Columbia River CCOP - - - - - - - - - 9 - - - - 

Columbia University - - - - - 1 - - - - - - - - 

Columbus CCOP - - - - - - - - - 1 - - - - 

Davis, U of CA - 1 3 1 - 4 - - 2 4 1 - - - 

Grand Rapids CCOP - - - - - - - 1 - 2 - - - - 

Greenville CCOP - - - - - 3 - - - - - 1 - 2 

H Lee Moffitt CC - - 4 - - 7 - - 11 - - 2 4 - 

Hawaii MBCCOP, U of - - - - - - - - - - - - - 2 

Irvine, U of CA 3 - 3 - - - - - - - - - - - 

KaiserPermanenteNCAL - - - - - 5 - - - - - - - - 

Kansas City CCOP - - - 1 - 1 - - - 5 - - - - 

Kansas, U of 3 - - - - - - - - 4 1 - - 1 

Kentucky, U of 4 - 1 - - - 1 - - 21 2 - - - 

LSU-Shreveport CCOP - - 1 - - - - - - - - - - - 

Lahey Clinic Med Ctr - 1 - - - - - - - - - - - - 

Loyola University 1 1 3 - - - 1 1 - 28 2 1 3 - 

MD Anderson - - - - - - - - - - 5 - - - 

MUSC, Hollings CC 8 8 6 - - - - 2 - 6 1 1 - - 

Michigan CRC CCOP 1 - - - - - - - - 2 - - - - 

Michigan, U of 5 - - 1 - - - - 1 14 - - - - 

Mississippi, Univ of - - - 1 - - - - - 1 - 3 1 - 

Montana CCOP - 1 - 3 - 2 - - 1 1 - - - - 

New Mexico MBCCOP 2 3 - - - - - - - 6 - - 4 - 

Ozarks Reg CCOP - - - 1 - - - - - - - - - - 

Providence Hosp - - 2 - - - - - 2 - - - - - 

Puget Sound 2 - - - - - - 1 6 - 5 - 2 - 

E2905 

E2906 

S0535 

S0605 

S0703 

S0805 

S0910 

S0919 

S1117 



Leukemia Committee 



C10403 

C10404 

C10603 

E1905 

E1908 

Rochester, Univ of 3 6 1 2 - - - - 4 5 - 4 3 - 

San Antonio, U of TX - 2 - - - 2 - - - - - - - - 

Santa Rosa CCOP - - - 1 - - - - - - - - - - 

So Calif, U of - - - - - - - - - 1 - - - - 

Southeast CCC CCOP - - - 2 - 1 - - - 3 - - - - 

St Louis CCOP - 2 - 2 - - - - - - - - - - 

St Louis University - 2 - - - - - - - - - - - - 

Stanford University 25 - 7 - - - - 6 - 12 1 6 - - 

Tennessee, U of - - 2 4 1 - - - 1 - - - - - 

Upstate Carolina - - - - - - - - 1 - - - - - 

Utah, U of 3 - - - - 1 - 1 - - - 2 - - 

Wayne State Univ 4 - - - - 2 - - - 7 1 - - - 

Wichita CCOP 2 4 1 - - - - 2 - 4 - - 2 - 

CALGB - - - - - - - 34 - - 9 - - - 

ECOG - - - - - - - 15 - - 10 - - 1 

NCCTG - - - - - - - - - - - - - 1 

Total 83 34 38 23 1 29 2 65 41 142 39 35 32 12 


E2905 

E2906 

S0535 

S0605 

S0703 

S0805 

S0910 

S0919 

S1117 


LUNG COMMITTEE 



Chair: 

Vice-Chair: 






Surgery: 


Pathology: 

Developmental Therapeutics: 


Designates 



Community Affiliate: 


Nurses: 






11:30 a.m. – 3:30 p.m. 

Opening Remarks 

David R. Gandara, M.D. 

Stephen G. Swisher, M.D. 

Anne Schott, M.D. 

Mary Redman, Ph.D. 

James Moon, M.S. 

Philip C. Mack, Ph.D. 

Fred R. Hirsch, M.D., Ph.D. 

Laurie E. Gaspar, M.D. 

Stephen G. Swisher, M.D. 

Karen Kelly, M.D. 

Ignacio I. Wistuba, M.D. 

Roy S. Herbst, M.D., Ph.D. 

Shirish M. Gadgeel, M.D. 

Courtney L. Williamson, C.C.R.P. 


Paul J. Hesketh, M.D. 

Larry Kaye 

Brian Zeller 


Vicki Green 

Kimberly M. Belzer, M.S., P.A.-C 

Rosalie Zablocki, R.N. 

Bonnie J. Addario 

Jorge G. Avila, Pharm.D. 

TBD 

Time/Location 

Agenda 

Translational Medicine Session - Dr. Mack 

Surgery Session - Dr. Swisher 

Scientific Session 

Dr. Lynch – “Optimal therapy for EGFR mutant NSCLC: Role of monoclonal 

antibodies and dual kinase inhibitors in overcoming resistance” 

Dr. Gadgeel – “MEK inhibition in the therapy of KRAS mutant 

NSCLC.” 

New Proposals 

■ ■ “Ipilimumab Plus EGFR Inhibitor for EGFR Mutated Non-Small 

Cell Lung Cancer.” Dr. Akerly. 

■ ■ 

■ ■ 

■ ■ 

■■ 

“Randomized Phase II Trial of Individualized Systemic Therapy in 

Stage III NSCLC.” Dr. Kalemkarian. 

“Implementation of Lung Cancer Screening.” Dr. Hesketh. 

“A Randomized Phase III Trial of Alisertib Versus Topotecan in 

Patients with Pretreated Small Cell Lung Cancer.” Dr. Liu. 

Dr. Ou 

Other 

■■ 

E2810, “Randomized, Double-Blind Phase III Study of Pazopanib 

Vs. Placebo in Patients with Metastatic Renal Cell Carcinoma 

Who Have No Evidence of Disease Following Metastatectomy.” 

Dr. Pal. 


■■ 


Factor Receptor (Her-1/EGFR) Inhibitor-Induced Dermatologic 


Therapy – EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRIinduced 

Skin Toxicities.” Dr. Wong. Activated: 11/15/11. 

■■ 

■■ 

■■ 

■■ 

S0905, “A Phase I / Randomized Phase II Study of Cediranib 

(NSC #732208) Versus Placebo in Combination with Cisplatin 

and Pemetrexed in Chemonaive Patients with Malignant Pleural 

Mesothelioma.” Drs. Tsao. Activated: 3/15/10, Phase I Closed: 

7/18/11; Phase II Activated: 9/15/11. 

S0819, “A Randomized, Phase III Study Comparing Carboplatin 

/ Paclitaxel or Carboplatin / Paclitaxel / Bevacizumab with or 

without Concurrent Cetuximab in Patients with Advanced Non- 

Small Cell Lung Cancer (NSCLC).” Drs. Herbst, Kim, Semrad, 

Gandara, Hirsch and Mack. Activated: 7/15/09. 

S0709, “A Phase II Selection Design of Pharmacodynamic 

Separation of Carboplatin / Paclitaxel / OSI-774 (Erlotinib; NSC- 

718781) or OSI-774 Alone in Advanced Non-Small Cell Lung 

Cancer (NSCLC) Patients with Performance Status 2 (PS-2) 

Selected by Serum Proteomics.” Drs. Lara, Hesketh, Mack and 

Hirsch. Activated: 12/1/08. 



Cancer Patients with Bone Metastases Starting Zoledronic Acid 




■■ 

■■ 

■■ 

■■ 

Treatment.” Drs. Van Poznak, Gralow, Schubert and Bagramian, 

and Ms. Hansen. Activated: 12/15/08. 

CTSU/CALGB 140503, “A Phase III Randomized Trial of 

Lobectomy versus Sublobar Resection for Small (≤ 2 cm) 

Peripheral Non-Small Cell Lung Cancer.” Dr. Mitchell. Activated: 

1/15/08. 

CTSU/CALGB 30801, “A Randomized Phase III Double Blind 

Trial Evaluating Selective COX-2 Inhibibition in COX-2 Expressing 

Advanced Non-Small Cell Lung Cancer.” Dr. Reckamp. 


CTSU/CALGB 30610, “Phase III Comparison of Thoracic 

Radiotherapy Regimens in Patients with Limited Small Cell Lung 

Cancer also Receiving Cisplatin and Etoposide.” Drs. Gaspar and 

Gadgeel. Activated: 4/1/08. 

CTSU/E1505, “A Phase III Randomized Trial of Adjuvant 

Chemotherapy with or without Bevacizumab for Patients with 

Completely Resected Stage IB (≥ 4 cm) – IIIA Non-Small Cell 

Lung Cancer (NSCLC).” Drs. Gandara and Vallieres. Activated: 

7/1/07. 

■■ 

S0635, “A Phase II Trial of the Combination of OSI-774 

(Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC- 

704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma 

(BAC) and Adenocarcinoma with BAC Features (AdenoBAC).” 

Drs. West, Lau, Hirsch and Wozniak. Activated: 7/15/07; Closed: 

8/15/11. 


■■ 

S1206, “Dose Finding Followed by Phase II Randomized, 

Placebo-Controlled Study of Veliparib (ABT-888) Added 

to Chemoradiotherapy with Carboplatin and Paclitaxel for 

Unresectable Stage III Non-Small Cell Lung Cancer, (NCI Study 

Number 8811).” Drs. Argiris, Cristea and Chen. 

■■ 

■■ 

S1220, “A Phase II Selection Design Study of MK-2206, a Novel 

Akt Inhibitor, in Relapsed, Small Cell Lung Cancer Patients as 

Monotherapy or in Combination with Weekly Topotecan.” Drs. 

Kelly, Huang and Mack. 

S1300, “A Randomized Phase II Trial of Crizotinib Plus 

Pemetrexed Versus Pemetrexed Alone in Non-Squamous NSCLC 

at Acquired Resistance to Crizotinib Monotherapy.” Drs. 

Camidge, Li and Doeble. 

■■ 

CTSU/N107C, “A Phase III Trial of Post-Surgical Stereotactic 

Radiosurgery (SRS) Compared with Whole Brain Radiotherapy 

(WBRT) for Resected Metastatic Brain Disease.” Dr. Gaspar. 



■■ 

S0802, “A Randomized Phase II Trial of Weekly Topotecan with 

and without AVE0005 (Aflibercept; NSC-724770) in Patients 

with Platinum Treated Extensive Stage Small Cell Lung Cancer 

(E-SCLC).” Drs. Allen, Gadgeel, Kelly and Mack. Activated: 

5/15/09; Closed: 3/1/12. 

■■ 

■■ 

■■ 

S0722, “A Phase II Trial of mTOR Inhibitor, Everolimus 

(RAD001), in Malignant Pleural Mesothelioma (MPM).” Drs. Ou, 

Garland and Mack. Activated: 12/1/08; Closed 9/15/11. 

S0720, “Phase II ERCC1 and RRM1-Based Adjuvant Therapy 

Trial in Patients with Stage I Non-Small Cell Lung Cancer 

(NSCLC).” Drs. Zinner, Calhoun, Kernstine, Williams and Mack. 


S0636, “A Phase II Trial of the Combination of OSI-774 

(Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; 

NSC-704865) in Never-Smokers with Stage IIIB and IV Primary 

NSCLC Adenocarcinomas.” Drs. West, Hirsch and Wozniak. 


■■ 

S1301, “A Randomized, Phase II Selection Design Trial of 

GSK212 (Trametinib) with Docetaxel or with GSK2141795 in 

Patients with Progressive Kras Mutation Positive Non-Small 

Cell Lung Cancer (NSCLC) following at Least One Prior Systemic 

Therapy.” Dr. Gadgeel. 

Publications 





■■ 

S0819 Design of a phase III clinical trial with prospective 

biomarker validation: SWOG S0819. M Redman, J Crowley, 

R Herbst, F Hirsch, D Gandara. Clinical Cancer Research 

18(15):4004-4012, 2012. http://www.ncbi.nlm.nih.gov/ 

pubmed/22592956 

■■ 

NCCTG/SWOG Multiple Studies Impact of disease progression 

date determination on progression free survival estimates in 

advanced lung cancer. Y Qi, A Ziegler, S Hillman, M Redman, 

S Schild, D Gandara, A Adjei, S Mandrekar. Cancer 2012 

Mar 20 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/ 

pubmed/22434489 





■■ 

S0526 SWOG phase II trial (S0526) of pemetrexed in patients 

with metastatic bronchioloalveolar carcinoma (BAC). DHM 

Lau, J Moon, AM Davies, R Sanborn, F Hirsch, W Franklin, J 

Ruzich, M Redman, DR Gandara. Clinical Lung Cancer, submitted 

8/15/12. 

■■ 

S0536 Phase II trial of combination carboplatin, paclitaxel, 

cetuximab and bevacizumab followed by cetuximab and and 

bevacizumab in patients with advanced non-small cell lung 

cancer: SWOG S0356. ES Kim, J Moon, RS Herbst, M Redman, 

SR Dakhil, MR Velasco, FR Hirsch, PC Mack, K Kelly and DR 

Gandara. Journal of Clinical Oncology, submitted 8/15/12. 



Lung Committee 



C140503 

C30610 

C30801 

E1505 

Arizona, U of - - - - - - - - 5 1 10 - 

Arkansas, U of - 1 - 2 1 - 1 - - 3 4 - 

Atlanta Reg CCOP - - - 3 3 3 - - - 5 8 - 

Bay Area CCOP - - - 1 - - - - - - 1 - 

Baylor College - - - - - - - - - 1 4 - 

Beaumont CCOP - - - 7 - - - - - - - - 

Boston Univ Med Ctr - - - 2 - - - - - - - - 

Brooke Army Med Ctr - - - 2 - - - - - 1 - - 

Central IL CCOP - 5 - - 4 - 2 3 1 20 37 1 

Cincinnati MC, U of - - - 4 - - - 1 - 1 3 - 

City of Hope Med Ctr - - 2 - - - - 3 - 2 - - 

Cleveland Clinic OH - - - 4 - - - - - 1 - - 

Colorado, U of 2 - - 10 4 - - 2 3 4 14 - 

Columbia River CCOP - - - - - 3 - 4 3 1 - - 

Columbia University - - - 2 - - - - - 2 4 - 

Columbus CCOP - - - - 5 - - 2 1 1 5 - 

Davis, U of CA 4 7 1 17 8 12 10 8 - 11 61 - 

Dayton CCOP - - - 3 - - - 4 3 14 14 - 

Grand Rapids CCOP - - - 10 8 1 - 2 - 4 9 - 

Greenville CCOP - - - 12 - - - 1 - - 24 - 

Gulf Coast MBCCOP - - - 3 - - - - - 2 1 - 

H Lee Moffitt CC - - - 18 - 2 - 5 - - 10 - 

Harrington CC - - - 2 - - - - - - - - 

Hawaii MBCCOP, U of - - 2 3 - - - 7 - - 5 - 

Henry Ford Hosp - - - 4 4 1 - - - - 6 1 

INCan - - - - - - - - - - 2 - 

Irvine, U of CA - - - 5 - - - - 4 - 10 - 

KaiserPermanenteNCAL - 1 - 12 8 17 6 - - - - - 

Kansas City CCOP - - - 1 - - - - - - 15 - 

Kansas, U of - - - 12 5 3 10 - - 11 30 - 

Kentucky, U of - - - - 1 1 - - - 2 28 - 

LSU-New Orleans CCOP - - - - - - - - - 6 3 - 

LSU-Shreveport CCOP - - 1 - - - - - - - 5 - 

Lahey Clinic Med Ctr - - - 3 - - 1 - - 1 2 - 

Loyola University - - 1 3 1 2 - - - 4 11 - 

MD Anderson - - - - - - - - 14 - 9 28 

S0635 

S0636 

S0709 

S0720 

S0722 

S0802 

S0819 

S0905 



Lung Committee 



C140503 

C30610 

C30801 

E1505 

MUSC, Hollings CC - 1 - - 3 4 - - - - 5 - 

Michigan CRC CCOP - - - - 3 6 3 12 3 9 22 - 

Michigan, U of - 1 - 2 - - - 1 3 5 - 5 

Mississippi, Univ of - - 2 6 - 3 - 1 1 1 2 - 

Montana CCOP - - - 4 6 5 1 3 2 4 4 1 

Nevada Cancer Inst - - - - - - - - - - 3 - 

New Mexico MBCCOP - - - - - - - - 2 - - - 

Northwest CCOP - - - 5 - - - - - - 12 - 

Oregon Hlth Sci Univ - - - 4 - - - 3 - 2 5 - 

Ozarks Reg CCOP - - 1 2 - 3 2 2 - 4 - - 

Providence Hosp - 2 1 1 - - - 2 - - 1 - 

Puget Sound 5 - 1 9 3 14 - 3 1 1 9 2 

Rochester, Univ of - - - 6 5 - - - 2 4 9 - 

San Antonio, U of TX - 3 - 9 - - - - - 3 22 - 

Scott & White CCOP - - - - - - - 4 - 1 - - 

So Calif, U of - - - 5 - - 1 - - - 12 - 

Southeast CCC CCOP - - - 6 1 - 1 - 3 26 13 1 

Southern Nevada CCOP - - - - - - - - - 1 7 - 

St Louis CCOP - - - 5 - - - - - 2 6 - 

St Louis University - - - - - - - - 1 - - - 

Tennessee, U of 2 - - 6 - - - - - 4 5 - 

Tulane University - - - 1 - - - - - - - - 

Upstate Carolina - - - 4 1 1 - 2 - 4 7 - 

Utah, U of - - - 5 1 - 9 - - 5 18 - 

Virginia Mason CCOP - - - 1 - - - - - - 1 - 

Wayne State Univ - 1 - 11 - - - 3 9 5 12 - 

Wichita CCOP - 12 - - 9 8 - 7 - 13 6 - 

Yale University - - - - - - - - - - 2 - 

ACOSOG - - - - - - - - - - 8 - 

CALGB - - - - - - - - - - 81 - 

CTSU-NOS - - - - - - - - - - 3 - 

ECOG - - - - - - - - - - 94 - 

NCCTG - - - - - - - - - - 91 - 

NSABP - - - - - - - - - - 11 - 

RTOG - - - - - - - - - - 9 - 

Total 13 34 12 237 84 89 47 85 61 192 815 39 

S0635 

S0636 

S0709 

S0720 

S0722 

S0802 

S0819 

S0905 

Note: Some studies may not be listed because they were either closed prior to July 1, 2011 or because 

they are currently active but have not had any accrual through September 6, 2012. 



LYMPHOMA COMMITTEE 


Chair: 

Vice-Chair: 






Pathology 


Designates 


Cancer Control: 


Nurse: 




Time/Location 



11:30 a.m. – 3:30 p.m. 

■■ 

■■ 

■■ 

■■ 

Richard I. Fisher, M.D. 

Thomas P. Miller, M.D. 


Michael LeBlanc, Ph.D. 

Hongli Li, M.S. 

Richard E. Davis, M.D. 

Louis S. Constine, M.D. 

Lisa M. Rimsza, M.D. 

Daruka Mahadevan, M.D., Ph.D. 

Ellen Chase, B.S. 

Erin M. Cebula, M.P.H. 

John W. Hayslip, M.D. 

Jeri Jardine 

Iris Syquia 

Nancy H. Sprouse, R.N. 

Hildy Dillon, M.P.H. 


Megan Hardin 

Agenda 

Hodgkin Lymphoma 

S0816, “A Phase II Trial of Response-Adapted Therapy of Stage 

III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging.” 

Drs. Press, Friedberg, Brown, Rimsza and Cook. Activated: 

7/1/09. 

CTSU/CALGB 50604, “Phase II Trial of Response-Adapted 

Chemotherapy Based on Positron Emission Tomography for 

Non-Bulky Stage I and II Hodgkin Lymphoma.” Dr. Shustov. 


E2410, “A Phase II Trial of Response-Adapted Therapy Based 

on Positron Emission Tomography (PET) for Bulky Stage I and 

II Classical Hodgkin Lymphoma (HL)”. Dr. Shustov. Activated: 

4/2/12. 

Non-Hodgkin Lymphoma 

S0806, “A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) 

in Combination with Rituximab-CHOP in Patients with Newly 


■■ 

■■ 

■■ 

Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma 

(DLBCL).” Drs. Persky, Miller and Rimsza. Activated: 11/15/10. 

S1001, “A Phase II Trial of PET-Directed Therapy for Limited 

Stage Diffuse Large B-Cell Lymphoma (DLBCL).” Drs. Persky, 

Miller, Constine, Rimsza, and Fitzgerald. Activated: 7/18/11. 

S1106, “ A Randomized Phase II Trial of R-HCVAD-MTX/ 

ARA-C Induction Followed by Consolidation With an Autologous 

Stem Cell Transplant vs. R-Bendamustine Induction Followed 

by Consolidation With an Autologous Stem Cell Transplant 

for Previously Untreated Patients

LYMPHOMA COMMITTEE 


■■ 

■■ 

■■ 

■■ 

Translational Medicine Studies 

S8809/S9800/S9911, “Association of Fcg receptor genotypes 

with response and clinical benefit with addition of rituximab to 

CHOP chemotherapy in patients with follicular lymphoma (FL) 

and diffuse large B cell lymphoma (DLBCL).” Drs. Persky and 

Rimsza. 

S8516/S8736/S9125/S9240/S9349/S9704/S0014, 

“Pharmacogenomics of Oxidative Stress-Related Genes in 

Lymphoma.“ Drs. Briehl, Rimsza and Ambrosone. 

S8947/S9800/S9911/S0016, “Vitamin D Insufficiency and 

Follicular Lymphoma Prognosis.” Drs. Kelly and Friedberg. 

S9704/S0014/S0313A, “Determining the Cell of Origin and 

Prognostic Gene Signatures in SWOG Trials of Diffuse Large 

B-Cell Lymphoma.” Drs. Persky and Rimsza. 

Other Business 

Translational Medicine Subcommittee Report (Dr. Davis) 

Publications 





■■ 

S0016 A phase III randomized intergroup trial of CHOP chemotherapy 

plus rituximab compared to CHOP chemotherapy plus 

131iodine-tositumomab for previously untreated follicular nonhodgkins 

lymphoma (SWOG S0016). OW Press, JM Unger, L 

Rimsza, JW Friedberg, M LeBlanc, M Czuczman, M Kaminski, R 

Braziel, C Spier, AK Gopal, DG Maloney, B Cheson, S Dakhil, TP 

Miller, RI Fisher. Journal of Clinical Oncology, accepted 8/20/12. 

■■ 

■■ 

S0350 Phase II trial of cisplatin plus etoposide plus gemcitabine 

plus solumedrol (PEGS) in peripheral T-cell non-Hodgkins 

lymphoma (SWOG S0350). D Mahadevan, J Unger, C Spier, D 

Persky, F Young, M LeBlanc, RI Fisher, TP Miller. Cancer 2012 

Jul 25 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/ 

pubmed/22833464 

S0515 A phase II trial of R-CHOP plus bevacizumab for patients 

with newly diagnosed diffuse large b-cell non-hodgkin lymphoma: 

SWOG 0515. A Stopeck, JM Unger, LM Rimsza, M LeBlanc, 

B Farnsworth, M Iannone, MJ Glenn, RI Fisher, TP Miller. 

Blood 120(6):1210-1217, 2012. http://www.ncbi.nlm.nih.gov/ 

pubmed/22734071 

■■ 

E2946 A randomized phase III trial of ABVD vs. Stanford V 

+/- radiation therapy in locally extensive and advanced stage 

hodgkins lymphoma: an intergroup study coordinated by the 

Eastern Cooperative Oncology Group (E2496). L Gordon, F 

Hong, RI Fisher, NL Bartlett, JM Connors, R Gascoyne, H 

Wagner, P Stiff, B Cheson, M Gospodarowicz, R Advani, B Kahl, 

J Friedberg, K Blum, T Habermann, J Tuscano, RT Hoppe, SJ 

Horning. Journal of Clinical Oncology, accepted 8/27/12. 


■■ 

S0213 A phase II multicenter trial of HyperCVAD MTX/Ara-C 

and rituximab in patients < 70 years of age with previously 

untreated mantle cell lymphoma: SWOG 0213. SH Bernstein, 

EM Epner, JM Unger, M LeBlanc, E Cebula, WR Burack, LM 

Rimsza, TP Miller, RI Fisher. Annals of Oncology, submitted 

9/12. 

■■ 

■■ 

■■ 

■■ 

BMT/CTN 0401 Phase III randomized study of rituximab/ 

carmustine, etoposide, cytarabine, melphalan (BEAM) compared 

with 131-iodine tositumomab/BEAM with autologous stem 

cell transplantation for relapsed diffuse large b-cell lymphoma 

(DLBCL): results from the Blood and Marrow Transplant Clinical 

Trials Network (BMT CTN) 0401 trial. J Vose, S Carter, LJ 

Burns, E Ayala, O Press, C Moskowitz, E Stadtmauer, S Mineshi, 

R Ambinder, T Fenske, M Horowitz, RI Fisher, M Tomblyn. 

Journal of Clinical Oncology, submitted 9/4/12. 

E2496 Gene expression and overall survival in advanced stage 

classic hodgkin lymphoma. DW Scott, FC Chan, F Hong, S Rogic, 

K Tan, B Meissner, S Ben-Neriah, M Boyle, R Kridel, A Telenius, 

B Woolcock, P Farinha, RI Fisher, L Rimsza, NL Bartlett, L 

Shepherd, RH Advani, JM Connors, BS Kahl, LI Gordon, SJ 

Horning, C Steidl, RD Gascoyne. Journal of Clinical Oncology, 

resubmitted with revisions 8/13/12. 

E2496 Plasma Epstein-Barr viral DNA as a marker of tumor 

response in Hodgkin lymphoma. JA Kanakry, H Li, LL Gellert, 

MV Lemas, W Hsieh, F Hong, KL Tan, R Gascoyne, LI Gordon, 

RI Fisher, NL Bartlett, P Stiff, B Cheson, R Advani, L Rimsza, B 

Hahl, SJ Horning. Blood, submitted 8/31/12. 

E2496 Efficacy and tolerability of ABVD and Stanford V in 

elderly hodgkin lymphoma from US intergroup trial E2496. AM 

Evens, F Hong, L Gordon, RI Fisher, P Stiff, T Miller, N Bartlett, 

J Connors, R Gascoyne, H Wagner, M Gospodarowicz, B Cheson, 

R Advani, R Hoppe, B Kahl, S Horning. Blood, under review 

8/24/12. 



Lymphoma Committee 



C50303 

C50604 

CTN0701 

Arizona, U of - 1 - 7 8 6 4 1 - 3 

Arkansas, U of - 1 - 1 - 1 3 - - - 

BC Cancer Agency - - - 1 - - - - - - 

Boston MC MBCCOP - - - - - - 1 - - - 

Boston Univ Med Ctr - - - - - - 2 - - - 

Brooke Army Med Ctr 2 2 - - - - - - - - 

Central IL CCOP 3 1 - 3 8 - 7 - - - 

City of Hope Med Ctr - 5 - - - 4 4 - - - 

Cleveland Clinic OH 1 3 - - - - 3 - - - 

Colorado, U of - - - - - - 1 - - - 

Columbia River CCOP - - - - - - 2 - - - 

Columbia University - - - - - - 4 - - - 

Columbus CCOP - - - - 3 - - - - - 

Davis, U of CA 4 1 2 2 - - 5 - - - 

Dayton CCOP - - - - 5 2 1 - 1 - 

Grand Rapids CCOP - - - - 4 - 1 - - - 

H Lee Moffitt CC - - 1 - - - - - - - 

Harrington CC 4 - - - - - - - - - 

Hawaii MBCCOP, U of - - - - - - 6 - - - 

Henry Ford Hosp - - - - - - 2 - - - 

KaiserPermanenteNCAL - - - 1 - - 3 - - - 

Kansas City CCOP - - - - - 3 - - - - 

Kansas, U of 5 - - - 2 - 3 - - - 

Kentucky, U of - 1 - 2 - - 3 - 1 - 

LSU-New Orleans CCOP - 2 - - - - 1 - - - 

LSU-Shreveport CCOP - - - 2 - - 2 - - 1 

Loyola University 1 - - 2 6 3 3 - - 1 

MD Anderson - - - - - - 16 - - - 

MUSC, Hollings CC 2 - - - - - 3 - - - 

Michigan CRC CCOP - - - 1 - - 5 - - - 

Michigan, U of - - - - - - 12 - - - 

Mississippi, Univ of 2 - - - - - - - - - 

Montana CCOP - - - - 3 - 1 - - - 

New Mexico MBCCOP 1 - - - - - 1 - - - 

Oregon Hlth Sci Univ - 1 - - - - - - - 1 

Providence Hosp 2 - - - - - - - - - 

S0350 

S0801 

S0806 

S0816 

S1001 

S1106 

S1108 



Lymphoma Committee 



C50303 

C50604 

CTN0701 

Puget Sound 7 1 - 2 19 1 13 - - - 

Rochester, Univ of 4 6 - 9 11 11 17 8 6 4 

San Antonio, U of TX 5 - - - - - - - - 1 

So Calif, U of 1 - - - - 2 - - - - 

Southeast CCC CCOP - - - - 2 1 2 - - - 

St Louis CCOP - - - - 2 - - - - - 

St Louis University 2 1 - - - - - - 1 - 

Tennessee, U of - - - - 1 - - - - - 

Upstate Carolina - 1 - 1 1 - 3 - - - 

Utah, U of - - - - 6 - 2 - - - 

Wayne State Univ - - - - - - 3 - - - 

Wichita CCOP 1 2 - - 6 3 4 1 1 - 

Yale University - - - - - - 1 - - - 

AMC - - - - - - 3 - - - 

CALGB - - - - - - 86 1 7 14 

ECOG - - - - - - 81 - 3 - 

NCCTG - - - - - - 15 - - - 

NSABP - - - - - - 3 - - - 

Total 47 29 3 34 87 37 332 11 20 25 

S0350 

S0801 

S0806 

S0816 

S1001 

S1106 

S1108 




MELANOMA COMMITTEE 


Chair: 

Vice-Chair: 






Surgery: 


Pathology: 

Non-Melanoma Skin Cancer: 


Designates 



Data Coordinator: 

Nurse: 





Room: Crystal A Ballroom 

7:30 a.m. – 9:30 a.m. 

Time/Location 

Agenda 

Antoni Ribas, M.D., Ph.D. 

William E. Carson III, M.D. 

Bruce G. Redman, D.O. 

Megan Othus, Ph.D. 

James Moon, M.S. 

Kim A. Margolin, M.D. 

Evan J. Wuthrick, M.D. 

Robert H.I. Andtbacka, M.D. 

Lawrence E. Flaherty, M.D. 

Jane L. Messina, M.D. 

Sancy A. Leachman, M.D., Ph.D. 

TBD 

Sandy Allten, R.N., O.C.N. 

TBD 


Karen L. Mack, R.N.P. 

Ann M. Lau Clarke, R.N., M.S.N. 

Valerie Guild 

Jorge G. Avila, Pharm.D. 


TBD 

Presentation 

How young adult research can be embedded into studies being developed 

in the SWOG Melanoma Committee (20 minutes) 

Leonard Sender, M.D., UCI 

Discussion on the imaging initiative (10 minutes) 

Kenneth F. Grossmann M.D., Ph.D. University of Utah. 

Update on Newly Proposed Studies (5-10 minutes each) 

■ ■ “Randomized Phase II Trial of Standard HD-IFN or HD-IFN for 

One Month Followed by Pegylated-Interferon.” Dr. Carson. 

■ ■ 

■■ 

■ ■ 

“Ipilimumab in Patients With Acral and Mucosal Melanoma.” Dr. 

Lao. 

ECOG 1612, “A Randomized Phase III Trial of Vemurafenib 

vs Ipilimumab in Patients with Advanced BRAFV600 Mutant 

Melanoma.” Dr. Chmielowski. 

“A Randomized Phase II study of the Combination of Carboplatin 

and Paclitaxel with or without Vemurafenib in patients with 

Metastatic Melanoma Harboring a V600 BRAF Mutation whose 

Tumors Have Progressed on a Prior BRAF Inhibitor.” Dr. Kim. 

Active Studies (5-10 Minutes each) 

■■ 

CTSU/E2607, “A Phase II Trial of Dasatinib in KIT-Positive 

Patients with Unresectable Locally Advanced or Stage IV 

Mucosal, Acral and Vulvovaginal Melanomas.” Dr. Margolin. 


■■ 

CTSU/E1609, “A Phase III Randomized Study of Adjuvant 

Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon 

Alpha-2b for Resected High-Risk Melanoma.” Dr. Flaherty. 


Closed Studies (5-10 minutes each) 

■■ 

S0933, “Phase II Study of RO4929097 (NSC-749225) in 

Advanced Melanoma.” Drs. Margolin and Gajewski. Activated: 

10/28/10; Closed: 11/15/11. 

■■ 

S0826, “A Phase II Trial of SCH 727965 (NSC 747135) in 

Patients with Stage IV Melanoma.” Drs. Lao and Fruehauf. 



■■ 

S1303, “Phase II trial of Trametinib in NRAS mutant melanoma.” 

Dr. Daud. 

■■ 

■■ 

S1223, “An Open-Label, Single-Arm Phase II Study of TH-302 

in Combination with Paclitaxel in Patients with Advanced 

Melanoma.” Dr. Cranmer. 

S1221, “Safety and efficacy of a AKT inhibitor in combination 

with dabrafenib in patients with acquired resistance to BRAF 

inhibitor-based therapy mediated by non-MAPK reactivation 

mechanisms.” Drs. Ribas and Lo. 

■■ 

EORTC 18081: “Adjuvant Pegylated-Interferon in Stage IIb.” Dr. 

Sondak. 

■■ 

S1208, “Prospective Validation of Karyometric Analysis of 

Cutaneous Squamous Cell Carcinoma.” Drs. Krouse and Glazer. 


Publications 







■■ 

S0512 Phase II trial of sorafenib in combination with carboplatin 

and paclitaxel in patients with carboplatin and paclitaxel in 

patients with metastatic uveal melanoma: SWOG S0512. S 

Bhatia, J Moon, K Margolin, J Weber, C Lao, M Othus, A 

Aparicio, A Ribas, V Sondak. PLoS ONE, undergoing revisions in 

response to reviewers’ comments 8/17/12. 

MELANOMA COMMITTEE 




Melanoma Committee 



E1609 

E1697 

E2607 

S0826 

Arizona, U of 5 10 - - 1 

Arkansas, U of 17 10 - 2 - 

Atlanta Reg CCOP - 12 - - - 

Bay Area CCOP - - - 1 - 

Baylor Univ Med Ctr 8 - - - - 

Beaumont CCOP - 3 - - 1 

Boston MC MBCCOP - - - 1 - 

Cincinnati MC, U of 2 4 - - - 

City of Hope Med Ctr - 2 - - - 

Cleveland Clinic OH 1 3 - - - 

Colorado, U of 12 2 - 3 - 

Columbia River CCOP - 14 - 4 - 

Columbia University 1 - - - 1 

Columbus CCOP - - - - 3 

Davis, U of CA 6 16 - - - 

Dayton CCOP 1 9 - 4 1 

Grand Rapids CCOP 3 - - 6 1 

Greenville CCOP 1 - - - - 

Gulf Coast MBCCOP - - - - 1 

H Lee Moffitt CC 15 2 - - - 

Harrington CC - 2 - - - 

Hawaii MBCCOP, U of - - 1 - - 

Irvine, U of CA 1 - - 1 - 

KaiserPermanenteNCAL 2 10 - - - 

Kansas City CCOP - - - 2 1 

Kansas, U of 2 2 - 1 1 

LSU-New Orleans CCOP - - - 2 - 

LSU-Shreveport - 1 - - - 

LSU-Shreveport CCOP - - - - 1 

Lahey Clinic Med Ctr 4 - - - - 

Loyola University 1 1 - 3 2 

MD Anderson - 1 - - - 

Michigan CRC CCOP - - - 2 - 

Michigan, U of 2 1 - 11 6 

Mississippi, Univ of 1 - - - - 

Montana CCOP 1 - - - 2 

Nevada Cancer Inst - - - 2 - 

Northwest CCOP 1 - - - - 

Ohio State Univ 1 - - - - 

Oregon Hlth Sci Univ 5 1 - 1 - 

S0933 



Melanoma Committee 



E1609 

E1697 

E2607 

S0826 

Ozarks Reg CCOP 3 2 - - - 

Puget Sound 6 5 - 1 3 

Rochester, Univ of 1 2 - 2 1 

San Antonio, U of TX 6 6 - 2 2 

Southeast CCC CCOP 3 7 - 4 2 

Southern Nevada CCOP - - - - 1 

St Louis CCOP 1 - - 3 2 

Tennessee, U of - - - 2 - 

Univ of Chicago MC - - - - 1 

Upstate Carolina - - - - 1 

Utah, U of 6 8 - 4 - 

Wayne State Univ 2 8 - 8 - 

Wichita CCOP - - - - 1 

Total 121 144 1 72 36 

S0933 

Note: Some studies may not be listed because they were either closed prior to July 1, 2011 or because they are currently 

active but have not had any accrual through September 6, 2012. 



Future Group Meeting Dates 

Mark Your Calendar! 

— May 1-4 — 

San Francisco, CA 

2013 

— October 9-12 — 

Chicago, IL 

— April 30-May 3 — 

San Francisco, CA 

2014 

— Oct 29-Nov 1 — 

Chicago, IL 

Check the SWOG website (swog.org) for updates! 



Do you have a few minutes between 

meetings Stop by the SWOG registration 

desk in the East Tower Concourse to check 

your e-mail and/or print your boarding pass! 


Fall 2012 Group Meeting Commercial Supporters* 

CME SUPPORTERS 

Double Platinum 

Eli Lilly & Co. 

Platinum 

Amgen 

Novartis 

Silver 

Genomic Health 

Bronze 

Bayer Healthcare 

Pharmaceuticals 

Bristol-Myers Squibb 

Eisai 

Merck 

Sigma-Tau Pharmaceuticals 

Varian 

*Supporters as of September 10, 2012 

NON-CME SUPPORTERS 

Double Platinum 

Millennium Pharmaceuticals 

Gold 

Otsuka 

Silver 

Celgene 

Bronze 

Agennix 

EXHIBITORS 

Boehringer Ingelheim 

Pharmaceuticals 

Genomic Health, Inc. 

Illumina 

Prometheus Labs 

Seattle Genetics 

We appreciate their support!

Download Swog Fall 2012 Group Meeting PDF

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?